S-4/A
S-4/Atrue0001665988P2YP1YP15D0.005031838589Per share information for the six months ended July 3, 2021 represents loss per share of Class A common stock and weighted-average shares of Class A common stock outstanding from February 16, 2021 through July 3, 2021, the period following Bioventus Inc.’s initial public offering and related transactions described in Note 1. Organization and Note 7. Earnings per share within the Notes to the Unaudited Condensed Consolidated Financial Statements. 0001665988 2021-04-04 2021-07-03 0001665988 2020-03-28 2020-06-27 0001665988 2021-01-04 2021-07-03 0001665988 2019-12-28 2020-06-27 0001665988 2021-01-01 2021-07-03 0001665988 2021-07-03 0001665988 2020-12-31 0001665988 2020-01-01 2020-06-27 0001665988 2020-01-01 2020-12-31 0001665988 2021-02-10 0001665988 2021-02-16 2021-07-03 0001665988 2020-03-29 2020-06-27 0001665988 2021-01-01 2021-04-03 0001665988 2021-01-12 2021-02-10 0001665988 2019-12-31 0001665988 2019-01-01 2019-12-31 0001665988 2018-01-01 2018-12-31 0001665988 2021-03-30 0001665988 2021-02-15 0001665988 2021-02-16 0001665988 2021-06-08 2021-06-08 0001665988 2020-04-01 2020-04-30 0001665988 2021-08-02 2021-08-02 0001665988 2021-08-02 0001665988 2021-04-03 0001665988 2020-03-28 0001665988 2020-06-27 0001665988 bvs:BionessIncMember 2021-04-04 2021-07-03 0001665988 bvs:LimitedLiabilityCompanyInterestsMember 2021-04-04 2021-07-03 0001665988 us-gaap:EmployeeStockOptionMember 2021-04-04 2021-07-03 0001665988 us-gaap:RestrictedStockUnitsRSUMember 2021-04-04 2021-07-03 0001665988 bvs:UnvestedClassACommonSharesMember 2021-04-04 2021-07-03 0001665988 country:US 2021-04-04 2021-07-03 0001665988 us-gaap:NonUsMember 2021-04-04 2021-07-03 0001665988 bvs:PainTreatmentsAndJointPreservationMember 2021-04-04 2021-07-03 0001665988 bvs:RestorativeTherapiesMember 2021-04-04 2021-07-03 0001665988 bvs:BoneGraftSubstitutesMember 2021-04-04 2021-07-03 0001665988 us-gaap:RestrictedStockUnitsRSUMember 2021-04-04 2021-07-03 0001665988 bvs:USSegmentMember us-gaap:OperatingSegmentsMember 2021-04-04 2021-07-03 0001665988 bvs:InternationalSegmentMember us-gaap:OperatingSegmentsMember 2021-04-04 2021-07-03 0001665988 us-gaap:MaterialReconcilingItemsMember 2021-04-04 2021-07-03 0001665988 us-gaap:AdditionalPaidInCapitalMember 2021-04-04 2021-07-03 0001665988 us-gaap:NoncontrollingInterestMember 2021-04-04 2021-07-03 0001665988 us-gaap:InterestRateSwapMember 2021-04-04 2021-07-03 0001665988 us-gaap:EmployeeStockMember 2021-04-04 2021-07-03 0001665988 bvs:A2021PlanMember 2021-04-04 2021-07-03 0001665988 bvs:SupplierOfSingleInjectionOAProductMember 2021-04-04 2021-07-03 0001665988 us-gaap:RetainedEarningsMember 2021-04-04 2021-07-03 0001665988 us-gaap:EmployeeStockMember srt:MinimumMember 2021-04-04 2021-07-03 0001665988 us-gaap:EmployeeStockMember srt:MaximumMember 2021-04-04 2021-07-03 0001665988 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2021-04-04 2021-07-03 0001665988 us-gaap:IPOMember us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-04-04 2021-07-03 0001665988 us-gaap:IPOMember us-gaap:AdditionalPaidInCapitalMember 2021-04-04 2021-07-03 0001665988 us-gaap:IPOMember 2021-04-04 2021-07-03 0001665988 bvs:BionessIncMember 2020-03-28 2020-06-27 0001665988 us-gaap:PhantomShareUnitsPSUsMember 2020-03-28 2020-06-27 0001665988 bvs:BioVentusLlcMember 2020-12-31 0001665988 bvs:BVLLCMember 2020-12-31 0001665988 bvs:BioventusIncMember 2020-12-31 0001665988 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember bvs:HarborMedtechIncMember 2020-12-31 0001665988 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember bvs:HarborMedtechIncMember bvs:BioVentusLlcMember 2020-12-31 0001665988 us-gaap:FairValueMeasurementsRecurringMember bvs:BioVentusLlcMember 2020-12-31 0001665988 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember bvs:BioVentusLlcMember 2020-12-31 0001665988 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember bvs:BioVentusLlcMember 2020-12-31 0001665988 us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001665988 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2020-12-31 0001665988 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2020-12-31 0001665988 us-gaap:RevolvingCreditFacilityMember bvs:TwoThousandNineteenCreditAgreementMember bvs:BioVentusLlcMember 2020-12-31 0001665988 us-gaap:RevolvingCreditFacilityMember bvs:TwoThousandNineteenCreditAgreementMember bvs:SwingLineCreditFacilityMember bvs:BioVentusLlcMember 2020-12-31 0001665988 us-gaap:DamagesFromProductDefectsMember bvs:BioVentusLlcMember 2020-12-31 0001665988 bvs:TermLoanMember bvs:TwoThousandNineteenCreditAgreementMember bvs:BioVentusLlcMember 2020-12-31 0001665988 us-gaap:DamagesFromProductDefectsMember 2020-12-31 0001665988 bvs:HarborMedtechIncMember 2020-12-31 0001665988 us-gaap:CommonClassAMember 2020-12-31 0001665988 us-gaap:CommonClassBMember 2020-12-31 0001665988 us-gaap:InterestRateSwapMember bvs:BioVentusLlcMember 2020-12-31 0001665988 bvs:BioVentusLlcMember bvs:UsaoAndOigMember 2020-12-31 0001665988 us-gaap:AssetUnderConstructionMember bvs:BioventusIncMember 2020-12-31 0001665988 us-gaap:MachineryAndEquipmentMember bvs:BioventusIncMember 2020-12-31 0001665988 us-gaap:FurnitureAndFixturesMember bvs:BioventusIncMember 2020-12-31 0001665988 us-gaap:LeaseholdImprovementsMember bvs:BioventusIncMember 2020-12-31 0001665988 bvs:ComputerEquipmentAndSoftwareMember bvs:BioventusIncMember 2020-12-31 0001665988 us-gaap:OperatingSegmentsMember bvs:BioventusIncMember 2020-12-31 0001665988 us-gaap:OperatingSegmentsMember bvs:InternationalSegmentMember bvs:BioventusIncMember 2020-12-31 0001665988 us-gaap:OperatingSegmentsMember bvs:USSegmentMember bvs:BioventusIncMember 2020-12-31 0001665988 bvs:BioVentusLlcMember bvs:BmpResearchAndDevelopmentProgrammeMember 2020-12-31 0001665988 us-gaap:DistributionRightsMember bvs:BioventusIncMember 2020-12-31 0001665988 us-gaap:IntellectualPropertyMember bvs:BioventusIncMember 2020-12-31 0001665988 us-gaap:TechnologyBasedIntangibleAssetsMember bvs:BioventusIncMember 2020-12-31 0001665988 us-gaap:CustomerRelationshipsMember bvs:BioventusIncMember 2020-12-31 0001665988 bvs:AcquiredInProcessResearchAndDevelopmentMember bvs:BioventusIncMember 2020-12-31 0001665988 us-gaap:OtherCurrentLiabilitiesMember bvs:BioVentusLlcMember 2020-12-31 0001665988 bvs:SupplierAMember us-gaap:SupplierConcentrationRiskMember 2020-12-31 0001665988 bvs:SupplierBMember us-gaap:SupplierConcentrationRiskMember 2020-12-31 0001665988 bvs:SupplierCMember us-gaap:SupplierConcentrationRiskMember 2020-12-31 0001665988 bvs:BioVentusLlcMember bvs:HarborMember 2020-12-31 0001665988 bvs:BioVentusLlcMember us-gaap:NonUsMember 2020-12-31 0001665988 bvs:FederalAndStateMember bvs:BioVentusLlcMember bvs:YearTwoThousandTwentyOneToYearTwoThousandAndThirtySevenMember 2020-12-31 0001665988 bvs:FederalAndStateMember bvs:BioVentusLlcMember bvs:IndefinitelyMember 2020-12-31 0001665988 bvs:BioVentusLlcMember bvs:HarborMedtechIncMember 2020-12-31 0001665988 bvs:BioVentusLlcMember us-gaap:InProcessResearchAndDevelopmentMember 2020-12-31 0001665988 bvs:BioVentusLlcMember us-gaap:VariableInterestEntityPrimaryBeneficiaryMember bvs:PromissoryNoteMember 2020-12-31 0001665988 bvs:BioVentusLlcMember bvs:CartiHealLtdMember 2020-12-31 0001665988 bvs:BioVentusLlcMember bvs:CartiHealLtdMember us-gaap:SeriesGPreferredStockMember 2020-12-31 0001665988 bvs:BioVentusLlcMember us-gaap:MeasurementInputExpectedTermMember bvs:EquityParticipationRightUnitMember us-gaap:ValuationTechniqueOptionPricingModelMember 2020-12-31 0001665988 bvs:BioVentusLlcMember srt:WeightedAverageMember us-gaap:MeasurementInputExpectedTermMember bvs:EquityParticipationRightUnitMember us-gaap:ValuationTechniqueOptionPricingModelMember 2020-12-31 0001665988 bvs:BioVentusLlcMember us-gaap:MeasurementInputRiskFreeInterestRateMember bvs:EquityParticipationRightUnitMember us-gaap:ValuationTechniqueOptionPricingModelMember 2020-12-31 0001665988 bvs:BioVentusLlcMember srt:WeightedAverageMember us-gaap:MeasurementInputRiskFreeInterestRateMember bvs:EquityParticipationRightUnitMember us-gaap:ValuationTechniqueOptionPricingModelMember 2020-12-31 0001665988 bvs:BioVentusLlcMember srt:MinimumMember bvs:MeasurementInputEquityVolatilityMember bvs:EquityParticipationRightUnitMember us-gaap:ValuationTechniqueOptionPricingModelMember 2020-12-31 0001665988 bvs:BioVentusLlcMember srt:MaximumMember bvs:MeasurementInputEquityVolatilityMember bvs:EquityParticipationRightUnitMember us-gaap:ValuationTechniqueOptionPricingModelMember 2020-12-31 0001665988 bvs:BioVentusLlcMember srt:WeightedAverageMember bvs:MeasurementInputEquityVolatilityMember bvs:EquityParticipationRightUnitMember us-gaap:ValuationTechniqueOptionPricingModelMember 2020-12-31 0001665988 bvs:BioVentusLlcMember us-gaap:MeasurementInputDiscountForLackOfMarketabilityMember bvs:EquityParticipationRightUnitMember us-gaap:ValuationTechniqueOptionPricingModelMember 2020-12-31 0001665988 bvs:BioVentusLlcMember srt:WeightedAverageMember us-gaap:MeasurementInputDiscountForLackOfMarketabilityMember bvs:EquityParticipationRightUnitMember us-gaap:ValuationTechniqueOptionPricingModelMember 2020-12-31 0001665988 bvs:BioVentusLlcMember bvs:EquityParticipationRightUnitMember us-gaap:ValuationTechniqueOptionPricingModelMember srt:MinimumMember 2020-12-31 0001665988 bvs:BioVentusLlcMember bvs:EquityParticipationRightUnitMember us-gaap:ValuationTechniqueOptionPricingModelMember srt:MaximumMember 2020-12-31 0001665988 bvs:BioVentusLlcMember srt:WeightedAverageMember bvs:EquityParticipationRightUnitMember us-gaap:ValuationTechniqueOptionPricingModelMember 2020-12-31 0001665988 bvs:TwoThousandAndTwelvePreferredUnitsMember bvs:BioVentusLlcMember 2020-12-31 0001665988 bvs:TwoThousandAndFifteenPreferredUnitsMember bvs:BioVentusLlcMember 2020-12-31 0001665988 bvs:EquityParticipationRightUnitMember bvs:BioVentusLlcMember 2020-12-31 0001665988 bvs:BioVentusLlcMember bvs:TwoThousandAndTwelveMember 2020-12-31 0001665988 bvs:BioVentusLlcMember bvs:TwoThousandAndFifteenMember 2020-12-31 0001665988 bvs:BioVentusLlcMember bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsMember 2020-12-31 0001665988 bvs:BioVentusLlcMember bvs:EquityParticipationRightUnitMember 2020-12-31 0001665988 bvs:TwoThousandNineteenCreditAgreementMember bvs:BioVentusLlcMember 2020-12-31 0001665988 bvs:TwoThousandNineteenCreditAgreementMember srt:MinimumMember bvs:BioVentusLlcMember 2020-12-31 0001665988 bvs:BioVentusLlcMember 2019-12-31 0001665988 bvs:BioventusIncMember 2019-12-31 0001665988 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember bvs:HarborMedtechIncMember bvs:BioVentusLlcMember 2019-12-31 0001665988 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember bvs:BioVentusLlcMember 2019-12-31 0001665988 bvs:BioVentusLlcMember bvs:UsaoAndOigMember 2019-12-31 0001665988 us-gaap:AssetUnderConstructionMember bvs:BioventusIncMember 2019-12-31 0001665988 us-gaap:MachineryAndEquipmentMember bvs:BioventusIncMember 2019-12-31 0001665988 us-gaap:FurnitureAndFixturesMember bvs:BioventusIncMember 2019-12-31 0001665988 us-gaap:LeaseholdImprovementsMember bvs:BioventusIncMember 2019-12-31 0001665988 bvs:ComputerEquipmentAndSoftwareMember bvs:BioventusIncMember 2019-12-31 0001665988 us-gaap:OperatingSegmentsMember bvs:BioventusIncMember 2019-12-31 0001665988 bvs:InternationalSegmentMember us-gaap:OperatingSegmentsMember bvs:BioventusIncMember 2019-12-31 0001665988 bvs:USSegmentMember us-gaap:OperatingSegmentsMember bvs:BioventusIncMember 2019-12-31 0001665988 us-gaap:DistributionRightsMember bvs:BioventusIncMember 2019-12-31 0001665988 us-gaap:IntellectualPropertyMember bvs:BioventusIncMember 2019-12-31 0001665988 us-gaap:TechnologyBasedIntangibleAssetsMember bvs:BioventusIncMember 2019-12-31 0001665988 us-gaap:CustomerRelationshipsMember bvs:BioventusIncMember 2019-12-31 0001665988 bvs:AcquiredInProcessResearchAndDevelopmentMember bvs:BioventusIncMember 2019-12-31 0001665988 us-gaap:OtherCurrentLiabilitiesMember bvs:BioVentusLlcMember 2019-12-31 0001665988 bvs:HarborMember bvs:BioVentusLlcMember 2019-12-31 0001665988 bvs:SupplierAMember us-gaap:SupplierConcentrationRiskMember 2019-12-31 0001665988 bvs:SupplierBMember us-gaap:SupplierConcentrationRiskMember 2019-12-31 0001665988 bvs:SupplierCMember us-gaap:SupplierConcentrationRiskMember 2019-12-31 0001665988 bvs:BioVentusLlcMember us-gaap:VariableInterestEntityPrimaryBeneficiaryMember bvs:PromissoryNoteMember us-gaap:OtherCurrentLiabilitiesMember 2019-12-31 0001665988 bvs:BioVentusLlcMember bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsMember 2019-12-31 0001665988 us-gaap:InterestRateSwapMember bvs:BioVentusLlcMember 2019-12-31 0001665988 bvs:BionessIncMember 2021-01-04 2021-07-03 0001665988 bvs:A2021PlanMember 2021-01-04 2021-07-03 0001665988 us-gaap:EmployeeStockMember 2021-01-04 2021-07-03 0001665988 bvs:BionessIncMember 2019-12-28 2020-06-27 0001665988 us-gaap:PhantomShareUnitsPSUsMember 2019-12-28 2020-06-27 0001665988 srt:MinimumMember us-gaap:RestrictedStockUnitsRSUMember 2019-12-28 2020-06-27 0001665988 srt:MaximumMember us-gaap:RestrictedStockUnitsRSUMember 2019-12-28 2020-06-27 0001665988 bvs:BioVentusLlcMember 2020-01-01 2020-12-31 0001665988 bvs:HarborMedtechIncMember 2020-01-01 2020-12-31 0001665988 bvs:EquityParticipationRightUnitMember bvs:BioVentusLlcMember 2020-01-01 2020-12-31 0001665988 bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsMember bvs:BioVentusLlcMember 2020-01-01 2020-12-31 0001665988 bvs:BioventusIncMember 2020-01-01 2020-12-31 0001665988 bvs:USSegmentMember us-gaap:OperatingSegmentsMember bvs:BioVentusLlcMember 2020-01-01 2020-12-31 0001665988 bvs:InternationalSegmentMember us-gaap:OperatingSegmentsMember bvs:BioVentusLlcMember 2020-01-01 2020-12-31 0001665988 us-gaap:MaterialReconcilingItemsMember bvs:BioVentusLlcMember 2020-01-01 2020-12-31 0001665988 us-gaap:InterestRateSwapMember bvs:BioVentusLlcMember 2020-01-01 2020-12-31 0001665988 us-gaap:MemberUnitsMember bvs:BioVentusLlcMember 2020-01-01 2020-12-31 0001665988 bvs:SupplierOfSingleInjectionOAProductMember bvs:BioVentusLlcMember 2020-01-01 2020-12-31 0001665988 us-gaap:IPOMember 2020-01-01 2020-12-31 0001665988 us-gaap:RetainedEarningsMember bvs:BioVentusLlcMember 2020-01-01 2020-12-31 0001665988 us-gaap:NoncontrollingInterestMember bvs:BioVentusLlcMember 2020-01-01 2020-12-31 0001665988 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember bvs:BioVentusLlcMember 2020-01-01 2020-12-31 0001665988 bvs:BioVentusLlcMember bvs:BmpResearchAndDevelopmentProgrammeMember 2020-01-01 2020-12-31 0001665988 bvs:BioVentusLlcMember bvs:PreferredUnitsMember 2020-01-01 2020-12-31 0001665988 bvs:ReclassificationOfIprdMember us-gaap:DevelopedTechnologyRightsMember bvs:BioventusIncMember 2020-01-01 2020-12-31 0001665988 us-gaap:AccountsPayableMember us-gaap:DistributionRightsMember 2020-01-01 2020-12-31 0001665988 bvs:USSegmentMember bvs:BioVentusLlcMember 2020-01-01 2020-12-31 0001665988 bvs:InternationalSegmentMember bvs:BioVentusLlcMember 2020-01-01 2020-12-31 0001665988 bvs:OAJointPainTreatmentAndJointPreservationMember bvs:BioVentusLlcMember 2020-01-01 2020-12-31 0001665988 bvs:MinimallyInvasiveFractureTreatmentMember bvs:BioVentusLlcMember 2020-01-01 2020-12-31 0001665988 bvs:BoneGraftSubstitutesMember bvs:BioVentusLlcMember 2020-01-01 2020-12-31 0001665988 us-gaap:ComputerEquipmentMember srt:MinimumMember bvs:BioventusIncMember 2020-01-01 2020-12-31 0001665988 us-gaap:ComputerEquipmentMember srt:MaximumMember bvs:BioventusIncMember 2020-01-01 2020-12-31 0001665988 us-gaap:LeaseholdImprovementsMember bvs:BioventusIncMember 2020-01-01 2020-12-31 0001665988 us-gaap:MachineryAndEquipmentMember bvs:BioventusIncMember 2020-01-01 2020-12-31 0001665988 us-gaap:FurnitureAndFixturesMember bvs:BioventusIncMember 2020-01-01 2020-12-31 0001665988 us-gaap:IntellectualPropertyMember srt:WeightedAverageMember bvs:BioventusIncMember 2020-01-01 2020-12-31 0001665988 us-gaap:DistributionRightsMember srt:WeightedAverageMember bvs:BioventusIncMember 2020-01-01 2020-12-31 0001665988 us-gaap:CustomerRelationshipsMember srt:WeightedAverageMember bvs:BioventusIncMember 2020-01-01 2020-12-31 0001665988 us-gaap:DevelopedTechnologyRightsMember srt:WeightedAverageMember bvs:BioventusIncMember 2020-01-01 2020-12-31 0001665988 us-gaap:ProductConcentrationRiskMember bvs:ProductAMember bvs:BioventusIncMember us-gaap:SalesRevenueNetMember 2020-01-01 2020-12-31 0001665988 bvs:ProductBMember us-gaap:ProductConcentrationRiskMember bvs:BioventusIncMember us-gaap:SalesRevenueNetMember 2020-01-01 2020-12-31 0001665988 us-gaap:ProductConcentrationRiskMember bvs:ProductCMember bvs:BioventusIncMember us-gaap:SalesRevenueNetMember 2020-01-01 2020-12-31 0001665988 us-gaap:ProductConcentrationRiskMember bvs:ProductDMember bvs:BioventusIncMember us-gaap:SalesRevenueNetMember 2020-01-01 2020-12-31 0001665988 bvs:SupplierAMember us-gaap:SupplierConcentrationRiskMember bvs:BioventusIncMember us-gaap:SalesRevenueNetMember 2020-01-01 2020-12-31 0001665988 bvs:SupplierBMember us-gaap:SupplierConcentrationRiskMember bvs:BioventusIncMember us-gaap:SalesRevenueNetMember 2020-01-01 2020-12-31 0001665988 bvs:SupplierCMember us-gaap:SupplierConcentrationRiskMember bvs:BioventusIncMember us-gaap:SalesRevenueNetMember 2020-01-01 2020-12-31 0001665988 us-gaap:TaxYear2015Member bvs:BioVentusLlcMember 2020-01-01 2020-12-31 0001665988 us-gaap:TaxYear2020Member bvs:BioVentusLlcMember 2020-01-01 2020-12-31 0001665988 bvs:BioVentusLlcMember us-gaap:VariableInterestEntityPrimaryBeneficiaryMember bvs:PromissoryNoteMember 2020-01-01 2020-12-31 0001665988 bvs:BioVentusLlcMember bvs:CartiHealLtdMember 2020-01-01 2020-12-31 0001665988 bvs:BioVentusLlcMember bvs:EmployeeSeveranceAndTemporaryLaborCostsMember 2020-01-01 2020-12-31 0001665988 bvs:BioVentusLlcMember bvs:OtherChargesMember 2020-01-01 2020-12-31 0001665988 bvs:BioVentusLlcMember bvs:TwoThousandAndEighteenPlanMember 2020-01-01 2020-12-31 0001665988 bvs:BioVentusLlcMember bvs:OtherPhantomUnitMember 2020-01-01 2020-12-31 0001665988 bvs:BioVentusLlcMember bvs:TwoThousandAndTwelveMember 2020-01-01 2020-12-31 0001665988 bvs:BioVentusLlcMember bvs:TwoThousandAndFifteenMember 2020-01-01 2020-12-31 0001665988 bvs:BioVentusLlcMember bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsMember 2020-01-01 2020-12-31 0001665988 bvs:BioVentusLlcMember bvs:TermLoanMember bvs:DebtInstrumentSchedulePeriodicPaymentPeriodOneMember 2020-01-01 2020-12-31 0001665988 bvs:BioVentusLlcMember bvs:TermLoanMember bvs:DebtInstrumentSchedulePeriodicPaymentPeriodTwoMember 2020-01-01 2020-12-31 0001665988 bvs:LeverageRatioRangeOneMember us-gaap:EurodollarMember bvs:BioVentusLlcMember 2020-01-01 2020-12-31 0001665988 bvs:LeverageRatioRangeOneMember us-gaap:BaseRateMember bvs:BioVentusLlcMember 2020-01-01 2020-12-31 0001665988 bvs:LeverageRatioRangeTwoMember us-gaap:EurodollarMember bvs:BioVentusLlcMember 2020-01-01 2020-12-31 0001665988 bvs:LeverageRatioRangeTwoMember us-gaap:BaseRateMember bvs:BioVentusLlcMember 2020-01-01 2020-12-31 0001665988 bvs:LeverageRatioRangeThreeMember us-gaap:EurodollarMember bvs:BioVentusLlcMember 2020-01-01 2020-12-31 0001665988 bvs:LeverageRatioRangeThreeMember us-gaap:BaseRateMember bvs:BioVentusLlcMember 2020-01-01 2020-12-31 0001665988 bvs:LeverageRatioRangeFourMember us-gaap:EurodollarMember bvs:BioVentusLlcMember 2020-01-01 2020-12-31 0001665988 bvs:LeverageRatioRangeFourMember us-gaap:BaseRateMember bvs:BioVentusLlcMember 2020-01-01 2020-12-31 0001665988 bvs:LeverageRatioRangeFiveMember us-gaap:EurodollarMember bvs:BioVentusLlcMember 2020-01-01 2020-12-31 0001665988 bvs:LeverageRatioRangeFiveMember us-gaap:BaseRateMember bvs:BioVentusLlcMember 2020-01-01 2020-12-31 0001665988 bvs:LeverageRatioRangeOneMember bvs:BioVentusLlcMember us-gaap:RevolvingCreditFacilityMember 2020-01-01 2020-12-31 0001665988 bvs:LeverageRatioRangeTwoMember bvs:BioVentusLlcMember us-gaap:RevolvingCreditFacilityMember 2020-01-01 2020-12-31 0001665988 bvs:LeverageRatioRangeThreeMember bvs:BioVentusLlcMember us-gaap:RevolvingCreditFacilityMember 2020-01-01 2020-12-31 0001665988 bvs:LeverageRatioRangeFourMember bvs:BioVentusLlcMember us-gaap:RevolvingCreditFacilityMember 2020-01-01 2020-12-31 0001665988 bvs:LeverageRatioRangeFiveMember bvs:BioVentusLlcMember us-gaap:RevolvingCreditFacilityMember 2020-01-01 2020-12-31 0001665988 bvs:TermLoanMember bvs:TwoThousandNineteenCreditAgreementMember bvs:BioVentusLlcMember 2020-01-01 2020-12-31 0001665988 bvs:TwoThousandNineteenCreditAgreementMember us-gaap:RevolvingCreditFacilityMember bvs:BioVentusLlcMember 2020-01-01 2020-12-31 0001665988 bvs:BioVentusLlcMember 2019-01-01 2019-12-31 0001665988 bvs:EquityParticipationRightUnitMember bvs:BioVentusLlcMember 2019-01-01 2019-12-31 0001665988 bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsMember bvs:BioVentusLlcMember 2019-01-01 2019-12-31 0001665988 bvs:BioventusIncMember 2019-01-01 2019-12-31 0001665988 bvs:USSegmentMember us-gaap:OperatingSegmentsMember bvs:BioVentusLlcMember 2019-01-01 2019-12-31 0001665988 bvs:InternationalSegmentMember us-gaap:OperatingSegmentsMember bvs:BioVentusLlcMember 2019-01-01 2019-12-31 0001665988 us-gaap:MaterialReconcilingItemsMember bvs:BioVentusLlcMember 2019-01-01 2019-12-31 0001665988 bvs:SupplierOfSingleInjectionOAProductMember bvs:BioVentusLlcMember 2019-01-01 2019-12-31 0001665988 us-gaap:MemberUnitsMember bvs:BioVentusLlcMember 2019-01-01 2019-12-31 0001665988 us-gaap:RetainedEarningsMember bvs:BioVentusLlcMember 2019-01-01 2019-12-31 0001665988 us-gaap:NoncontrollingInterestMember bvs:BioVentusLlcMember 2019-01-01 2019-12-31 0001665988 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember bvs:BioVentusLlcMember 2019-01-01 2019-12-31 0001665988 bvs:BioVentusLlcMember bvs:UsaoAndOigMember 2019-01-01 2019-12-31 0001665988 bvs:BioVentusLlcMember bvs:BmpResearchAndDevelopmentProgrammeMember 2019-01-01 2019-12-31 0001665988 bvs:PreferredUnitsMember bvs:BioVentusLlcMember 2019-01-01 2019-12-31 0001665988 bvs:USSegmentMember bvs:BioVentusLlcMember 2019-01-01 2019-12-31 0001665988 bvs:InternationalSegmentMember bvs:BioVentusLlcMember 2019-01-01 2019-12-31 0001665988 bvs:OAJointPainTreatmentAndJointPreservationMember bvs:BioVentusLlcMember 2019-01-01 2019-12-31 0001665988 bvs:MinimallyInvasiveFractureTreatmentMember bvs:BioVentusLlcMember 2019-01-01 2019-12-31 0001665988 bvs:BoneGraftSubstitutesMember bvs:BioVentusLlcMember 2019-01-01 2019-12-31 0001665988 us-gaap:ProductConcentrationRiskMember bvs:ProductAMember bvs:BioventusIncMember us-gaap:SalesRevenueNetMember 2019-01-01 2019-12-31 0001665988 bvs:ProductBMember us-gaap:ProductConcentrationRiskMember bvs:BioventusIncMember us-gaap:SalesRevenueNetMember 2019-01-01 2019-12-31 0001665988 us-gaap:ProductConcentrationRiskMember bvs:ProductCMember bvs:BioventusIncMember us-gaap:SalesRevenueNetMember 2019-01-01 2019-12-31 0001665988 us-gaap:ProductConcentrationRiskMember bvs:ProductDMember bvs:BioventusIncMember us-gaap:SalesRevenueNetMember 2019-01-01 2019-12-31 0001665988 bvs:SupplierAMember us-gaap:SupplierConcentrationRiskMember bvs:BioventusIncMember us-gaap:SalesRevenueNetMember 2019-01-01 2019-12-31 0001665988 bvs:SupplierBMember us-gaap:SupplierConcentrationRiskMember bvs:BioventusIncMember us-gaap:SalesRevenueNetMember 2019-01-01 2019-12-31 0001665988 bvs:SupplierCMember us-gaap:SupplierConcentrationRiskMember bvs:BioventusIncMember us-gaap:SalesRevenueNetMember 2019-01-01 2019-12-31 0001665988 bvs:BioVentusLlcMember us-gaap:VariableInterestEntityPrimaryBeneficiaryMember bvs:PromissoryNoteMember 2019-01-01 2019-12-31 0001665988 bvs:BioVentusLlcMember bvs:EmployeeSeveranceAndTemporaryLaborCostsMember 2019-01-01 2019-12-31 0001665988 bvs:BioVentusLlcMember bvs:OtherChargesMember 2019-01-01 2019-12-31 0001665988 bvs:BioVentusLlcMember bvs:TwoThousandAndTwelveMember bvs:OtherPhantomUnitMember 2019-01-01 2019-12-31 0001665988 bvs:BioVentusLlcMember bvs:TwoThousandAndFifteenMember bvs:OtherPhantomUnitMember 2019-01-01 2019-12-31 0001665988 bvs:BioVentusLlcMember bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsMember 2019-01-01 2019-12-31 0001665988 bvs:BioVentusLlcMember bvs:OtherPhantomUnitMember 2019-01-01 2019-12-31 0001665988 bvs:PriorCreditAgreementMember bvs:BioVentusLlcMember 2019-01-01 2019-12-31 0001665988 bvs:BioVentusLlcMember 2018-01-01 2018-12-31 0001665988 bvs:USSegmentMember us-gaap:OperatingSegmentsMember bvs:BioVentusLlcMember 2018-01-01 2018-12-31 0001665988 bvs:InternationalSegmentMember us-gaap:OperatingSegmentsMember bvs:BioVentusLlcMember 2018-01-01 2018-12-31 0001665988 us-gaap:MaterialReconcilingItemsMember bvs:BioVentusLlcMember 2018-01-01 2018-12-31 0001665988 bvs:SupplierOfSingleInjectionOAProductMember bvs:BioVentusLlcMember 2018-01-01 2018-12-31 0001665988 us-gaap:MemberUnitsMember bvs:BioVentusLlcMember 2018-01-01 2018-12-31 0001665988 us-gaap:RetainedEarningsMember bvs:BioVentusLlcMember 2018-01-01 2018-12-31 0001665988 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember bvs:BioVentusLlcMember 2018-01-01 2018-12-31 0001665988 bvs:BioVentusLlcMember bvs:BmpResearchAndDevelopmentProgrammeMember 2018-01-01 2018-12-31 0001665988 bvs:PreferredUnitsMember bvs:BioVentusLlcMember 2018-01-01 2018-12-31 0001665988 bvs:BioventusIncMember 2018-01-01 2018-12-31 0001665988 bvs:USSegmentMember bvs:BioVentusLlcMember 2018-01-01 2018-12-31 0001665988 bvs:InternationalSegmentMember bvs:BioVentusLlcMember 2018-01-01 2018-12-31 0001665988 bvs:OAJointPainTreatmentAndJointPreservationMember bvs:BioVentusLlcMember 2018-01-01 2018-12-31 0001665988 bvs:MinimallyInvasiveFractureTreatmentMember bvs:BioVentusLlcMember 2018-01-01 2018-12-31 0001665988 bvs:BoneGraftSubstitutesMember bvs:BioVentusLlcMember 2018-01-01 2018-12-31 0001665988 us-gaap:ProductConcentrationRiskMember bvs:ProductAMember bvs:BioventusIncMember us-gaap:SalesRevenueNetMember 2018-01-01 2018-12-31 0001665988 bvs:ProductBMember us-gaap:ProductConcentrationRiskMember bvs:BioventusIncMember us-gaap:SalesRevenueNetMember 2018-01-01 2018-12-31 0001665988 us-gaap:ProductConcentrationRiskMember bvs:ProductCMember bvs:BioventusIncMember us-gaap:SalesRevenueNetMember 2018-01-01 2018-12-31 0001665988 us-gaap:ProductConcentrationRiskMember bvs:ProductDMember bvs:BioventusIncMember us-gaap:SalesRevenueNetMember 2018-01-01 2018-12-31 0001665988 bvs:SupplierAMember us-gaap:SupplierConcentrationRiskMember bvs:BioventusIncMember us-gaap:SalesRevenueNetMember 2018-01-01 2018-12-31 0001665988 bvs:SupplierBMember us-gaap:SupplierConcentrationRiskMember bvs:BioventusIncMember us-gaap:SalesRevenueNetMember 2018-01-01 2018-12-31 0001665988 bvs:SupplierCMember us-gaap:SupplierConcentrationRiskMember bvs:BioventusIncMember us-gaap:SalesRevenueNetMember 2018-01-01 2018-12-31 0001665988 bvs:BioVentusLlcMember bvs:TwoThousandAndTwentyPlanMember 2018-01-01 2018-12-31 0001665988 bvs:BioVentusLlcMember bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsMember 2018-01-01 2018-12-31 0001665988 bvs:BionessIncMember 2021-03-30 2021-03-30 0001665988 us-gaap:IntellectualPropertyMember bvs:BionessIncMember 2021-03-30 2021-03-30 0001665988 us-gaap:CustomerRelationshipsMember bvs:BionessIncMember 2021-03-30 2021-03-30 0001665988 bvs:BionessIncMember us-gaap:ConvertibleDebtMember 2021-03-30 2021-03-30 0001665988 bvs:BioventusIncMember 2021-07-03 0001665988 bvs:BionessIncMember 2021-07-03 0001665988 bvs:CartiHealMember 2021-07-03 0001665988 us-gaap:FairValueMeasurementsRecurringMember 2021-07-03 0001665988 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2021-07-03 0001665988 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2021-07-03 0001665988 us-gaap:FairValueInputsLevel3Member us-gaap:ValuationTechniqueDiscountedCashFlowMember us-gaap:MeasurementInputDiscountRateMember srt:MinimumMember 2021-07-03 0001665988 us-gaap:FairValueInputsLevel3Member us-gaap:ValuationTechniqueDiscountedCashFlowMember us-gaap:MeasurementInputDiscountRateMember srt:MaximumMember 2021-07-03 0001665988 srt:MinimumMember 2021-07-03 0001665988 srt:MaximumMember 2021-07-03 0001665988 us-gaap:CommonClassAMember 2021-07-03 0001665988 us-gaap:CommonClassBMember 2021-07-03 0001665988 us-gaap:DamagesFromProductDefectsMember 2021-07-03 0001665988 us-gaap:FairValueInputsLevel2Member 2021-07-03 0001665988 bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsMember 2021-07-03 0001665988 us-gaap:InterestRateSwapMember 2021-07-03 0001665988 bvs:BVLLCMember 2021-07-03 0001665988 bvs:BVLLCMember us-gaap:SubsequentEventMember 2021-07-03 0001665988 bvs:PaycheckProtectionProgramCARESActMember 2021-07-03 0001665988 us-gaap:CommonClassAMember bvs:A2021PlanMember 2021-07-03 0001665988 bvs:CartiHealMember us-gaap:SeriesGPreferredStockMember 2021-07-03 0001665988 us-gaap:EmployeeStockMember srt:MinimumMember 2021-07-03 0001665988 us-gaap:EmployeeStockMember srt:MaximumMember 2021-07-03 0001665988 us-gaap:CommonClassBMember us-gaap:SubsequentEventMember 2021-07-03 0001665988 bvs:BionessIncMember 2021-03-30 0001665988 us-gaap:IntellectualPropertyMember bvs:BionessIncMember 2021-03-30 0001665988 us-gaap:InProcessResearchAndDevelopmentMember bvs:BionessIncMember 2021-03-30 0001665988 us-gaap:CustomerRelationshipsMember bvs:BionessIncMember 2021-03-30 0001665988 srt:MaximumMember bvs:BionessIncMember 2021-03-30 0001665988 bvs:BionessIncMember bvs:ObtainingFDAApprovalOfCertainProductsMember 2021-03-30 0001665988 bvs:BionessIncMember bvs:MeetingNetSalesTargetsOverAThreeYearPeriodPaymentOneMember 2021-03-30 0001665988 bvs:BionessIncMember bvs:MeetingNetSalesTargetsOverAThreeYearPeriodPaymentTwoMember 2021-03-30 0001665988 bvs:BionessIncMember bvs:ForObtainingCMSCoverageAndReimbursementForCertainProductsMember 2021-03-30 0001665988 us-gaap:CommonClassAMember us-gaap:IPOMember 2021-02-16 2021-02-16 0001665988 us-gaap:CommonClassAMember us-gaap:OverAllotmentOptionMember 2021-02-16 2021-02-16 0001665988 us-gaap:IPOMember us-gaap:CommonClassAMember bvs:BioventusIncMember 2021-02-16 2021-02-16 0001665988 us-gaap:CommonClassAMember us-gaap:OverAllotmentOptionMember bvs:BioventusIncMember 2021-02-16 2021-02-16 0001665988 us-gaap:SubsequentEventMember us-gaap:CommonClassAMember us-gaap:IPOMember 2021-02-16 2021-02-16 0001665988 us-gaap:OverAllotmentOptionMember us-gaap:CommonClassAMember us-gaap:SubsequentEventMember 2021-02-16 2021-02-16 0001665988 bvs:EquityParticipationRightUnitMember 2021-02-16 2021-02-16 0001665988 us-gaap:IPOMember 2021-02-16 2021-02-16 0001665988 us-gaap:IPOMember bvs:BioventusIncMember 2021-02-16 2021-02-16 0001665988 us-gaap:IPOMember us-gaap:SubsequentEventMember 2021-02-16 2021-02-16 0001665988 bvs:BVLLCMember 2021-02-16 2021-02-16 0001665988 bvs:BVLLCMember bvs:BioventusIncMember 2021-02-16 2021-02-16 0001665988 bvs:BVLLCMember us-gaap:CommonClassAMember 2021-02-16 2021-02-16 0001665988 us-gaap:CommonClassBMember 2021-02-16 2021-02-16 0001665988 bvs:BVLLCMember us-gaap:SubsequentEventMember 2021-02-16 2021-02-16 0001665988 us-gaap:SubsequentEventMember bvs:BVLLCMember us-gaap:CommonClassAMember 2021-02-16 2021-02-16 0001665988 us-gaap:CommonClassBMember us-gaap:SubsequentEventMember 2021-02-16 2021-02-16 0001665988 us-gaap:CommonClassAMember us-gaap:IPOMember 2021-02-16 0001665988 us-gaap:IPOMember us-gaap:CommonClassAMember bvs:BioventusIncMember 2021-02-16 0001665988 us-gaap:SubsequentEventMember us-gaap:IPOMember us-gaap:CommonClassAMember 2021-02-16 0001665988 us-gaap:CommonClassAMember 2021-02-16 0001665988 us-gaap:CommonClassBMember 2021-02-16 0001665988 bvs:BioVentusLlcMember us-gaap:SubsequentEventMember bvs:RestatedLimitedLiabilityCompanyAgreementMember 2021-02-16 0001665988 us-gaap:SubsequentEventMember bvs:BioVentusLlcMember bvs:ContinuingLlcOwnerMember 2021-02-16 0001665988 us-gaap:CommonClassAMember us-gaap:SubsequentEventMember 2021-02-16 0001665988 us-gaap:CommonClassBMember us-gaap:SubsequentEventMember 2021-02-16 0001665988 us-gaap:SubsequentEventMember 2021-02-16 0001665988 bvs:BioVentusLlcMember us-gaap:SubsequentEventMember bvs:NewLlcOwnerMember 2021-02-16 0001665988 us-gaap:SubsequentEventMember bvs:BVLLCMember 2021-02-16 0001665988 bvs:BioventusIncMember 2021-02-16 0001665988 srt:ScenarioForecastMember bvs:MisonixIncMember 2021-10-01 2021-12-31 0001665988 srt:ScenarioForecastMember bvs:MisonixIncMember 2021-12-31 0001665988 bvs:BioventusIncMember 2021-12-31 0001665988 bvs:BVLLCMember us-gaap:SubsequentEventMember 2021-08-10 2021-08-10 0001665988 bvs:BioventusIncMember us-gaap:SubsequentEventMember 2021-08-10 2021-08-10 0001665988 bvs:BionessIncMember bvs:PaycheckProtectionProgramCARESActMember 2020-12-30 2021-03-29 0001665988 bvs:BionessIncMember bvs:PaycheckProtectionProgramCARESActMaturingApril102022Member 2020-12-30 2021-03-29 0001665988 bvs:BionessIncMember bvs:PaycheckProtectionProgramCARESActMaturingFebruary52026Member 2020-12-30 2021-03-29 0001665988 us-gaap:SecuredDebtMember us-gaap:SubsequentEventMember bvs:TermLoanFacilityMember 2021-07-29 2021-07-29 0001665988 bvs:PaycheckProtectionProgramCARESActMember 2021-03-29 0001665988 us-gaap:SubsequentEventMember bvs:PaycheckProtectionProgramLoanMember bvs:BionessIncMember 2021-07-01 2021-07-31 0001665988 us-gaap:SubsequentEventMember bvs:TermLoanFacilityMember us-gaap:SecuredDebtMember 2021-07-29 0001665988 us-gaap:SubsequentEventMember bvs:A2019CreditAgreementMember us-gaap:SecuredDebtMember 2021-07-29 0001665988 bvs:HarborMember bvs:BioVentusLlcMember 2019-08-23 2019-08-23 0001665988 bvs:HarborMember 2019-08-23 2019-08-23 0001665988 bvs:BioVentusLlcMember us-gaap:VariableInterestEntityPrimaryBeneficiaryMember us-gaap:SeriesCPreferredStockMember bvs:HarborMedtechIncMember 2019-08-23 2019-08-23 0001665988 bvs:ThreeInjectionOAProductMember bvs:BioVentusLlcMember 2016-02-09 2016-02-09 0001665988 bvs:ThreeInjectionOAProductMember 2016-02-09 2016-02-09 0001665988 bvs:HarborMember 2020-12-22 2020-12-22 0001665988 bvs:ThreeInjectionOAProductMember bvs:BioVentusLlcMember 2020-12-22 2020-12-22 0001665988 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-07-03 0001665988 bvs:LimitedLiabilityCompanyInterestsMember 2021-01-01 2021-07-03 0001665988 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-07-03 0001665988 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-07-03 0001665988 bvs:UnvestedClassACommonSharesMember 2021-01-01 2021-07-03 0001665988 country:US 2021-01-01 2021-07-03 0001665988 us-gaap:NonUsMember 2021-01-01 2021-07-03 0001665988 bvs:PainTreatmentsAndJointPreservationMember 2021-01-01 2021-07-03 0001665988 bvs:RestorativeTherapiesMember 2021-01-01 2021-07-03 0001665988 bvs:BoneGraftSubstitutesMember 2021-01-01 2021-07-03 0001665988 bvs:EquityParticipationRightUnitMember 2021-01-01 2021-07-03 0001665988 bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsMember 2021-01-01 2021-07-03 0001665988 bvs:USSegmentMember us-gaap:OperatingSegmentsMember 2021-01-01 2021-07-03 0001665988 bvs:InternationalSegmentMember us-gaap:OperatingSegmentsMember 2021-01-01 2021-07-03 0001665988 us-gaap:MaterialReconcilingItemsMember 2021-01-01 2021-07-03 0001665988 bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsMember 2021-01-01 2021-07-03 0001665988 bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsMember bvs:BVLLCEmployeesTerminatedPriorToIPOMember 2021-01-01 2021-07-03 0001665988 us-gaap:NoncontrollingInterestMember 2021-01-01 2021-07-03 0001665988 bvs:BionessIncMember 2021-01-01 2021-07-03 0001665988 us-gaap:MemberUnitsMember 2021-01-01 2021-07-03 0001665988 us-gaap:InterestRateSwapMember 2021-01-01 2021-07-03 0001665988 us-gaap:PhantomShareUnitsPSUsMember us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-07-03 0001665988 us-gaap:EmployeeStockOptionMember srt:MinimumMember 2021-01-01 2021-07-03 0001665988 us-gaap:EmployeeStockOptionMember srt:MaximumMember 2021-01-01 2021-07-03 0001665988 bvs:BVLLCEmployeesActiveAtIPOMember bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsMember us-gaap:CommonClassAMember 2021-01-01 2021-07-03 0001665988 bvs:SupplierOfSingleInjectionOAProductMember 2021-01-01 2021-07-03 0001665988 us-gaap:IPOMember 2021-01-01 2021-07-03 0001665988 us-gaap:MemberUnitsMember us-gaap:IPOMember 2021-01-01 2021-07-03 0001665988 us-gaap:RetainedEarningsMember 2021-01-01 2021-07-03 0001665988 us-gaap:CommonClassBMember 2021-01-01 2021-07-03 0001665988 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-07-03 0001665988 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2021-01-01 2021-07-03 0001665988 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2021-01-01 2021-07-03 0001665988 us-gaap:CommonStockMember us-gaap:CommonClassBMember 2021-01-01 2021-07-03 0001665988 us-gaap:CommonStockMember bvs:PublicOfferingMember us-gaap:CommonClassAMember 2021-01-01 2021-07-03 0001665988 us-gaap:CommonStockMember us-gaap:IPOMember us-gaap:CommonClassAMember 2021-01-01 2021-07-03 0001665988 us-gaap:AdditionalPaidInCapitalMember bvs:PublicOfferingMember 2021-01-01 2021-07-03 0001665988 bvs:PublicOfferingMember 2021-01-01 2021-07-03 0001665988 us-gaap:AdditionalPaidInCapitalMember us-gaap:IPOMember 2021-01-01 2021-07-03 0001665988 bvs:CartiHealMember 2021-01-01 2021-07-03 0001665988 us-gaap:CommonClassBMember us-gaap:SubsequentEventMember 2021-01-01 2021-07-03 0001665988 us-gaap:CommonClassAMember us-gaap:SubsequentEventMember 2021-01-01 2021-07-03 0001665988 country:US 2020-01-01 2020-06-27 0001665988 us-gaap:NonUsMember 2020-01-01 2020-06-27 0001665988 bvs:PainTreatmentsAndJointPreservationMember 2020-01-01 2020-06-27 0001665988 bvs:RestorativeTherapiesMember 2020-01-01 2020-06-27 0001665988 bvs:BoneGraftSubstitutesMember 2020-01-01 2020-06-27 0001665988 bvs:USSegmentMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-06-27 0001665988 bvs:InternationalSegmentMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-06-27 0001665988 us-gaap:MaterialReconcilingItemsMember 2020-01-01 2020-06-27 0001665988 us-gaap:InterestRateSwapMember 2020-01-01 2020-06-27 0001665988 bvs:SupplierOfSingleInjectionOAProductMember 2020-01-01 2020-06-27 0001665988 us-gaap:MemberUnitsMember 2020-01-01 2020-06-27 0001665988 bvs:BioVentusLlcMember 2021-02-15 0001665988 us-gaap:SubsequentEventMember bvs:BVLLCMember 2021-08-10 0001665988 us-gaap:SubsequentEventMember bvs:BioventusIncMember 2021-08-10 0001665988 bvs:BioventusIncMember 2020-04-01 2020-04-30 0001665988 country:US 2020-03-29 2020-06-27 0001665988 us-gaap:NonUsMember 2020-03-29 2020-06-27 0001665988 bvs:PainTreatmentsAndJointPreservationMember 2020-03-29 2020-06-27 0001665988 bvs:RestorativeTherapiesMember 2020-03-29 2020-06-27 0001665988 bvs:BoneGraftSubstitutesMember 2020-03-29 2020-06-27 0001665988 bvs:USSegmentMember us-gaap:OperatingSegmentsMember 2020-03-29 2020-06-27 0001665988 bvs:InternationalSegmentMember us-gaap:OperatingSegmentsMember 2020-03-29 2020-06-27 0001665988 us-gaap:MaterialReconcilingItemsMember 2020-03-29 2020-06-27 0001665988 us-gaap:InterestRateSwapMember 2020-03-29 2020-06-27 0001665988 bvs:SupplierOfSingleInjectionOAProductMember 2020-03-29 2020-06-27 0001665988 us-gaap:MemberUnitsMember 2020-03-29 2020-06-27 0001665988 bvs:VaporoxMember 2021-06-24 0001665988 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-04-03 0001665988 bvs:ManagementIncentivePlanAwardMember 2021-01-12 2021-02-10 0001665988 us-gaap:PhantomShareUnitsPSUsMember 2021-01-12 2021-02-10 0001665988 bvs:BioventusIncMember 2020-07-01 2021-07-31 0001665988 bvs:BioVentusLlcMember us-gaap:SubsequentEventMember bvs:ConvertibleDebtInstrumentsMember 2021-01-04 2021-01-04 0001665988 bvs:BioVentusLlcMember us-gaap:SubsequentEventMember bvs:NewLlcOwnerMember us-gaap:CommonClassAMember 2021-02-17 2021-02-17 0001665988 bvs:BioVentusLlcMember us-gaap:SubsequentEventMember bvs:NewLlcOwnerMember 2021-02-17 2021-02-17 0001665988 us-gaap:SubsequentEventMember bvs:BioventusIncMember bvs:ContinuingLlcOwnerMember 2021-02-17 2021-02-17 0001665988 bvs:BioventusIncMember us-gaap:SubsequentEventMember 2021-02-17 2021-02-17 0001665988 bvs:BioVentusLlcMember us-gaap:SubsequentEventMember bvs:NewLlcOwnerMember us-gaap:CommonClassAMember 2021-02-17 0001665988 us-gaap:SubsequentEventMember bvs:BioVentusLlcMember bvs:ContinuingLlcOwnerMember 2021-02-17 0001665988 bvs:NewLlcOwnerMember us-gaap:SubsequentEventMember bvs:BioVentusLlcMember 2021-02-17 0001665988 bvs:BioVentusLlcMember bvs:UsaoAndOigMember us-gaap:SubsequentEventMember 2021-02-23 2021-02-23 0001665988 bvs:BioVentusLlcMember bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsMember us-gaap:SubsequentEventMember 2021-02-01 2021-02-28 0001665988 us-gaap:SubsequentEventMember 2021-02-01 2021-02-28 0001665988 us-gaap:CommonClassAMember bvs:A2021PlanMember us-gaap:SubsequentEventMember 2021-02-01 2021-02-28 0001665988 srt:MaximumMember bvs:OptionAndEquityPurchaseAgreementMember us-gaap:SubsequentEventMember 2021-02-01 2021-02-28 0001665988 srt:MaximumMember bvs:RestrictedStockUnitsAgreementMember us-gaap:SubsequentEventMember 2021-02-01 2021-02-28 0001665988 us-gaap:SubsequentEventMember srt:MinimumMember bvs:OptionAndEquityPurchaseAgreementMember 2021-02-01 2021-02-28 0001665988 us-gaap:SubsequentEventMember srt:MinimumMember bvs:RestrictedStockUnitsAgreementMember 2021-02-01 2021-02-28 0001665988 bvs:EquityParticipationRightUnitMember us-gaap:SubsequentEventMember bvs:BioVentusLlcMember 2021-02-01 2021-02-28 0001665988 bvs:BioVentusLlcMember bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsMember us-gaap:SubsequentEventMember 2021-02-28 0001665988 us-gaap:SubsequentEventMember 2021-02-28 0001665988 us-gaap:SubsequentEventMember us-gaap:EmployeeStockMember us-gaap:CommonClassAMember 2021-02-28 0001665988 us-gaap:SubsequentEventMember us-gaap:EmployeeStockMember srt:MaximumMember 2021-02-28 0001665988 us-gaap:SubsequentEventMember us-gaap:EmployeeStockMember 2021-03-22 2021-03-22 0001665988 bvs:BioVentusLlcMember bvs:PromissoryNoteMember us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2020-03-27 0001665988 bvs:BioVentusLlcMember us-gaap:VariableInterestEntityPrimaryBeneficiaryMember bvs:PromissoryNoteMember 2020-03-27 2020-03-27 0001665988 bvs:BioVentusLlcMember bvs:PromissoryNoteMember bvs:HarborSeriesCPreferredStockMember us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2020-03-27 2020-03-27 0001665988 bvs:BioVentusLlcMember bvs:PromissoryNoteMember bvs:HarborCommonStockMember 2020-03-27 2020-03-27 0001665988 bvs:BioVentusLlcMember bvs:PromissoryNoteMember us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2020-11-30 0001665988 bvs:BioVentusLlcMember bvs:PromissoryNoteMember us-gaap:VariableInterestEntityPrimaryBeneficiaryMember bvs:HarborSeriesCPreferredStockMember 2020-11-30 0001665988 bvs:BioVentusLlcMember bvs:PromissoryNoteMember us-gaap:VariableInterestEntityPrimaryBeneficiaryMember bvs:HarborSeriesCPreferredStockMember 2020-11-30 2020-11-30 0001665988 bvs:BioVentusLlcMember bvs:HarborSeriesCPreferredStockMember us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2020-10-05 2020-10-05 0001665988 bvs:BioVentusLlcMember bvs:CartiHealLtdMember 2018-01-30 0001665988 bvs:BioVentusLlcMember bvs:CartiHealLtdMember bvs:SeriesFConvertiblePreferredStockMember 2018-01-30 2018-01-30 0001665988 bvs:BioVentusLlcMember bvs:CartiHealLtdMember bvs:SimpleAgreementForFutureEquityMember 2020-01-22 2020-01-22 0001665988 bvs:BioVentusLlcMember bvs:CartiHealLtdMember bvs:SeriesG1PreferredStockMember 2020-07-15 2020-07-15 0001665988 bvs:BioVentusLlcMember bvs:CartiHealLtdMember bvs:OptionAndEquityPurchaseAgreementMember 2020-07-15 2020-07-15 0001665988 bvs:BioVentusLlcMember bvs:CartiHealLtdMember bvs:OptionAndEquityPurchaseAgreementMember us-gaap:SeriesGPreferredStockMember 2020-07-15 0001665988 bvs:BioVentusLlcMember bvs:CartiHealLtdMember 2020-07-15 0001665988 bvs:BioVentusLlcMember bvs:CartiHealLtdMember 2020-01-31 0001665988 bvs:BioVentusLlcMember 2012-05-01 2012-05-31 0001665988 bvs:TwoThousandAndTwelvePreferredUnitsMember bvs:BioVentusLlcMember 2012-05-01 2012-05-31 0001665988 bvs:TwoThousandAndFifteenPreferredUnitsMember bvs:BioVentusLlcMember 2015-11-01 2015-11-30 0001665988 bvs:BioVentusLlcMember bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsMember 2020-06-30 0001665988 bvs:BioVentusLlcMember bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsMember 2020-06-01 2020-06-30 0001665988 bvs:BioVentusLlcMember bvs:TwoThousandNineteenCreditAgreementMember 2019-12-06 0001665988 bvs:BioVentusLlcMember bvs:TwoThousandNineteenCreditAgreementMember bvs:TermLoanMember 2019-12-06 0001665988 bvs:BioVentusLlcMember bvs:TwoThousandNineteenCreditAgreementMember us-gaap:RevolvingCreditFacilityMember 2019-12-06 0001665988 us-gaap:RevolvingCreditFacilityMember bvs:TwoThousandNineteenCreditAgreementMember us-gaap:LetterOfCreditMember bvs:BioVentusLlcMember 2019-12-06 0001665988 us-gaap:EurodollarMember bvs:TwoThousandNineteenCreditAgreementMember bvs:BrInterestRateBasisMember bvs:BioVentusLlcMember 2019-12-06 0001665988 bvs:BioVentusLlcMember 2019-12-06 0001665988 bvs:BioVentusLlcMember bvs:TwoThousandNineteenCreditAgreementMember 2019-12-06 2019-12-06 0001665988 us-gaap:EurodollarMember bvs:TwoThousandNineteenCreditAgreementMember bvs:BioVentusLlcMember 2019-12-06 2019-12-06 0001665988 us-gaap:BaseRateMember bvs:TwoThousandNineteenCreditAgreementMember bvs:BioVentusLlcMember 2019-12-06 2019-12-06 0001665988 bvs:TwoThousandNineteenCreditAgreementMember us-gaap:RevolvingCreditFacilityMember bvs:BioVentusLlcMember 2019-12-06 2019-12-06 0001665988 bvs:TwoThousandNineteenCreditAgreementMember us-gaap:RevolvingCreditFacilityMember bvs:SwingLineCreditFacilityMember srt:MinimumMember bvs:BioVentusLlcMember 2019-12-06 2019-12-06 0001665988 bvs:BioVentusLlcMember 2019-12-06 2019-12-06 0001665988 bvs:TwoThousandNineteenCreditAgreementMember us-gaap:RevolvingCreditFacilityMember bvs:SwingLineCreditFacilityMember bvs:BioVentusLlcMember 2019-12-06 2019-12-06 0001665988 bvs:TermLoanMember bvs:TwoThousandNineteenCreditAgreementMember bvs:BrInterestRateBasisMember bvs:BioVentusLlcMember 2019-12-06 2019-12-06 0001665988 us-gaap:RevolvingCreditFacilityMember bvs:TwoThousandNineteenCreditAgreementMember bvs:BioVentusLlcMember 2020-07-01 2020-09-30 0001665988 bvs:BioVentusLlcMember 2021-02-10 0001665988 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-04-03 0001665988 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2021-04-03 0001665988 us-gaap:AdditionalPaidInCapitalMember 2021-04-03 0001665988 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2021-04-03 0001665988 us-gaap:RetainedEarningsMember 2021-04-03 0001665988 us-gaap:NoncontrollingInterestMember 2021-04-03 0001665988 us-gaap:RestrictedStockUnitsRSUMember 2021-07-03 0001665988 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-07-03 0001665988 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2021-07-03 0001665988 us-gaap:AdditionalPaidInCapitalMember 2021-07-03 0001665988 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2021-07-03 0001665988 us-gaap:RetainedEarningsMember 2021-07-03 0001665988 us-gaap:NoncontrollingInterestMember 2021-07-03 0001665988 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember bvs:BioVentusLlcMember 2020-12-31 0001665988 us-gaap:RetainedEarningsMember bvs:BioVentusLlcMember 2020-12-31 0001665988 us-gaap:NoncontrollingInterestMember bvs:BioVentusLlcMember 2020-12-31 0001665988 bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsMember bvs:BioVentusLlcMember 2020-12-31 0001665988 bvs:BioVentusLlcMember bvs:EmployeeSeveranceAndTemporaryLaborCostsMember 2020-12-31 0001665988 bvs:BioVentusLlcMember bvs:OtherChargesMember 2020-12-31 0001665988 bvs:BioVentusLlcMember bvs:TwoThousandAndTwelveMember 2019-12-31 0001665988 bvs:BioVentusLlcMember bvs:TwoThousandAndFifteenMember 2019-12-31 0001665988 us-gaap:MemberUnitsMember bvs:BioVentusLlcMember 2020-12-31 0001665988 bvs:BioventusIncMember 2018-12-31 0001665988 bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsMember bvs:BioVentusLlcMember 2018-12-31 0001665988 bvs:EquityParticipationRightUnitMember bvs:BioVentusLlcMember 2018-12-31 0001665988 us-gaap:MemberUnitsMember 2018-12-31 0001665988 bvs:EquityParticipationRightUnitMember bvs:BioVentusLlcMember 2019-12-31 0001665988 bvs:BioVentusLlcMember 2018-12-31 0001665988 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember bvs:BioVentusLlcMember 2019-12-31 0001665988 us-gaap:RetainedEarningsMember bvs:BioVentusLlcMember 2019-12-31 0001665988 us-gaap:NoncontrollingInterestMember bvs:BioVentusLlcMember 2019-12-31 0001665988 bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsMember bvs:BioVentusLlcMember 2019-12-31 0001665988 bvs:BioVentusLlcMember bvs:EmployeeSeveranceAndTemporaryLaborCostsMember 2018-12-31 0001665988 bvs:BioVentusLlcMember bvs:OtherChargesMember 2018-12-31 0001665988 bvs:BioVentusLlcMember bvs:EmployeeSeveranceAndTemporaryLaborCostsMember 2019-12-31 0001665988 bvs:BioVentusLlcMember bvs:OtherChargesMember 2019-12-31 0001665988 bvs:BioVentusLlcMember bvs:TwoThousandAndTwelveMember bvs:OtherPhantomUnitMember 2018-12-31 0001665988 bvs:BioVentusLlcMember bvs:TwoThousandAndFifteenMember bvs:OtherPhantomUnitMember 2018-12-31 0001665988 bvs:BioVentusLlcMember bvs:TwoThousandAndTwelveMember bvs:OtherPhantomUnitMember 2019-12-31 0001665988 bvs:BioVentusLlcMember bvs:TwoThousandAndFifteenMember bvs:OtherPhantomUnitMember 2019-12-31 0001665988 us-gaap:MemberUnitsMember bvs:BioVentusLlcMember 2019-12-31 0001665988 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember bvs:BioVentusLlcMember 2017-12-31 0001665988 us-gaap:RetainedEarningsMember bvs:BioVentusLlcMember 2017-12-31 0001665988 us-gaap:NoncontrollingInterestMember bvs:BioVentusLlcMember 2017-12-31 0001665988 bvs:BioVentusLlcMember 2017-12-31 0001665988 us-gaap:MemberUnitsMember bvs:BioVentusLlcMember 2017-12-31 0001665988 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember bvs:BioVentusLlcMember 2018-12-31 0001665988 us-gaap:RetainedEarningsMember bvs:BioVentusLlcMember 2018-12-31 0001665988 us-gaap:MemberUnitsMember bvs:BioVentusLlcMember 2018-12-31 0001665988 bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsMember 2020-12-31 0001665988 bvs:EquityParticipationRightUnitMember 2020-12-31 0001665988 us-gaap:MemberUnitsMember 2020-12-31 0001665988 bvs:EquityParticipationRightUnitMember 2021-07-03 0001665988 bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsMember 2021-07-03 0001665988 us-gaap:MemberUnitsMember 2020-06-27 0001665988 us-gaap:MemberUnitsMember 2020-03-28 0001665988 us-gaap:RestrictedStockUnitsRSUMember 2020-12-31 0001665988 us-gaap:RestrictedStockUnitsRSUMember 2021-04-03 iso4217:USD xbrli:shares xbrli:pure utr:Year utr:Month utr:Day iso4217:USD xbrli:shares bvs:EMPLOYEE bvs:employee bvs:Plan bvs:Segment bvs:Business bvs:Loans bvs:Vote bvs:Entities
Table of Contents
As filed with the U.S. Securities and Exchange Commission on September 22, 2021
Registration
No. 333-259392
 
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Amendment No. 1
to
FORM
S-4
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
 
BIOVENTUS INC.
(Exact Name of Registrant as Specified in Its Charter)
 
 
Delaware
 
3841
 
94-0980861
(State of Incorporation)
 
(Primary Standard Industrial
Classification Code Number)
 
(IRS Employer
Identification No.)
4721 Emperor Boulevard, Suite 400
Durham, North Carolina 27703
(919)
474-6700
(Address, including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive Offices)
 
Kenneth M. Reali
Chief Executive Officer
Bioventus Inc.
4721 Emperor Boulevard, Suite 400
Durham, North Carolina 27703
(919) 474-6700
(Name, Address, including Zip Code, and Telephone Number, including Area Code, of Agent for Service)
 
Copies to:
 
Wesley Holmes
Mark Bekheit
Latham & Watkins LLP
140 Scott Drive
Menlo Park, California 94025
(650)
328-4600
 
Jonn R. Beeson, Esq.
Jones Day
3161 Michelson Drive, Suite 800
Irvine, California 92612
(949)
553-7528
 
Approximate date of commencement of proposed sale of the securities to the public:
As soon as practicable after this registration statement is declared effective.
If the securities being registered on this form are being offered in connection with the formation of a holding company and there is compliance with General Instruction G, please check the following box.  ☐
If this form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act of 1933, as amended (the “Securities Act”), check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  ☐
If this form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
non-accelerated
filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule
12b-2
of the Exchange Act.
 
Large accelerated filer      Accelerated filer  
       
Non-accelerated
filer
     Smaller reporting company  
       
         Emerging growth company  
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  
If applicable, place an X in the box to designate the appropriate rule provision relied upon in conducting this transaction:
Exchange Act Rule 13e-4(i) (Cross-Border Issuer Tender Offer)  ☐
Exchange Act Rule 14d-1(d) (Cross-Border Third-Party Tender Offer)  ☐
 
CALCULATION OF REGISTRATION FEE
 
 
Title of each class of
securities to be registered
 
Amount
to be
registered
(1)
 
Proposed
maximum
offering price
per share
(2)
 
Proposed
maximum
aggregate
offering price
(2)
 
Amount of
registration fee
(3)
Class A Common Stock, $0.001 par value per share
 
18,322,984
 
$25.95
 
$268,985,195.25
 
$29,346.28
(4)
 
 
(1)
The number of shares of class A common stock, par value $0.001 per share (“Bioventus class A common stock”), of the registrant, Bioventus Inc. (“Bioventus”), being registered is based upon the estimated maximum number of shares of Bioventus class A common stock issuable upon completion of the merger of Oyster Merger Sub I, Inc., a wholly owned subsidiary of Bioventus (“Merger Sub I”), with and into Misonix, Inc. (“Misonix”), with Misonix as the surviving corporation, described in the joint proxy statement/prospectus contained herein, and is calculated by assuming that the stock election consideration is oversubscribed by holders of Misonix common stock, which results in proration of the stock election consideration based on the maximum cash amount.
(2)
Estimated solely for purposes of calculating the registration fee required by Section 6(b) of the Securities Act of 1933, as amended (the “Securities Act”), and calculated in accordance with Rules 457(c), 457(f)(1) and 457(f)(3) promulgated thereunder. The proposed maximum aggregate offering price is solely for the purposes of calculating the registration fee and was calculated based upon the market value of shares of Misonix common stock (the securities to be cancelled in the merger) in accordance with Rule 457(c) under the Securities Act as follows: (a) the product of (i) $25.95, the average of the high and low prices per share of Misonix common stock on September 7, 2021, as quoted on the Nasdaq Global Market, and (ii) 17,410,045, the estimated number of shares of Misonix common stock estimated to be outstanding immediately prior to the merger based on the number of shares presently outstanding, minus (b) $182,805,472.50, which is the estimated maximum amount of cash consideration to be delivered in the merger based on the number of shares of Misonix common stock presently outstanding.
(3)
Calculated pursuant to Section 6(b) of the Securities Act at a rate equal to $109.10 per $1,000,000 of the proposed maximum aggregate offering price.
(4)
Paid in connection with the initial filing of this registration statement.
The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act or until the registration statement shall become effective on such date as the U.S. Securities and Exchange Commission, acting pursuant to said section 8(a), may determine.
 
 
 

Table of Contents
The information in this joint proxy statement/prospectus is not complete and may be changed. A registration statement relating to the securities described in this joint proxy statement/prospectus has been filed with the U.S. Securities and Exchange Commission. These securities may not be issued or sold until the registration statement filed with the U.S. Securities and Exchange Commission is effective. This joint proxy statement/prospectus does not constitute an offer to sell or the solicitation of offers to buy these securities in any jurisdiction where the offer or sale is not permitted.
 
PRELIMINARY—SUBJECT TO COMPLETION, DATED SEPTEMBER 22, 2021
 
  
MERGER PROPOSAL—YOUR VOTE IS VERY IMPORTANT
Dear Bioventus Stockholders and Misonix Stockholders:
On July 29, 2021, Bioventus Inc., which is referred to as “Bioventus,” Oyster Merger Sub I, Inc., a wholly owned subsidiary of Bioventus, which is referred to as “Merger Sub I,” Oyster Merger Sub II, LLC, a wholly owned subsidiary of Bioventus, which is referred to as “Merger Sub II,” and Misonix, Inc., which is referred to as “Misonix,” entered into an Agreement and Plan of Merger, as it may be amended from time to time, which is referred to as the “merger agreement,” that provides for the acquisition of Misonix by Bioventus. Upon the terms and subject to the conditions of the merger agreement, Bioventus will acquire Misonix through a merger of Merger Sub I with and into Misonix, with Misonix continuing as the surviving corporation, which is referred to as the “first merger,” followed by a merger of Misonix with and into Merger Sub II, with Merger Sub II continuing as the surviving entity and a wholly owned subsidiary of Bioventus, which is referred to as the “second merger” and, together with the first merger is referred to as the “mergers.” The combined company created by the mergers will be named Bioventus Inc.
Upon the successful completion of the mergers, each issued and outstanding share of Misonix common stock (other than treasury shares of Misonix, shares held by a subsidiary of Misonix, Bioventus or Merger Sub I, and shares held by Misonix stockholders who have not voted in favor of the Misonix merger proposal and perfected and not withdrawn a demand for appraisal rights pursuant to Delaware law) will be converted into the right to receive either an amount in cash equal to $28.00 or 1.6839 validly issued, fully paid and
non-assessable
shares of Bioventus class A common stock, based on the election of the holder thereof and subject to automatic proration and adjustment in accordance with the terms of the merger agreement, as described below and in the accompanying joint proxy statement/prospectus. Bioventus stockholders will continue to own their existing shares of Bioventus common stock. The exchange ratio is fixed and will not be adjusted for changes in the market price of either Bioventus class A common stock or Misonix common stock between the date of signing of the merger agreement and the completion date of the first merger. As such, the market value of the merger consideration payable to Misonix stockholders will fluctuate with the market price of the Bioventus class A common stock and will not be known at the time that Misonix stockholders vote on the merger agreement. Upon completion of the mergers, former Misonix stockholders are expected to own approximately 25% of the outstanding shares of Bioventus common stock and Bioventus stockholders immediately prior to the mergers are expected to own approximately 75% of the outstanding shares of Bioventus common stock. Bioventus class A common stock is traded on the Nasdaq Global Select Market, which is referred to as “Nasdaq,” under the symbol “BVS.” Misonix common stock is traded on Nasdaq under the symbol “MSON.” We encourage you to obtain current quotes for both the Bioventus class A common stock and the Misonix common stock before voting at the special meetings of stockholders described below.
The aggregate amount of cash payable by Bioventus in the mergers will be equal to $10.50 multiplied by the number of outstanding shares of Misonix common stock at 5:00 p.m., New York City time, on the election deadline. If the aggregate amount of cash that holders of Misonix common stock elect to receive exceeds the available cash amount, the number of shares of Misonix common stock as to which the holder elected to receive cash consideration will be reduced on a pro rata basis and each such share will be paid $28.00 per share in cash, and the remainder of such shares of Misonix common stock as to which a cash election was made will be paid 1.6839 shares of Bioventus class A common stock. In such case, for each share of Misonix common stock as to which the holder elected to receive the stock consideration or made no election, the holder will receive 1.6839 shares of Bioventus common stock. If the aggregate amount of cash that holders of Misonix common stock elect to receive is less than the available cash amount, each share of Misonix common stock as to which the holder elected to receive cash consideration will receive $28.00 per share in cash. In such case, the remaining excess cash consideration will be first paid at a rate of $28.00 for each share of Misonix common stock as to which the holder made no election (with such cash being distributed on a pro rata basis based on the number of shares for

Table of Contents
which no election was made if the number of such shares multiplied by $28.00 is less than the remaining cash to be paid), and thereafter (to the extent any excess cash consideration remains) at a rate of $28.00 per share in cash to the shares of Misonix common stock as to which the holder elected to receive the stock consideration on a pro rata basis based on the amount of cash remaining to be paid, if any. The balance of the shares of Misonix common stock will receive 1.6839 shares of Bioventus class A common stock.
While the value of merger consideration to be received by a specific holder of Misonix common stock will depend on whether they elect to receive the cash consideration, elect to receive the stock consideration, or make no election, if all Misonix stockholders elect to receive the cash consideration (or if all Misonix stockholders elect to receive the stock consideration), each holder of Misonix common stock would receive, on an aggregate basis, $10.50 in cash and 1.0524 shares of Bioventus class A common stock for each share of Misonix common stock that they own. Based on the Bioventus class A common stock price of $ $16.63 per share, which is the average of the daily volume weighted average price per share for the seven consecutive trading day period up to and including July 27, 2021, two trading days prior to the entry by Bioventus and Misonix into the merger agreement, the implied value of the merger consideration to Misonix stockholders (assuming all Misonix stockholders elect to receive the cash consideration or all Misonix stockholders elect to receive the stock consideration), was $28.00 per share of Misonix common stock. On September 1, 2021, the latest practicable trading day before the date of the filing of this joint proxy statement/prospectus, the closing price of Bioventus class A common stock on Nasdaq was $14.98 per share, resulting in the implied value of the merger consideration to Misonix stockholders (assuming all Misonix stockholders elect to receive the cash consideration or all Misonix stockholders elect to receive the stock consideration), was $26.27 per share of Misonix common stock. The value of the merger consideration to Misonix stockholders will continue to fluctuate with the value of Bioventus class A common stock until the completion of the mergers.
Bioventus and Misonix will each hold special meetings of their respective stockholders to vote on the proposals necessary to complete the mergers. Such special meetings are referred to as the “Bioventus special meeting” and the “Misonix special meeting,” respectively.
At the Bioventus special meeting, Bioventus stockholders will be asked to consider and vote on (i) a proposal to approve the issuance of shares of Bioventus class A common stock to Misonix stockholders in connection with the first merger, which proposal is referred to as the “Bioventus share issuance proposal,” and (ii) a proposal to adjourn the Bioventus special meeting to solicit additional proxies if there are insufficient votes to approve the Bioventus share issuance proposal or to ensure that any supplement or amendment to this joint proxy statement/prospectus is timely provided to Bioventus stockholders.
The Bioventus board unanimously recommends that Bioventus stockholders vote “FOR” each of the proposals to be considered at the Bioventus special meeting.
At the Misonix special meeting, Misonix stockholders will be asked to consider and vote on (i) a proposal to adopt the merger agreement, which proposal is referred to as the “Misonix merger proposal,” (ii) a proposal to approve, on a
non-binding
advisory basis, the compensation that may be paid or become payable to Misonix named executive officers that is based on or otherwise relates to the transactions contemplated by the merger agreement and (iii) a proposal to adjourn the Misonix special meeting to solicit additional proxies, if necessary or appropriate, if there are insufficient votes to approve the Misonix merger proposal or to ensure that any supplement or amendment to this joint proxy statement/prospectus is timely provided to Misonix stockholders.
The Misonix board unanimously recommends that Misonix stockholders vote “FOR” each of the proposals to be considered at the Misonix special meeting.
We cannot complete the mergers unless the Bioventus share issuance proposal is approved by Bioventus stockholders and the Misonix merger proposal is approved by Misonix stockholders.
Your vote on these matters is very important, regardless of the number of shares you own. Whether or not you plan to attend your company’s respective special meeting, please vote by proxy over the internet or telephone using the instructions included with the accompanying proxy card, or promptly complete your proxy card and return it in the enclosed postage-paid envelope, in order to authorize the individuals named on your proxy card to vote your shares at the applicable special meeting.

Table of Contents
The accompanying joint proxy statement/prospectus provides you with important information about the special meetings, the mergers and each of the proposals. We encourage you to read the entire document carefully, in particular the information under “Risk Factors” beginning on page 39 for a discussion of risks relevant to the mergers.
We look forward to the successful completion of the mergers.
Sincerely,
 
Ken Reali
Chief Executive Officer
Biovenuts Inc.
  
Stavros Vizirgianakis
Chief Executive Officer
Misonix, Inc.
* * * * *
Neither the U.S. Securities and Exchange Commission nor any state securities commission has approved or disapproved of the mergers, the adoption of the merger agreement, the Bioventus class A common stock to be issued in the first merger or any of the other transactions described in the accompanying joint proxy statement/prospectus or determined if the accompanying joint proxy statement/prospectus is accurate or complete. Any representation to the contrary is a criminal offense.
The accompanying joint proxy statement/prospectus is dated as of, and is first being mailed to Bioventus and Misonix stockholders on or about, [●], 2021.

Table of Contents
4721 Emperor Boulevard, Suite 400
Durham, North Carolina 27703
(919)
474-6700
NOTICE OF SPECIAL MEETING OF STOCKHOLDERS
TO BE HELD ON [
], 2021
To the Stockholders of Bioventus Inc.:
Notice is hereby given that Bioventus Inc., which is referred to as “Bioventus,” will hold a special meeting of its stockholders, which is referred to as the “Bioventus special meeting,” virtually via live webcast on [●], 2021, beginning at [●], Eastern Time.
In light of ongoing developments related to the
COVID-19
pandemic, the Bioventus special meeting will be held solely in a virtual meeting format via live webcast. You will be able to virtually attend and vote at the Bioventus special meeting by visiting www.virtualshareholdermeeting.com/BVS2021SM, which is referred to as the “Bioventus special meeting website.”
The Bioventus special meeting will be held for the purpose of Bioventus stockholders considering and voting on the following proposals:
 
  1.
to approve the issuance of shares of Bioventus class A common stock to the stockholders of Misonix, Inc., which is referred to as “Misonix,” in connection with the merger contemplated by the Agreement and Plan of Merger, dated July 29, 2021, as it may be amended from time to time, which is referred to as the “merger agreement,” by and among Bioventus, Oyster Merger Sub I, Inc., a wholly owned subsidiary of Bioventus, Oyster Merger Sub II, LLC, a wholly owned subsidiary of Bioventus and Misonix, which issuance is referred to as the “share issuance” and which proposal is referred to as the “Bioventus share issuance proposal”; and
 
  2.
to approve the adjournment of the Bioventus special meeting, if necessary or appropriate, to solicit additional proxies if there are insufficient votes at the time of the Bioventus special meeting to approve the Bioventus share issuance proposal or to ensure that any supplement or amendment to the accompanying joint proxy statement/prospectus is timely provided to Bioventus stockholders, which proposal is referred to as the “Bioventus adjournment proposal.”
Bioventus will transact no other business at the Bioventus special meeting except such business as may properly be brought before the Bioventus special meeting or any adjournment or postponement thereof. The accompanying joint proxy statement/prospectus, including the merger agreement attached as
Annex
 A
thereto, contains further information relating to these matters.
Only holders of record of Bioventus common stock at the close of business on [●], 2021, the record date for voting at the Bioventus special meeting, which is referred to as the “Bioventus record date,” are entitled to notice of and to vote at the Bioventus special meeting and any adjournments or postponements thereof.
The Bioventus board has unanimously determined that the terms of the merger agreement and the merger are fair to and in the best interests of Bioventus and its stockholders, and has approved and declared advisable the merger agreement and the transactions contemplated thereby, including the merger and the share issuance.
Accordingly, the Bioventus board unanimously recommends that Bioventus stockholders vote:
 
 
 
“FOR” the Bioventus share issuance proposal; and
 
 
 
“FOR” the Bioventus adjournment proposal.

Table of Contents
Your vote is very important, regardless of the number of shares of Bioventus common stock you own.
The parties cannot complete the merger unless the Bioventus share issuance proposal is approved by Bioventus stockholders. Assuming a quorum is present at the Bioventus special meeting, approval of the Bioventus share issuance proposal requires the affirmative vote of the holders of a majority in voting power of the votes cast on the Bioventus share issuance proposal.
Your vote is important. Whether or not you plan to virtually attend the Bioventus special meeting, please vote by proxy over the internet or telephone using the instructions included with the accompanying proxy card, or promptly complete your proxy card and return it in the enclosed postage-paid envelope, in order to authorize the individuals named on your proxy card to vote your shares of Bioventus common stock at the Bioventus special meeting. If you hold your shares through a broker, bank or other nominee in “street name” (instead of as a registered holder) please follow the instructions on the voting instruction form provided by your bank, broker or nominee to vote your shares. The list of Bioventus stockholders entitled to vote at the Bioventus special meeting will be available at Bioventus’ headquarters during regular business hours for examination by any Bioventus stockholder for any purpose germane to the Bioventus special meeting for a period of at least ten days prior to the Bioventus special meeting. If you would like to examine the list of Bioventus stockholders of record, please contact Bioventus’ Corporate Secretary at tony.dadamio@bioventus.com.com to schedule an appointment or request access. If Bioventus’ headquarters are closed for health and safety reasons related to the
COVID-19
pandemic during such period, the list of stockholders will be made available for examination electronically upon request to Bioventus’ Corporate Secretary, subject to satisfactory verification of stockholder status. The list of Bioventus stockholders entitled to vote at the Bioventus special meeting will also be available for examination by any Bioventus stockholder during the Bioventus special meeting via the Bioventus special meeting website.
If you have any questions about the transactions, please contact Bioventus at (919)
474-6700
or write to Bioventus Inc., Attn: Corporate Secretary, at tony.dadamio@bioventus.com.com.
By Order of the Board of Directors,
William A. Hawkins III
Chairperson
Bioventus Inc.
Durham, North Carolina
Dated: [●], 2021

Table of Contents
1938 New Highway
Farmingdale, New York 11735
(631)
694-9555
NOTICE OF SPECIAL MEETING OF STOCKHOLDERS
TO BE HELD ON [
], 2021
To the Stockholders of Misonix, Inc.:
Notice is hereby given that Misonix, Inc., which is referred to as “Misonix,” will hold a special meeting of its stockholders, which is referred to as the “Misonix special meeting,” at Misonix’s corporate offices, located at 1938 New Highway, Farmingdale, NY 11735 on [●], 2021, beginning at [●], Eastern Time.
As part of Misonix’s precautions regarding the novel coronavirus or
COVID-19,
Misonix is planning for the possibility that the meeting may be held solely by means of remote communications. If Misonix takes this step, Misonix will announce the decision to do so in advance, and details on how to participate, including details on how to inspect a list of stockholders of record, will be posted on our website at www.misonix.com and filed with the SEC as proxy material.
The Misonix special meeting will be held for the purpose of Misonix stockholders considering and voting on the following proposals:
 
  1.
to adopt the Agreement and Plan of Merger, dated July 29, 2021, as it may be amended from time to time, which is referred to as the “merger agreement,” by and among Bioventus Inc. (which is referred to as “Bioventus”), Oyster Merger Sub I, Inc., a wholly owned subsidiary of Bioventus, Oyster Merger Sub II, LLC, a wholly owned subsidiary of Bioventus, and Misonix, a copy of which is attached as
Annex A
to the accompanying joint proxy statement/prospectus and which proposal is referred to as the “Misonix merger proposal”;
 
  2.
to approve, on a
non-binding
advisory basis, the compensation that may be paid or become payable to Misonix named executive officers that is based on or otherwise relates to the transactions contemplated by the merger agreement, which proposal is referred to as the “Misonix compensation proposal”; and
 
  3.
to approve the adjournment of the Misonix special meeting, if necessary or appropriate, to solicit additional proxies if there are insufficient votes at the time of the Misonix special meeting to approve the Misonix merger proposal or to ensure that any supplement or amendment to the accompanying joint proxy statement/prospectus is timely provided to Misonix stockholders, which proposal is referred to as the “Misonix adjournment proposal.”
Misonix will transact no other business at the Misonix special meeting except such business as may properly be brought before the Misonix special meeting or any adjournment or postponement thereof. The accompanying joint proxy statement/prospectus, including the merger agreement attached as
Annex
 A
thereto, contains further information relating to these matters.
Only holders of record of Misonix common stock at the close of business on [●], 2021, the record date for voting at the Misonix special meeting, which is referred to as the “Misonix record date,” are entitled to notice of and to vote at the Misonix special meeting and any adjournments or postponements thereof.
The Misonix board has unanimously determined that the terms of the merger agreement and the merger are fair to and in the best interests of Misonix and its stockholders, and has approved and declared advisable the merger agreement and the transactions contemplated thereby, including the mergers.
Accordingly, the Misonix board unanimously recommends that Misonix stockholders vote:
 
 
 
“FOR” the Misonix merger proposal;

Table of Contents
 
 
“FOR” the Misonix compensation proposal; and
 
 
 
“FOR” the Misonix adjournment proposal.
Your vote is very important, regardless of the number of shares of Misonix common stock you own.
The parties cannot complete the merger unless the Misonix merger proposal is approved by Misonix stockholders. Assuming a quorum is present at the Misonix special meeting, approval of the Misonix merger proposal requires the affirmative vote of the holders of a majority of the issued and outstanding shares of Misonix common stock.
Your vote is important. Whether or not you plan to attend the Misonix special meeting, please vote your shares of Misonix common stock either electronically over the Internet, by telephone, or by completing and returning the accompanying proxy card. Voting instructions are provided in the accompanying joint proxy statement/prospectus and in the Notice of Internet Availability of Proxy Materials. By submitting your proxy promptly, you will save us the expense of further proxy solicitation. We encourage you to submit your proxy as soon as possible by Internet, by telephone or by signing, dating and returning the accompanying proxy cards provided.
If you have any questions about the transactions, please contact Misonix at misonixproxy@misonix.com or write to Misonix, Inc., Attn: Secretary, at our principal executive offices at 1938 New Highway, Farmingdale, New York 11735.
If you have any questions about how to vote or direct a vote in respect of your shares of Misonix common stock, please contact, MacKenzie Partners, Inc., Misonix’s proxy solicitor, by telephone toll-free at
1-800-322-2885,
Monday through Friday (except bank holidays), between 8:00 a.m. and 8:00 p.m., Eastern time, or by email at proxy@mackenziepartners.com.
By Order of the Board of Directors,
Joseph P. Dwyer
Secretary
Misonix, Inc.
Farmingdale, New York
Dated: [●], 2021

Table of Contents
REFERENCES TO ADDITIONAL INFORMATION
This joint proxy statement/prospectus incorporates important business and financial information about Bioventus and Misonix from other documents that Bioventus and Misonix have filed with the SEC and that are not contained in and are instead incorporated by reference in this joint proxy statement/prospectus. For a list of documents incorporated by reference in this joint proxy statement/prospectus, see “Where You Can Find More Information.” This information is available for you, without charge, to review through the SEC’s website at www.sec.gov.
You may request a copy of this joint proxy statement/prospectus, any of the documents incorporated by reference in this joint proxy statement/prospectus or other information filed with the SEC by Bioventus or Misonix, without charge, by written or telephonic request directed to the appropriate company at the following contacts:
 
For Bioventus stockholders:
  
For Misonix stockholders:
Bioventus Inc.
Attention: Corporate Secretary
tony.dadamio@bioventus.com
(919)
474-6700
  
Misonix, Inc.
Attention: Secretary
misonixproxy@misonix.com
(631)
694-9555
In order for you to receive timely delivery of the documents in advance of the special meeting of Bioventus stockholders to be held on [
], 2021, which is referred to as the “Bioventus special meeting,” or the special meeting of Misonix stockholders to be held on [
], 2021, which is referred to as the “Misonix special meeting,” as applicable, you must request the information no later than [
], 2021.
If you have any questions about the Misonix special meeting, or need to obtain proxy cards or other information, please contact MacKenzie Partners, Inc., Misonix’s proxy solicitor, by telephone toll-free at
1-800-322-2885,
or for banks and brokers, collect at (212)
929-5500,
Monday through Friday (except bank holidays), between 8:00 a.m. and 8:00 p.m., Eastern time, or by email at proxy@mackenziepartners.com.
 
 
The contents of the websites of the SEC, Bioventus, Misonix or any other entity are not incorporated in this joint proxy statement/prospectus.
The information about how you can obtain certain documents that are incorporated by reference in this joint proxy statement/prospectus at these websites is being provided only for your convenience.

Table of Contents
ABOUT THIS JOINT PROXY STATEMENT/PROSPECTUS
This joint proxy statement/prospectus, which forms part of a registration statement on Form
S-4
filed with the SEC by Bioventus, constitutes a prospectus of Bioventus under Section 5 of the Securities Act with respect to the shares of Bioventus class A common stock to be issued to Misonix stockholders pursuant to the Agreement and Plan of Merger, dated July 29, 2021, as it may be amended from time to time, by and among Bioventus, Merger Sub I, Merger Sub II and Misonix, which is referred to as the “merger agreement.” This document also constitutes a proxy statement of each of Bioventus and Misonix under Section 14(a) of the Exchange Act. This joint proxy statement/prospectus also constitutes a notice of meeting with respect to each of the Bioventus and Misonix special meetings.
Bioventus has supplied all information contained or incorporated by reference in this joint proxy statement/prospectus relating to Bioventus, Merger Sub I and Merger Sub II, and Misonix has supplied all such information relating to Misonix. Bioventus and Misonix have both contributed to such information relating to the mergers.
You should rely only on the information contained or incorporated by reference in this joint proxy statement/prospectus. Bioventus and Misonix have not authorized anyone to provide you with information that is different from that contained or incorporated by reference in this joint proxy statement/prospectus. This joint proxy statement/prospectus is dated [●], 2021, and you should not assume that the information contained in this joint proxy statement/prospectus is accurate as of any date other than such date unless otherwise specifically provided herein.
Further, you should not assume that the information incorporated by reference in this joint proxy statement/prospectus is accurate as of any date other than the date of the incorporated document. Neither the mailing of this joint proxy statement/prospectus to Bioventus or Misonix stockholders nor the issuance by Bioventus of shares of Bioventus class A common stock pursuant to the merger agreement will create any implication to the contrary.
This joint proxy statement/prospectus does not constitute an offer to sell, or a solicitation of an offer to buy, any securities, or the solicitation of a proxy, in any jurisdiction to or from any person to whom it is unlawful to make any such offer or solicitation in such jurisdiction.
Unless otherwise indicated or the context otherwise requires, when used in this joint proxy statement/prospectus:
 
   
“Bioventus” refers to Bioventus Inc., a Delaware corporation;
 
   
“Bioventus adjournment proposal” refers to the proposal to approve the adjournment of the Bioventus special meeting, if necessary or appropriate, to solicit additional proxies if there are insufficient votes at the time of the Bioventus special meeting to approve the Bioventus share issuance proposal or to ensure that any supplement or amendment to the accompanying joint proxy statement/prospectus is timely provided to Bioventus stockholders;
 
 
   
“Bioventus board” refers to the board of directors of Bioventus;
 
   
“Bioventus class A common stock” refers to the Class A common stock, par value $0.001 per share, of Bioventus;
 
   
“Bioventus class B common stock” refers to the Class B common stock, par value $0.001 per share, of Bioventus;
 
   
“Bioventus common stock” refers Bioventus class A common stock and the Bioventus Class B common stock;
 
   
“Bioventus LLC agreement” refers to the Second Amended and Restated Limited Liability Company Agreement of Bioventus LLC dated as of February 16, 2021;
 
   
“Bioventus record date” refers to [●], 2021;
 
   
“Bioventus share issuance proposal” refers to the proposal to approve the issuance of shares of Bioventus common stock to Misonix stockholders in connection with the mergers;

Table of Contents
   
“Bioventus special meeting” refers to the special meeting of Bioventus stockholders to consider and vote upon the Bioventus share issuance proposal and the Bioventus adjournment proposal;
 
   
“BV LLC” refers to Bioventus LLC, a subsidiary of Bioventus Inc.;
 
   
“cash election consideration” refers to an amount of cash equal to $28.00, without interest, which reflects the amount of cash that Misonix stockholders will be entitled to receive in the first merger for each share of Misonix common stock held immediately prior to the effective time, if such stockholder elects the cash election consideration and subject to proration under the terms of the merger agreement;
 
   
“Code” refers to the Internal Revenue Code of 1986, as amended;
 
   
“combined company” refers to Bioventus immediately following the completion of the merger and the other transactions contemplated by the merger agreement;
 
   
“DGCL” refers to the General Corporation Law of the State of Delaware;
 
   
“DLLCA” refers to the Limited Liability Company Act of the State of Delaware;
 
   
“effective time” refers to the date and time when the first merger becomes effective under the DGCL, which will be the date and time at which the certificate of merger with respect to the first merger is filed with the Secretary of State of the State of Delaware, or such later date and time as may be mutually agreed to in writing by Bioventus and Misonix and specified in such certificate of merger;
 
   
“end date” refers to January 31, 2022, the date on which, subject to certain limitations in the merger agreement, the merger agreement may be terminated and the merger abandoned by either Bioventus or Misonix (which date will be automatically extended in certain circumstances related to the receipt of required regulatory approvals or the absence of restraints under certain competition laws to March 31, 2022, pursuant to the terms of the merger agreement);
 
   
“Exchange Act” refers to the Securities Exchange Act of 1934, as amended;
 
   
“first merger” refers to the merger of Merger Sub I with and into Misonix;
 
   
“former LLC owners” refers to certain members of BV LLC;
 
   
“GAAP” refers to U.S. generally accepted accounting principles;
 
   
“HSR Act” refers to the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended;
 
   
“J.P Morgan” refers to J.P. Morgan Securities LLC, financial advisor to Misonix in connection with the proposed mergers;
 
   
“LLC interests” refers to single class of common membership interests in BV LLC;
 
   
“mergers” refers to the first merger and the second merger;
 
   
“merger agreement” refers to the Agreement and Plan of Merger, dated July 29, 2021, as it may be amended from time to time, by and among Bioventus, Merger Sub I, Merger Sub II and Misonix;
 
   
“merger consideration” refers to the aggregate cash election consideration and stock election consideration;
 
   
“Merger Sub I” refers to Oyster Merger Sub I, Inc., a Delaware corporation and wholly owned subsidiary of Bioventus, formed for the purpose of effecting the first merger as described in this joint proxy statement/prospectus;
 
   
“Merger Sub II” refers to Oyster Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of Bioventus, formed for the purpose of effecting the second merger as described in this joint proxy statement/prospectus;
 
   
“Misonix” refers to Misonix, Inc., a Delaware corporation;
 
   
“Misonix adjournment proposal” refers to the proposal to approve the adjournment of the Misonix special meeting, if necessary or appropriate, to solicit additional proxies if there are insufficient votes

Table of Contents
 
at the time of the Misonix special meeting to approve the Misonix merger proposal or to ensure that any supplement or amendment to the accompanying joint proxy statement/prospectus is timely provided to Misonix stockholders;
 
   
“Misonix board” refers to the board of directors of Misonix;
 
   
“Misonix common stock” refers to the common stock, par value $0.0001 per share, of Misonix;
 
   
“Misonix compensation proposal” refers to the proposal to approve, on a
non-binding
advisory basis, the compensation that may be paid or become payable to Misonix named executive officers that is based on or otherwise relates to the transactions contemplated by the merger agreement;
 
   
“Misonix merger proposal” refers to the proposal to adopt the merger agreement;
 
   
“Misonix record date” refers to [●], 2021;
 
   
“Misonix special meeting” refers to the special meeting of Misonix stockholders to consider and vote upon the Misonix merger proposal and related matters;
 
   
“Nasdaq” refers to the Nasdaq Global Select Market;
 
   
“original LLC owners” refers to the holders of BV LLC membership interests prior to the execution of the Bioventus LLC agreement;
 
   
“Perella Weinberg” refers to Perella Weinberg Partners L.P., financial advisor to Bioventus in connection with the proposed mergers;
 
   
“SEC” refers to the U.S. Securities and Exchange Commission;
 
   
“second effective time” refers to the date and time when the second merger becomes effective under the DGCL, which will be the date and time at which the certificate of merger with respect to the second merger is filed with the Secretary of State of the State of Delaware, or such later date and time as may be mutually agreed to in writing by Bioventus and Misonix and specified in such certificate of merger;
 
   
“second merger” refers to the merger of Misonix with and into Merger Sub II;
 
   
“Securities Act” refers to the Securities Act of 1933, as amended;
 
   
“share issuance” refers to the issuance of shares of Bioventus class A common stock to Misonix stockholders in connection with the merger;
 
   
“stock election consideration” refers to 1.6839 validly issued, fully paid and
non-assessable
shares of Bioventus class A common stock, which figure reflects the number of shares of Bioventus class A common stock that Misonix stockholders will be entitled to receive in the first merger for each share of Misonix common stock held immediately prior to the effective time if such stockholder elects the stock election consideration;
 
   
“stockholders agreement” refers to Stockholders Agreement, dated February 16, 2021, by and among Bioventus Inc., Bioventus LLC and the principal stockholders named therein;
 
   
“TRA” refers to the Tax Receivable Agreement, dated as of February 16, 2021, by and among Bioventus Inc., Bioventus LLC and the continuing LLC owner; and
 
   
“transaction” refers to the transactions contemplated by the merger agreement including the mergers.

Table of Contents
TABLE OF CONTENTS
 
     1  
     19  
     36  
     37  
     39  
     117  
     119  
     126  
     127  
     128  
     134  
     135  
     136  
     137  
     198  
     230  
     246  
     294  
     326  
     336  
     337  
     338  
     343  
     351  
     361  
     367  
     368  
     369  
     372  
     374  
     375  
     376  

Table of Contents
     F-1  
     II-1  
    
A-1
 
    
B-1
 
    
C-1
 
    
D-1
 

Table of Contents
QUESTIONS AND ANSWERS
The following are brief answers to certain questions that you, as a Bioventus stockholder or Misonix stockholder, may have regarding the mergers and the other matters being considered at the Bioventus and Misonix special meetings, as applicable. You are urged to carefully read this joint proxy statement/prospectus and the other documents referred to in this joint proxy statement/prospectus in their entirety because this section may not provide all the information that is important to you regarding these matters. See “Summary” for a summary of important information regarding the merger agreement, the mergers and the related transactions. Additional important information is contained in the annexes to, and the documents incorporated by reference in, this joint proxy statement/prospectus. You may obtain the information incorporated by reference in this joint proxy statement/prospectus, without charge, by following the instructions under “Where You Can Find More Information.”
Why am I receiving this joint proxy statement/prospectus?
You are receiving this joint proxy statement/prospectus because Misonix has agreed to be acquired by Bioventus through a merger of Merger Sub I with and into Misonix with Misonix continuing as the surviving corporation, and immediately following, a merger of Misonix with and into Merger Sub II, with Merger Sub II continuing as the surviving entity in the merger and a wholly owned subsidiary of Bioventus. The merger agreement, which governs the terms and conditions of the mergers, is attached as
Annex A
hereto.
Your vote is required in connection with the mergers. Bioventus and Misonix are sending these materials to their respective stockholders to help them decide how to vote their shares at the Bioventus special meeting and Misonix special meeting.
What matters am I being asked to vote on?
In order to complete the mergers, among other things:
 
   
Bioventus stockholders must approve the Bioventus share issuance proposal; and
 
   
Misonix stockholders must approve the Misonix merger proposal.
Bioventus
: Bioventus is holding the Bioventus special meeting to obtain approval of the Bioventus share issuance proposal and the Bioventus adjournment proposal.
Misonix
: Misonix is holding the Misonix special meeting to obtain approval of the Misonix merger proposal. At the Misonix special meeting, Misonix stockholders will also be asked to consider and vote on the Misonix compensation proposal and the Misonix adjournment proposal.
Your vote is very important, regardless of the number of shares that you own. The approval of the Bioventus share issuance proposal and the Misonix merger proposal are conditions to the obligations of Bioventus and Misonix to complete the mergers. The approval of the Bioventus adjournment proposal, the Misonix compensation proposal and the Misonix adjournment proposal are not conditions to the obligations of Bioventus or Misonix to complete the mergers.
When and where will each of the special meetings take place?
Bioventus
: The Bioventus special meeting will be held solely virtually via live webcast on [●], 2021, beginning at [●], Eastern Time. Bioventus stockholders will be able to virtually attend and vote at the Bioventus special meeting by visiting www.virtualshareholdermeeting.com/BVS2021SM, which is referred to as the “Bioventus special meeting website.” In order to virtually attend and vote at the Bioventus special meeting, you will need the
16-digit
control number located on your proxy card. Bioventus has retained Broadridge Financial Solutions,
 
1

Table of Contents
which is referred to as “Broadridge,” to host the live webcast of the Bioventus special meeting. Thirty minutes prior to the Bioventus special meeting, Broadridge may be contacted at (855)
499-0991
(U.S. toll-free) or (720)
378-5962
(international toll), and will be available to answer any questions regarding how to virtually attend the Bioventus special meeting or if you encounter any technical difficulty accessing or during the Bioventus special meeting. Technical support phone numbers will also be available via the virtual meeting url 30 minutes prior to the start of the meeting. See “The Bioventus Special Meeting—Virtually Attending the Bioventus Special Meeting.”
Misonix
: The Misonix special meeting will be held at Misonix’s corporate offices, located at 1938 New Highway, Farmingdale, NY 11735 on [●], 2021, beginning at [●], Eastern Time. As part of Misonix’s precautions regarding the novel coronavirus or
COVID-19,
Misonix is planning for the possibility that the meeting may be held solely by means of remote communications. If Misonix takes this step, Misonix will announce the decision to do so in advance, and details on how to participate, including details on how to inspect a list of stockholders of record, will be posted on our website at www.misonix.com and filed with the SEC as proxy material.
Even if you plan to attend your respective company’s special meeting, Bioventus and Misonix recommend that you vote by proxy in advance as described below so that your vote will be counted if you later decide not to or become unable to attend the applicable special meeting.
If you hold your shares in “street name,” you may attend and vote at your respective company’s special meeting only if you obtain a specific control number from your bank, broker or other nominee giving you the right to vote such shares.
Does my vote matter?
Yes, your vote is very important, regardless of the number of shares that you own. The mergers cannot be completed unless the Bioventus share issuance proposal is approved by Bioventus stockholders and the Misonix merger proposal is approved by Misonix stockholders.
Bioventus
 
   
Bioventus Share Issuance Proposal.
Assuming a quorum is present at the Bioventus special meeting, approval of the Bioventus share issuance proposal requires the affirmative vote of the holders of a majority in voting power of the votes cast on the Bioventus share issuance proposal. Accordingly, any shares not virtually present or represented by proxy (including due to the failure of a Bioventus stockholder who holds shares of Bioventus common stock in “street name” through a bank, broker or other nominee to provide voting instructions to such bank, broker or other nominee) will have no effect on the outcome of the Bioventus share issuance proposal. An abstention, or other failure of any shares of Bioventus common stock virtually present or represented by proxy and entitled to vote at the Bioventus special meeting on the Bioventus share issuance proposal to vote on the Bioventus share issuance proposal, will have the same effect as a vote “
AGAINST
” the Bioventus share issuance proposal. However, assuming a quorum is present at the Bioventus special meeting, if a Bioventus stockholder who holds shares in “street name” through a bank, broker or other nominee provides voting instructions for one or more other proposals, but not for the Bioventus share issuance proposal, voting power will deemed to be withheld with respect to the Bioventus share issuance proposal and such failure to provide voting instructions will have no effect on the Bioventus share issuance proposal.
 
   
Bioventus Adjournment Proposal.
Whether or not a quorum is present at the Bioventus special meeting, approval of the Bioventus adjournment proposal requires the affirmative vote of the holders of a majority in voting power of the votes cast on the Bioventus adjournment proposal. Accordingly, any shares not virtually present or represented by proxy (including due to the failure of an Bioventus stockholder who holds shares in “street name” through a bank, broker or other nominee to provide voting instructions to such bank, broker or other nominee) will have no effect on the outcome of the
 
2

Table of Contents
 
Bioventus adjournment proposal. An abstention or other failure of any shares of Bioventus common stock virtually present or represented by proxy and entitled to vote at the Bioventus special meeting on the Bioventus adjournment proposal to vote on the Bioventus adjournment proposal, will have the same effect as a vote “
AGAINST
” the Bioventus adjournment proposal. However, if a Bioventus stockholder who holds shares of Bioventus common stock in “street name” through a bank, broker or other nominee provides voting instructions for one or more other proposals, but not for the Bioventus adjournment proposal, voting power will deemed to be withheld with respect to the Bioventus adjournment proposal and such failure to provide voting instructions will have no effect on the Bioventus adjournment proposal.
Misonix
 
   
Misonix merger proposal
. Assuming a quorum is present at the Misonix special meeting, approval of the Misonix merger proposal requires the affirmative vote of the holders of a majority of the outstanding shares of Misonix common stock. For the Misonix compensation proposal, a Misonix stockholder may indicate “FOR,” “AGAINST” or “ABSTAIN” on the proxy card. Brokerage firms and nominees will not have the authority to vote their customers’ unvoted shares on the Misonix merger proposal or to vote their customers’ shares if the customers have not furnished voting instructions within a specified period of time prior to the Misonix special meeting. Any shares not present or represented by proxy (including due to the failure of a Misonix stockholder who holds shares of Misonix common stock in “street name” through a bank, broker or other nominee to provide voting instructions to such bank, broker or other nominee) and any abstention, or other failure of any shares of Misonix common stock present or represented by proxy and entitled to vote at the Misonix special meeting on the Misonix merger proposal to vote on the Misonix merger proposal, will each have the same effect as a vote “
AGAINST
” the Misonix merger proposal.
 
   
Misonix compensation proposal
. Assuming a quorum is present at the Misonix special meeting, approval of the Misonix compensation proposal requires the affirmative vote of the holders of a majority of the votes cast on the Misonix compensation proposal by holders of Misonix common stock present or represented by proxy at the Misonix special meeting. For the Misonix compensation proposal, a Misonix stockholder may indicate “FOR,” “AGAINST” or “ABSTAIN” on the proxy card. For purposes of determining the number of votes cast with respect to the Misonix compensation proposal, only those votes cast “FOR” or “AGAINST” are included. Brokerage firms and nominees will not have the authority to vote their customers’ unvoted shares on the Misonix compensation proposal or to vote their customers’ shares if the customers have not furnished voting instructions within a specified period of time prior to the Misonix special meeting. Abstentions and broker
non-votes
are counted only for purposes of determining whether a quorum is present at the meeting and therefore will have no effect on the outcome of the vote for the Misonix compensation proposal. Approval of the Misonix compensation proposal is not a condition to completion of the mergers, and the vote with respect to this proposal is advisory only and will not be binding on Misonix, the surviving corporation, the surviving company or Bioventus. If the mergers are completed, the transactions-related executive compensation may be paid to Misonix’s named executive officers to the extent payable in accordance with the terms of the compensation arrangements even if Misonix stockholders fail to approve, by
non-binding,
advisory vote, the Misonix compensation proposal.
 
   
Misonix adjournment proposal.
Whether or not a quorum is present at the Misonix special meeting, approval of the Misonix adjournment proposal requires the affirmative vote of the holders of a majority in voting power of the shares of Misonix common stock present or represented by proxy at the Misonix special meeting. Accordingly, any shares not present or represented by proxy (including due to the failure of a Misonix stockholder who holds shares in “street name” through a bank, broker or other nominee to provide voting instructions to such bank, broker or other nominee) will have no effect on the outcome of the Misonix adjournment proposal. An abstention, or other failure of any shares of Misonix common stock present or represented by proxy and entitled to vote at the Misonix special
 
3

Table of Contents
 
meeting on the Misonix adjournment proposal to vote on the Misonix adjournment proposal, will have the same effect as a vote “
AGAINST
” the Misonix adjournment proposal. However, if a Misonix stockholder who holds shares of Misonix common stock in “street name” through a bank, broker or other nominee provides voting instructions for one or more other proposals, but not for the Misonix adjournment proposal, voting power will deemed to be withheld with respect to the Misonix adjournment proposal and such failure to provide voting instructions will have no effect on the Misonix adjournment proposal.
What will Misonix stockholders receive for their shares of Misonix common stock if the mergers are completed?
If the mergers are completed, each issued and outstanding share of Misonix common stock (other than treasury shares of Misonix, shares held by a subsidiary of Misonix, Bioventus, Merger Sub I or Merger Sub II, and shares held by Misonix stockholders who have not voted in favor of the Misonix merger proposal and perfected and not withdrawn a demand for appraisal rights pursuant to Delaware law) will be converted into the right to receive either an amount in cash equal to $28.00 or 1.6839 validly issued, fully paid and
non-assessable
shares of Bioventus class A common stock, based on the election of the holder thereof and, in each case, subject to automatic proration and adjustment in accordance with the terms of the merger agreement, as described under “The Merger Agreement—The Mergers; Merger Consideration—Proration and Reallocation”
What is the value of the merger consideration payable to holders of Misonix common stock?
The exchange ratio of 1.6839 shares of Bioventus class A common stock is fixed and will not be adjusted for changes in the market price of either Bioventus class A common stock or Misonix common stock between the date of signing of the merger agreement and the completion date of the first merger. As such, the market value of the merger consideration payable to Misonix stockholders will fluctuate with the market price of the Bioventus class A common stock and will not be known at the time that Misonix stockholders vote on the Misonix merger proposal. Upon completion of the mergers, former Misonix stockholders are expected to own approximately 25% of the outstanding shares of Bioventus common stock and Bioventus stockholders immediately prior to the mergers are expected to own approximately 75% of the outstanding shares of Bioventus common stock. Bioventus class A common stock is traded on the Nasdaq Global Select Market, which is referred to as “Nasdaq,” under the symbol “BVS.” Misonix common stock is traded on Nasdaq under the symbol “MSON.” We encourage you to obtain current quotes for both the Bioventus class A common stock and the Misonix common stock before voting at the Misonix special meeting.
While the value of merger consideration to be received by a specific holder of Misonix common stock will depend on whether they elect to receive the cash consideration, elect to receive the stock consideration, or make no election, if all Misonix stockholders elect to receive the cash consideration (or if all Misonix stockholders elect to receive the stock consideration), each holder of Misonix common stock would receive, on an aggregate basis, $10.50 in cash and 1.0524 shares of Bioventus class A common stock for each share of Misonix common stock that they own. Based on the Bioventus class A common stock price of $16.63 per share, which is the average of the daily volume weighted average price per share for the seven consecutive trading day period up to and including July 27, 2021, two trading days prior to the entry by Bioventus and Misonix into the merger agreement, the implied value of the merger consideration to Misonix stockholders (assuming all Misonix stockholders elect to receive the cash consideration or all Misonix stockholders elect to receive the stock consideration), was $28.00 per share of Misonix common stock. On September 1, 2021, the latest practicable trading day before the date of the filing of this joint proxy statement/prospectus, the closing price of Bioventus class A common stock on the Nasdaq was $14.98 per share, resulting in the implied value of the merger consideration to Misonix stockholders (assuming all Misonix stockholders elect to receive the cash consideration or all Misonix stockholders elect to receive the stock consideration), was $26.27 per share of Misonix common stock.
 
4

Table of Contents
How do I elect the type of merger consideration I prefer to receive?
Not less than 30 days prior to the anticipated closing date of the first merger, letter of election and transmittal will be mailed to each Misonix stockholder that is a holder of record as of five business days prior to the mailing date. To elect to receive the cash consideration, the stock consideration or a combination of the two, you must indicate on the letter of election and transmittal the number of shares of Misonix common stock with respect to which you elect to receive the cash consideration, the number of shares of Misonix common stock with respect to which you elect to receive the stock consideration and the number of shares of Misonix common stock with respect to which you make no election. Misonix intends to issue a press release at least five business days prior to the expiration of the election period informing Misonix, stockholders of the expiration of the election period, which expiration we refer to as the “election deadline.” You must return the letter of election and transmittal in the
pre-addressed,
return envelope provided so that it is received no later than 5:00 p.m. (New York City time) on the election deadline for your election to be properly submitted.
If you hold shares of Misonix common stock in “street name”, you should receive instructions from the bank, brokerage firm or other nominee that is holding your shares advising you of the procedures for making your election. If these instructions are not received, you should contact the bank, brokerage firm or other nominee holding your shares of Misonix common stock as soon as possible. Election forms must be returned to the broker, bank or nominee in time for it to respond prior to the election deadline, therefore, you are encouraged to pay close attention to, and abide by, any election deadlines provided by the bank, brokerage firm or other nominee holding your shares, as that deadline may be earlier than the election deadline described in this joint proxy statement/prospectus.
Can I make one election for some of my shares of Misonix common stock and another election for the rest?
Yes. The letter of election and transmittal permits you to specify, among the shares of Misonix common stock you hold, (i) the number of shares of Misonix common stock for which you are electing to receive the cash consideration of $28.00 per share, (ii) the number of shares of Misonix common stock for which you are electing to receive the stock consideration of 1.6839 shares of Bioventus class A common stock, or (iii) the number of shares of Misonix common stock for which you make no election.
What if I do not make an election or my letter of election and transmittal is not received before the election deadline?
If you do not submit a properly completed and signed letter of election and transmittal to the exchange agent by the election deadline (or if you submit a properly completed letter of election and transmittal indicating no election), then you will be deemed to have made no election and will therefore receive the cash consideration or the stock consideration or a combination of both, depending on the elections made by other Misonix stockholders (as described in the section entitled “The Merger Agreement—The Mergers; Effects of the Mergers—Proration and Reallocation” of this joint proxy statement/prospectus), except with respect to shares as to which you have not voted in favor of the Misonix merger proposal and perfected and not withdrawn a demand for appraisal rights pursuant to Delaware law.
For Misonix share certificates and Misonix book-entry shares not held through DTC, Misonix stockholders should complete and return the letter of election and transmittal to the exchange agent even if the stockholder is making no election because the exchange agent will require your transmittal information requested in the letter. Stockholders who do not return a letter of election and transmittal to the exchange agent prior to the election deadline will be mailed a letter of transmittal from the exchange agent following the consummation of the merger.
Can I change my election after I submit a letter of election and transmittal?
Yes. You may revoke your election of the form of merger consideration you will receive with respect to all or a portion of your shares of Misonix common stock by delivering written notice of your revocation to the exchange
 
5

Table of Contents
agent prior to the election deadline. If you instructed a bank, brokerage firm or other nominee to submit an election for your shares, you must follow its directions for changing those instructions, as the deadline to revoke your election may be earlier than the election deadline described in this joint proxy statement/prospectus. In addition, any election of merger consideration you make will automatically be revoked if the merger agreement is terminated.
Misonix stockholders will not be entitled to revoke or change their election following the election deadline. For Misonix stockholders who hold shares in “street name”, the election deadline provided by the bank, brokerage firm or other nominee holding your shares may be earlier than the election deadline described in this joint proxy statement/prospectus. As a result, if you make an election, you will be unable to revoke your election or sell your shares of Misonix common stock after the applicable election deadline unless the merger agreement is terminated.
May I submit a letter of election and transmittal even if I vote against the Misonix merger proposal?
Yes. You should submit a letter of election and transmittal even if you vote against the Misonix merger proposal.
May I transfer my shares of Misonix common stock once I have made an election?
Yes you may transfer your shares prior to the election deadline, however, for Misonix stockholders who have made an election, any further transfer of shares made on the stock transfer books of Misonix will be deemed to be a revocation of their election. Furthermore, you will not be able to transfer your shares of Misonix common stock after the election deadline unless the merger agreement is terminated.
What happens if I am eligible to receive a fraction of a share of Bioventus class A common stock as part of the merger consideration?
If the aggregate number of shares of Bioventus class A common stock, if any, that you are entitled to receive as merger consideration includes a fraction of a share of Bioventus class A common stock, you will receive cash in lieu of that fractional share. See the section entitled “The Merger Agreement—Fractional Shares” of this joint proxy statement/prospectus.
What will holders of Misonix equity compensation awards receive in the mergers?
Each outstanding Misonix stock option held by employees and directors of Misonix who meet the
S-8
definition of “employee” shall (i) become fully vested immediately upon the effective time and (ii) be assumed by Bioventus and converted automatically into an option to purchase Bioventus Class A Common Stock based on the option exchange ratio (with the exercise price with respect to such option being adjusted based on the option exchange ratio). Aside from the foregoing adjustments, the assumed options will generally remain subject to the same vesting and other terms and conditions that applied to such awards immediately prior to the effective time.
Each outstanding Misonix stock option held by an individual who does not meet the
S-8
definition of “employee” will become fully vested and be settled in cash immediately prior to the effective time in an amount equal to the product of (x) the number of shares of Misonix common stock subject to the applicable option and (y) the excess, if any, of (i) the average of the volume-weighted average trading price per share of Bioventus Class A Common Stock on Nasdaq (as reported by Bloomberg L.P.) on each of the five consecutive trading days ending on (and including) the trading day that is three trading days prior to the date of the effective time over (ii) the per share exercise price of such option.
See the section entitled “The Merger Agreement—Treatment of Misonix Equity Awards” of this joint proxy statement/prospectus.
 
6

Table of Contents
How will the mergers be financed?
Bioventus expects to fund the aggregate cash consideration upon completion of the mergers with cash on hand, together with the proceeds of senior secured term loans in an aggregate principal amount of approximately $262.0 to be incurred initially by Merger Sub I. The receipt of financing by Bioventus is not a condition to completion of the mergers and, accordingly, Bioventus will be required to complete the mergers (assuming that all of the conditions to its obligations under the merger agreement are satisfied) whether or not debt financing is available at all or on acceptable terms. See the section entitled “Financing of the Mergers” of this joint proxy statement/prospectus.
How does the Bioventus board recommend that I vote at the Bioventus special meeting?
The Bioventus board unanimously recommends that you vote “
FOR
” the Bioventus share issuance proposal and “
FOR
” the Bioventus adjournment proposal.
Other than with respect to continued service for, employment by and the right to continued indemnification by the combined company, as of the date of this joint proxy statement/prospectus, Bioventus directors and executive officers do not have interests in the merger that are different from, or in addition to, the interests of other Bioventus stockholders generally. See “Interests of Bioventus Directors and Executive Officers in the Merger.”
How does the Misonix board recommend that I vote at the Misonix special meeting?
The Misonix board unanimously recommends that you vote “
FOR
” the Misonix merger proposal, “
FOR
” the Misonix compensation proposal and “
FOR
” the Misonix adjournment proposal. For a description of some of the factors considered by the Misonix board in reaching its decision to approve the merger agreement and the transactions contemplated thereby, including the merger, and additional information on the recommendation of the Misonix board, see “The Merger—Recommendation of the Misonix Board of Directors; Misonix’s Reasons for the Merger.”
Who is entitled to vote at each special meeting?
Bioventus
All holders of record of shares of Bioventus common stock who held shares at the close of business on [●], 2021 (the Bioventus record date) are entitled to receive notice of, and to vote at, the Bioventus special meeting. Each such holder of Bioventus common stock is entitled to cast one vote on each matter properly brought before the Bioventus special meeting for each share of Bioventus common stock that such holder owned of record as of the Bioventus record date. Virtual attendance at the Bioventus special meeting via the Bioventus special meeting website is not required to vote. See below and “The Bioventus Special Meeting—Methods of Voting” for instructions on how to vote without virtually attending the Bioventus special meeting.
Misonix
All holders of record of shares of Misonix common stock who held shares at the close of business on [●], 2021 (the Misonix record date) are entitled to receive notice of, and to vote at, the Misonix special meeting. Each such holder of Misonix common stock is entitled to cast one vote on each matter properly brought before the Misonix special meeting for each share of Misonix common stock that such holder owned of record as of the Misonix record date. Physical attendance at the Misonix special meeting is not required to vote. See below and “The Misonix Special Meeting—Methods of Voting” for instructions on how to vote without attending the Misonix special meeting.
 
7

Table of Contents
What is a proxy?
A proxy is a stockholder’s legal designation of another person to vote shares owned by such stockholder on their behalf. The document used to designate a proxy to vote your shares of Bioventus or Misonix common stock, as applicable, is referred to as a “proxy card.”
How many votes do I have at each special meeting?
Bioventus
Each Bioventus stockholder is entitled to one vote for each share of Bioventus common stock held of record as of the close of business on the Bioventus record date. As of the close of business on the Bioventus record date, there were [●] shares of Bioventus common stock outstanding.
Misonix
Each Misonix stockholder is entitled to one vote for each share of Misonix common stock held of record as of the close of business on the Misonix record date. As of the close of business on the Misonix record date, there were [●] shares of Misonix common stock outstanding.
What constitutes a quorum for each special meeting?
Bioventus
A quorum is the minimum number of shares required to be represented, either through virtual attendance or through representation by proxy, to hold a valid meeting.
The holders of a majority of in voting power of the stock issued and outstanding and entitled to vote at the meeting, must be present in person, or by remote communication, if applicable, or represented by proxy to constitute a quorum.
Misonix
The holders of a majority in voting power of the shares of stock issued and outstanding and entitled to vote at the meeting, present in person or represented by proxy, will constitute a quorum.
Where will the Bioventus common stock that I receive in the merger be publicly traded?
The shares of Bioventus class A common stock to be issued to Misonix stockholders in the merger will be listed for trading on Nasdaq under the symbol “BVS.”
What happens if the merger is not completed?
If the Bioventus share issuance proposal is not approved by Bioventus stockholders, if the Misonix merger proposal is not approved by Misonix stockholders or if the mergers are not completed for any other reason, Misonix stockholders will not receive the merger consideration or any other consideration in connection with the mergers, and their shares of Misonix common stock will remain outstanding.
If the mergers are not completed, Misonix will remain an independent public company, the Misonix common stock will continue to be listed and traded on Nasdaq under the symbol “MSON” and Bioventus will not complete the share issuance contemplated by the merger agreement, regardless of whether the Bioventus share issuance proposal has been approved by Bioventus stockholders.
 
8

Table of Contents
Under the merger agreement, Bioventus and Misonix will each be required to pay a termination fee of $20,661,000 to the other party if the merger agreement is terminated in certain circumstances, including if the respective party’s board changes its recommendation in connection with the mergers and the other party terminates the merger agreement. Additionally, Misonix may terminate the merger agreement if it enters into an alternative acquisition agreement with respect to a superior proposal and pays Bioventus the termination fee. See “The Merger Agreement—Termination Fee.”
How can I vote my shares at my respective special meeting?
Bioventus
Shares held directly in your name as a Bioventus stockholder of record may be virtually voted at the Bioventus special meeting via the Bioventus special meeting website. You will need the
16-digit
control number included on your proxy card in order to access and vote via the Bioventus special meeting website as described under “The Bioventus Special Meeting—Virtually Attending the Bioventus Special Meeting.”
Shares held in “street name” may be virtually voted at the Bioventus special meeting via the Bioventus special meeting website only if you obtain a specific control number and follow the instructions provided by your bank, broker or other nominee. See “The Bioventus Special Meeting—Virtually Attending the Bioventus Special Meeting.”
Misonix
You may vote by attending the Misonix special meeting and voting in person or by submitting a proxy. The method of voting by proxy differs (i) depending on whether you are viewing this proxy statement on the Internet or submitting a paper copy and (ii) for shares of Misonix common stock held as a record holder and shares held in “street name.”
If you hold your shares of Misonix common stock as a record holder and you are viewing this joint proxy statement/prospectus on the Internet, you may submit a proxy over the Internet by following the instructions on the proxy card that was included with this joint proxy statement/prospectus. If you hold your shares of Misonix common stock as a record holder and you are reviewing a paper copy of this joint proxy statement/prospectus, you may submit a proxy over the Internet or by telephone by following the instructions on the proxy card, or by completing, dating and signing the proxy card that was included with this joint proxy statement/prospectus and promptly returning it in the
pre-addressed,
postage-paid envelope provided to you.
“Street name” holders generally cannot submit a proxy or vote their shares directly and must instead instruct the broker, bank, trust or other nominee how to vote their shares using the methods described below. If you hold your shares of Misonix common stock in street name, you will receive a notice from your broker, bank, trust or other nominee that includes instructions on how to vote your shares. Your broker, bank, trust or other nominee may allow you to deliver your voting instructions over the Internet and may also permit you to submit your voting instructions by telephone. In addition, you may request paper copies of this proxy statement and accompanying proxy card from your broker by following the instructions on the notice provided by your broker, bank, trust or other nominee.
For additional information on virtually attending the special meetings, see “The Bioventus Special Meeting” and “The Misonix Special Meeting.”
How can I vote my shares without attending my company’s special meeting?
Whether you hold your shares directly as a stockholder of record of Bioventus or Misonix or beneficially in “street name,” you may direct your vote by proxy without attending the Bioventus or Misonix special meeting, as applicable. If you are a stockholder of record, you can vote by proxy over the internet, by telephone or by mail by
 
9

Table of Contents
following the instructions provided in the enclosed proxy card. If you hold shares beneficially in “street name,” you should follow the voting instructions provided by your bank, broker or other nominee.
For additional information on voting procedures, see “The Bioventus Special Meeting” and “The Misonix Special Meeting.”
What is a “broker
non-vote”?
Under Nasdaq rules, banks, brokers and other nominees may use their discretion to vote “uninstructed” shares (i.e., shares of record held by banks, brokers or other nominees, but with respect to which the beneficial owner of such shares has not provided instructions on how to vote on a particular proposal) with respect to matters that are considered to be “routine,” but not with respect to
“non-routine”
matters. All of the proposals currently expected to be brought before the Bioventus and Misonix special meetings are
“non-routine”
matters under Nasdaq rules.
A “broker
non-vote”
occurs on an item when (i) a bank, broker or other nominee has discretionary authority to vote on one or more proposals to be voted on at a meeting of stockholders, but is not permitted to vote on other proposals without instructions from the beneficial owner of the shares, and (ii) the beneficial owner fails to provide the bank, broker or other nominee with such instructions. Because all of the proposals currently expected to be voted on at the Bioventus and Misonix special meetings are
non-routine
matters under Nasdaq rules for which brokers do not have discretionary authority to vote, Bioventus and Misonix do not expect there to be any broker
non-votes
at the Bioventus or Misonix special meetings.
Are there any Misonix stockholders already committed to vote in favor of the Misonix merger proposal and Misonix compensation proposal? Are there any Bioventus stockholders already committed to vote in favor of the Bioventus share issuance proposal?
Bioventus:
Yes. Subsequent to the execution of the merger agreement, Misonix entered into a voting agreement (the “Bioventus support agreement”) with EW Healthcare Partners Acquisition Fund, L.P., White Pine Medical, LLC (a subsidiary of EW Partners Acquisition Fund, L.P.), Smith & Nephew, Inc., Smith & Nephew USD Ltd and
AMP-CF
Holdings, LLC (together, the “Bioventus supporting stockholders”), pursuant to which such stockholders have agreed, among other things, to vote the shares of Bioventus common stock that they beneficially own at the time such vote is taken in favor of Bioventus share issuance proposal and against approval of any proposal made in opposition to, in competition with, or inconsistent with, the merger agreement or the transaction. As of the record date for the Bioventus special meeting, such stockholders beneficially own approximately [●]% of the outstanding shares of Bioventus common stock. Therefore, the Bioventus supporting stockholders hold a sufficient number of shares of Bioventus common stock in order to approve the Bioventus share issuance proposal. On July 29, 2021, in connection with execution of the merger agreement, each of the Bioventus supporting stockholders have entered into lock up agreements with Bioventus (each a “lock up agreement”) restricting the sale and transfer of the capital stock of Bioventus for a period of 90 or 180 days, subject to the terms of the lock up agreement.
Misonix:
Yes. Subsequent to the execution of the merger agreement, Bioventus entered into a voting agreement (the “Misonix support agreement”) with each of Stavros G. Vizirgianakis, 1315 Capital, LLC, SV Life Sciences Fund VI Strategic Partners, L.P. and SV Life Sciences Fund VI, L.P. (together, the “Misonix supporting stockholders”), pursuant to which such stockholders have agreed, among other things, to vote the shares of Misonix common stock that they own at the time such vote is taken in favor of the Misonix merger proposal and Misonix compensation proposal and against approval of any proposal made in opposition to, in competition with, or inconsistent with, the merger agreement or the transaction. As of the record date for the Misonix special meeting, the Misonix supporting stockholders beneficially own approximately [●]% of the outstanding shares of Misonix common stock.
 
10

Table of Contents
What stockholder vote is required for the approval of each proposal at the Bioventus special meeting? What will happen if I fail to vote or abstain from voting on each proposal at the Bioventus special meeting?
Bioventus Proposal 1: Bioventus Share Issuance Proposal
Assuming a quorum is present at the Bioventus special meeting, approval of the Bioventus share issuance proposal requires the affirmative vote of the holders of a majority in voting power of the votes cast on the Bioventus share issuance proposal. Accordingly, any shares not virtually present or represented by proxy (including due to the failure of an Bioventus stockholder who holds shares in “street name” through a bank, broker or other nominee to provide voting instructions to such bank, broker or other nominee) will have no effect on the outcome of the Bioventus share issuance proposal. An abstention or other failure of any shares virtually present or represented by proxy and entitled to vote at the Bioventus special meeting on the Bioventus share issuance proposal to vote on the Bioventus share issuance proposal will have the same effect as a vote “
AGAINST
” the Bioventus share issuance proposal. However, assuming a quorum is present at the Bioventus special meeting, if a Bioventus stockholder who holds shares in “street name” through a bank, broker or other nominee provides voting instructions for one or more other proposals, but not for the Bioventus share issuance proposal, voting power will deemed to be withheld with respect to the Bioventus share issuance proposal and such failure to provide voting instructions will have no effect on the Bioventus share issuance proposal.
Bioventus Proposal 2: Bioventus Adjournment Proposal
Whether or not a quorum is present at the Bioventus special meeting, approval of the Bioventus adjournment proposal requires the affirmative vote of the holders of a majority in voting power of the votes cast on the Bioventus adjournment proposal. Accordingly, any shares not virtually present or represented by proxy (including due to the failure of a Bioventus stockholder who holds shares in “street name” through a bank, broker or other nominee to provide voting instructions to such bank, broker or other nominee) will have no effect on the outcome of the Bioventus adjournment proposal. An abstention or other failure of any shares virtually present or represented by proxy and entitled to vote at the Bioventus special meeting on the Bioventus adjournment proposal to vote on the Bioventus adjournment proposal will have the same effect as a vote “AGAINST” the Bioventus adjournment proposal. However, if a Bioventus stockholder who holds shares in “street name” through a bank, broker or other nominee provides voting instructions for one or more other proposals, but not for the Bioventus adjournment proposal, voting power will deemed to be withheld with respect to the Bioventus adjournment proposal and such failure to provide voting instructions will have no effect on the Bioventus adjournment proposal.
What stockholder vote is required for the approval of each proposal at the Misonix special meeting? What will happen if I fail to vote or abstain from voting on each proposal at the Misonix special meeting?
Misonix Proposal 1: Misonix Merger Proposal
Assuming a quorum is present at the Misonix special meeting, approval of the Misonix merger proposal requires the affirmative vote of the holders of a majority of the outstanding shares of Misonix common stock. For the Misonix compensation proposal, a Misonix stockholder may indicate “FOR,” “AGAINST” or “ABSTAIN” on the proxy card. Brokerage firms and nominees will not have the authority to vote their customers’ unvoted shares on the Misonix merger proposal or to vote their customers’ shares if the customers have not furnished voting instructions within a specified period of time prior to the Misonix special meeting. Any shares not present or represented by proxy (including due to the failure of a Misonix stockholder who holds shares of Misonix common stock in “street name” through a bank, broker or other nominee to provide voting instructions to such bank, broker or other nominee) and any abstention, or other failure of any shares of Misonix common stock present or represented by proxy and entitled to vote at the Misonix special meeting on the Misonix merger proposal to vote on the Misonix merger proposal, will each have the same effect as a vote
“AGAINST”
the Misonix merger proposal.
 
11

Table of Contents
Misonix Proposal 2: Misonix Compensation Proposal
Assuming a quorum is present at the Misonix special meeting, approval of the Misonix compensation proposal requires the affirmative vote of the holders of a majority of the votes cast on the Misonix compensation proposal by holders of Misonix common stock present or represented by proxy at the Misonix special meeting. For the Misonix compensation proposal, a Misonix stockholder may indicate “FOR,” “AGAINST” or “ABSTAIN” on the proxy card. For purposes of determining the number of votes cast with respect to the Misonix compensation proposal, only those votes cast “FOR” or “AGAINST” are included. Brokerage firms and nominees will not have the authority to vote their customers’ unvoted shares on the Misonix compensation proposal or to vote their customers’ shares if the customers have not furnished voting instructions within a specified period of time prior to the Misonix special meeting. Abstentions and broker
non-votes
are counted only for purposes of determining whether a quorum is present at the meeting and therefore will have no effect on the outcome of the vote for the Misonix compensation proposal. Approval of the Misonix compensation proposal is not a condition to completion of the mergers, and the vote with respect to this proposal is advisory only and will not be binding on Misonix, the surviving corporation, the surviving company or Bioventus. If the mergers are completed, the transactions-related executive compensation may be paid to Misonix’s named executive officers to the extent payable in accordance with the terms of the compensation arrangements even if Misonix stockholders fail to approve, by
non-binding,
advisory vote, the Misonix compensation proposal.
Misonix Proposal 3: Misonix Adjournment Proposal
Whether or not a quorum is present at the Misonix special meeting, approval of the Misonix adjournment proposal requires the affirmative vote of the holders of a majority in voting power of the shares of Misonix common stock present or represented by proxy at the Misonix special meeting. Accordingly, any shares not present or represented by proxy (including due to the failure of a Misonix stockholder who holds shares in “street name” through a bank, broker or other nominee to provide voting instructions to such bank, broker or other nominee) will have no effect on the outcome of the Misonix adjournment proposal. An abstention, or other failure of any shares of Misonix common stock present or represented by proxy and entitled to vote at the Misonix special meeting on the Misonix adjournment proposal to vote on the Misonix adjournment proposal, will have the same effect as a vote “
AGAINST
” the Misonix adjournment proposal. However, if a Misonix stockholder who holds shares of Misonix common stock in “street name” through a bank, broker or other nominee provides voting instructions for one or more other proposals, but not for the Misonix adjournment proposal, voting power will deemed to be withheld with respect to the Misonix adjournment proposal and such failure to provide voting instructions will have no effect on the Misonix adjournment proposal.
Why am I being asked to consider and vote on a proposal to approve, by
non-binding
advisory vote, the merger-related compensation for named executive officers (the Misonix compensation proposal)?
Under SEC rules, Misonix is required to seek a
non-binding
advisory vote of its stockholders relating to the compensation that may be paid or become payable to Misonix named executive officers that is based on or otherwise relates to the merger (also known as “golden parachute” compensation).
What happens if Misonix stockholders do not approve, by
non-binding
advisory vote, the merger-related compensation for Misonix named executive officers (the Misonix compensation proposal)?
Because the vote on the proposal to approve the Misonix compensation proposal is advisory in nature, the outcome of the vote will not be binding upon Misonix or the combined company. Accordingly, the merger-related compensation, which is described under “Interests of Misonix Directors and Executive Officers in the Merger,” may be paid to Misonix named executive officers even if Misonix stockholders do not approve the Misonix compensation proposal.
 
12

Table of Contents
What if I hold shares of both Bioventus and Misonix common stock?
If you are both a Bioventus stockholder and a Misonix stockholder, you will receive two separate packages of proxy materials. A vote cast as a Bioventus stockholder will not count as a vote cast as a Misonix stockholder, and a vote cast as a Misonix stockholder will not count as a vote cast as a Bioventus stockholder.
Therefore, please follow the instructions received with each set of materials you receive in order to submit separate proxies for your shares of Bioventus common stock and your shares of Misonix common stock.
What is the difference between holding shares as a stockholder of record and as a beneficial owner of shares held in “street name”?
If your shares of Bioventus or Misonix common stock are registered directly in your name with the transfer agent of Bioventus and Misonix, respectively, you are considered the stockholder of record with respect to those shares. As the stockholder of record, you have the right to vote directly at the applicable special meeting. You may also grant a proxy directly to Bioventus or Misonix, as applicable, or to a third party to vote your shares at the applicable special meeting.
If your shares of Bioventus or Misonix common stock are held by a bank, broker or other nominee, you are considered the beneficial owner of shares held in “street name.” Your bank, broker or other nominee will send you, as the beneficial owner, a package describing the procedures for voting your shares. You should follow the instructions provided by them to vote your shares. In order to attend and vote at the Bioventus special meeting via the Bioventus special meeting website or the Misonix special meeting in person, you will need to obtain a specific control number and follow the other procedures provided by your bank, broker or other nominee.
If my shares of Bioventus or Misonix common stock are held in “street name” by my bank, broker or other nominee, will my bank, broker or other nominee automatically vote those shares for me?
No. Your bank, broker or other nominee will only be permitted to vote your shares of Bioventus or Misonix common stock, as applicable, if you instruct your bank, broker or other nominee how to vote. You should follow the procedures provided by your bank, broker or other nominee regarding the voting of your shares. Under Nasdaq rules, banks, brokers and other nominees who hold shares of Bioventus or Misonix common stock in “street name” for their customers have authority to vote on “routine” proposals when they have not received instructions from beneficial owners. However, banks, brokers and other nominees are prohibited from exercising their voting discretion with respect to
non-routine
matters, which include all the proposals currently scheduled to be considered and voted on at the Bioventus and Misonix special meetings. As a result, absent specific instructions from the beneficial owner of such shares, banks, brokers and other nominees are not empowered to vote such shares.
For Bioventus stockholders, the effect of not instructing your bank, broker or other nominee how you wish to vote your shares of Bioventus common stock will have no effect on the Bioventus share issuance proposal or the Bioventus adjournment proposal (assuming a quorum is present at the Bioventus special meeting).
For Misonix stockholders, the effect of not instructing your bank, broker or other nominee how you wish to vote your shares of Misonix common stock will be the same as a vote “
AGAINST
” the Misonix merger proposal, but will have no effect on the Misonix compensation proposal (assuming a quorum is present at the Misonix special meeting) or the Misonix adjournment proposal. In addition, if a Misonix stockholder who holds shares in “street name” through a bank, broker or other nominee provides voting instructions for one or more other proposals, but not for the Misonix compensation proposal or the Misonix adjournment proposal, it will have the same effect as a vote “
AGAINST
” such proposal.
 
13

Table of Contents
What should I do if I receive more than one set of voting materials for the same special meeting?
If you hold shares of Bioventus or Misonix common stock in “street name” and also directly in your name as a stockholder of record or otherwise, or if you hold shares of Bioventus or Misonix common stock in more than one brokerage account, you may receive more than one set of voting materials relating to the same special meeting.
Record Holders
. For shares held directly, please vote by proxy over the internet or telephone using the instructions included with the accompanying proxy card, or promptly complete your proxy card and return it in the enclosed postage-paid envelope, in order to ensure that all of your shares of Bioventus or Misonix common stock are voted.
Shares in “street name.”
For shares held in “street name” through a bank, broker or other nominee, you should follow the procedures provided by your bank, broker or other nominee to submit a proxy or vote your shares.
If a stockholder gives a proxy, how are the shares of Bioventus or Misonix common stock voted?
Regardless of the method you choose to vote, the individuals named on the enclosed proxy card will vote your shares of Bioventus or Misonix common stock, as applicable, in the way that you indicate. For each item before the Bioventus or Misonix special meeting, as applicable, you may specify whether your shares of Bioventus or Misonix common stock, as applicable, should be voted for or against, or abstain from voting.
How will my shares of Bioventus common stock be voted if I return a blank proxy?
If you sign, date and return your proxy and do not indicate how you want your shares of Bioventus common stock to be voted, then your shares of Bioventus common stock will be voted in accordance with the recommendation of the Bioventus board: “
FOR
” the Bioventus share issuance proposal and “
FOR
” the Bioventus adjournment proposal.
How will my shares of Misonix common stock be voted if I return a blank proxy?
If you sign, date and return your proxy and do not indicate how you want your shares of Misonix common stock to be voted, then your shares of Misonix common stock will be voted in accordance with the recommendation of the Misonix board: “
FOR
” the Misonix merger proposal, “
FOR
” the Misonix compensation proposal and “
FOR
” the Misonix adjournment proposal.
Can I change my vote after I have submitted my proxy?
Any Bioventus or Misonix’s stockholder giving a proxy has the right to revoke the proxy and change their vote before the proxy is voted at the applicable special meeting by doing any of the following:
 
   
subsequently submitting a new proxy (including over the internet or telephone) for the applicable special meeting that is received by the deadline specified on the accompanying proxy card;
 
   
giving timely written notice of your revocation to Bioventus’ or Misonix’s Corporate Secretary, as applicable; or
 
   
attending and voting at the applicable special meeting.
 
14

Table of Contents
Execution or revocation of a proxy will not in any way affect your right to attend and vote at the applicable special meeting, whether in person or, in the case of the Bioventus special meeting, via the special meeting website. Written notices of revocation and other communications relating to the revocation of proxies should be addressed:
 
If you are an Bioventus stockholder:
  
If you are a Misonix stockholder:
Bioventus Inc.
4721 Emperor Boulevard, Suite 400
Durham, North Carolina 27703
Attention: Corporate Secretary
tony.dadamio@bioventus.com
(919)
474-6700
Bioventus Inc.
  
Misonix, Inc.
1938 New Highway
Farmingdale, NY 11735
Attention: Secretary
misonixproxy@misonix.com
(631) 694-9555
Misonix, Inc.
See “The Bioventus Special Meeting—Revocability of Proxies” and “The Misonix Special Meeting—Revocability of Proxies.”
If I hold my shares in “street name,” can I change my voting instructions after I have submitted voting instructions to my bank, broker or other nominee?
If your shares are held in the name of a bank, broker or other nominee and you previously provided voting instructions to your bank, broker or other nominee, you should follow the instructions provided by your bank, broker or other nominee to revoke or change your voting instructions.
Where can I find the voting results of the special meetings?
The preliminary voting results for each special meeting are expected to be announced at that special meeting. In addition, within four business days following certification of the final voting results, each of Bioventus and Misonix will file the final voting results of its respective special meeting (or, if the final voting results have not yet been certified, the preliminary results) with the SEC on a Current Report on Form
8-K.
Do Misonix stockholders have dissenters’ or appraisal rights?
Subject to the closing of the mergers, Misonix stockholders who do not vote in favor of the Misonix merger proposal and otherwise comply with the procedures and satisfy the conditions set forth in Section 262 of the DGCL are entitled to appraisal rights under Section 262 of the DGCL. For more information regarding appraisal rights, see the section entitled “Appraisal Rights,” In addition, a copy of Section 262 of the DGCL is attached as
Annex D
to this joint proxy statement/prospectus. Failure to strictly comply with Section 262 of the DGCL may result in your waiver of, or inability to, exercise appraisal rights.
Are there any risks that I should consider in deciding whether to vote for the approval of the Bioventus share issuance proposal or the Misonix merger proposal?
Yes. You should read and carefully consider the risk factors set forth under “Risk Factors.” You also should read and carefully consider the risk factors relating to Bioventus and Misonix that are contained in the documents that are incorporated by reference in this joint proxy statement/prospectus.
What happens if I sell my shares of Bioventus or Misonix common stock after the respective record date but before the respective special meeting?
The Bioventus record date is earlier than the date of the Bioventus special meeting, and the Misonix record date is earlier than the date of the Misonix special meeting. If you sell or otherwise transfer your shares of Bioventus
 
15

Table of Contents
or Misonix common stock after the applicable record date but before the applicable special meeting, you will, unless special arrangements are made, retain your right to vote at the applicable special meeting.
Who will solicit and pay the cost of soliciting proxies?
Misonix has engaged the services of MacKenzie Partners to assist in the distribution of the proxies. Misonix estimates that it will pay a fee of approximately $18,500 plus reasonable
out-of-pocket
expenses to MacKenzie Partners for this service.
Bioventus and Misonix also may be required to reimburse banks, brokers and other custodians, nominees and fiduciaries or their respective agents for their expenses in forwarding proxy materials to beneficial owners of Bioventus Misonix common stock, respectively. Bioventus and Misonix directors, officers and employees also may solicit proxies by telephone, by electronic means or in person. They will not be paid any additional amounts for soliciting proxies.
When are the mergers expected to be completed?
Subject to the satisfaction or waiver of the closing conditions described under “The Merger Agreement—Conditions to the Completion of the Merger,” including approval of the Bioventus share issuance proposal by Bioventus stockholders and approval of the Misonix merger proposal by Misonix stockholders, the mergers are currently expected to be completed by the end of the 2021 calendar year. However, neither Bioventus nor Misonix can predict the actual date on which the mergers will be completed, or if the mergers will be completed at all, because completion of the mergers is subject to conditions and factors beyond the control of both companies, including the receipt of certain required regulatory approvals. Bioventus and Misonix hope to complete the merger as soon as reasonably practicable. Also see “The Mergers—Regulatory Approvals.”
What respective equity stakes will Bioventus and Misonix stockholders hold in the combined company immediately following the merger?
Based on the number of shares of Bioventus and Misonix common stock outstanding on September 1, 2021, the latest practicable date prior to the date of this joint proxy statement/prospectus, upon completion of the merger, former Misonix stockholders are expected to own approximately 25% of the outstanding shares of Bioventus common stock and Bioventus stockholders immediately prior to the merger are expected to own approximately 75% of the outstanding shares of Bioventus common stock. The relative ownership interests of Bioventus stockholders and former Misonix stockholders in the combined company immediately following the merger will depend on the number of shares of Bioventus and Misonix common stock issued and outstanding immediately prior to the merger.
If I am a Misonix stockholder, how will I receive the merger consideration to which I am entitled?
Your receipt of the merger consideration will depend on whether your shares of Misonix common stock are represented by stock certificates (“Misonix stock certificates”) or if you hold book-entry shares (“Misonix book-entry shares”). Not less than 30 days prior to the anticipated closing date of the first merger, the exchange agent will mail to each holder of record of Misonix common stock a letter of election and transmittal. You are encouraged to complete and return your letter of election and transmittal in accordance with the instructions therein as soon as reasonably practicable.
For Misonix stock certificates, no later than three business days after the consummation of the mergers, the exchange agent will mail to each holder of record of Misonix stock certificates (a) a notice advising such holder of the effectiveness of the mergers, and (b) a letter of transmittal and (c) instructions for surrendering Misonix stock certificates to the exchange agent.
 
16

Table of Contents
Upon surrender of a Misonix stock certificate and a duly executed letter of election and transmittal (or letter of transmittal if an election is not submitted) to the exchange agent in compliance with the instructions for surrender, the exchange agent will mail to each holder of record, as promptly as reasonably practicable thereafter:
 
   
a statement reflecting the number of whole shares of Bioventus class A common stock, if any, that such holder is entitled to receive in
non-certificated
book-entry form in the name of such record holder; and
 
   
a check, or wire transfer of immediately available funds (provided that such holder has provided wire transfer instructions and is entitled to cash in excess of $250,000), in the amount (after giving effect to any required tax withholdings as provided in the merger agreement) of (a) any applicable cash election consideration, (b) any cash in lieu of fractional shares of Bioventus class A common stock plus (c) any unpaid cash dividends and any other dividends or other distributions that such holder has the right to receive pursuant to the merger agreement.
For Misonix book-entry shares that are not held through DTC, upon the later of the consummation of the mergers and the holder’s delivery to the exchange agent of a duly executed letter of election and transmittal (or letter of transmittal, if an election is not submitted), the exchange agent will pay and deliver to each such holder of record of any such Misonix book-entry shares:
 
   
the applicable stock election consideration, if any, that such holder is entitled to receive in
non-certificated
book-entry form in the name of such record holder; and
 
   
a check, or wire transfer of immediately available funds (provided that such holder has provided wire transfer instructions and is entitled to cash in excess of $250,000), in the amount (after giving effect to any required tax withholdings as provided in the merger agreement) of (a) any applicable cash election consideration, (b) any cash in lieu of fractional shares of Bioventus class A common stock plus (c) any unpaid cash dividends and any other dividends or distributions that such holder has the right to receive pursuant to the merger agreement. The exchange agent will promptly cancel each such
non-DTC
book-entry share.
For Misonix share certificates and Misonix book-entry shares not held through DTC, Misonix stockholders should complete and return the letter of election and transmittal to the exchange agent even if the stockholder is making no election because the exchange agent will require your transmittal information requested in the letter. Stockholders who do not return a letter of election and transmittal to the exchange agent prior to the election deadline will be mailed a letter of transmittal from the exchange agent following the consummation of the merger.
For Misonix book-entry shares that are held through DTC, no later than three business days after the consummation of the mergers, the exchange agent will transmit to DTC or its nominees, upon surrender of shares held of record by DTC or its nominees in accordance with DTC’s customary surrender procedures:
 
   
the applicable stock election consideration, if any, that such holder is entitled to receive in
non-certificated
book-entry form in the name of such record holder; and
 
   
a check, or wire transfer of immediately available funds (provided that such holder has provided wire transfer instructions and is entitled to cash in excess of $250,000), in the amount (after giving effect to any required tax withholdings as provided in the merger agreement) of (a) any applicable cash election consideration, (b) any cash in lieu of fractional shares of Bioventus Class A Common Stock plus (c) any unpaid cash dividends and any other dividends or distributions that such holder has the right to receive pursuant to the merger agreement. The exchange agent will promptly cancel each such DTC book-entry share.
What should I do now?
You should read this joint proxy statement/prospectus carefully and in its entirety, including the annexes. Then, you may vote by proxy over the internet or telephone using the instructions included with the accompanying proxy card, or promptly complete your proxy card and return it in the enclosed postage-paid envelope, so that your shares will be voted in accordance with your instructions.
 
17

Table of Contents
How can I find more information about Bioventus and Misonix?
You can find more information about Bioventus and Misonix from various sources described under “Where You Can Find More Information.”
Whom do I call if I have questions about the special meetings or the merger?
If you have questions about the special meetings or the merger, or desire additional copies of this joint proxy statement/prospectus or additional proxies, you may contact the applicable company contacts below:
 
If you are an Bioventus stockholder:
 
Bioventus Inc.,
Attn: Corporate Secretary
4721 Emperor Boulevard, Suite 100,
Durham, North Carolina 27703
tony.dadamio@bioventus.com
(919)
474-6700
  
If you are a Misonix stockholder:
 
Misonix, Inc.
Attention: Secretary
1938 New Highway
Farmingdale, NY 11735
misonixproxy@misonix.com
(631)
694-9555
 
18

Table of Contents
SUMMARY
For your convenience, provided below is a brief summary of certain information contained in this joint proxy statement/prospectus. This summary highlights selected information from this joint proxy statement/ prospectus and does not contain all of the information that may be important to you as a Bioventus or Misonix stockholder. To understand the merger fully and for a more complete description of the terms of the merger, you should read carefully this entire joint proxy statement/prospectus, its annexes and the other documents to which you are referred. Items in this summary include a page reference directing you to a more complete description of those items. You may obtain the information incorporated by reference in this joint proxy statement/prospectus, without charge, by following the instructions under “Where You Can Find More Information.”
The Parties to the Merger
(Page 117)
Bioventus Inc.
Bioventus is a global leader of innovations for active healing. Through a combination of internal product development, product/business acquisition, and distribution agreements, it will bring to market products which address a growing need for clinically effective, cost efficient, minimally invasive medical treatments, that engage and enhance the body’s natural healing processes. Bioventus’ principal place of business is 4721 Emperor Boulevard, Suite 100, Durham, North Carolina 27703, and its telephone number is (919)
474-6700.
Misonix, Inc.
Misonix designs, manufactures and markets minimally invasive surgical ultrasonic medical devices. These products are used for precise bone sculpting, removal of soft and hard tumors, and tissue debridement, primarily in the areas of neurosurgery, orthopedic surgery, plastic surgery, wound care and maxillo-facial surgery. Misonix also exclusively markets, sells and distributes skin allografts and wound care products used to support healing of wounds, and which complement Misonix’s ultrasonic medical devices. Misonix’s principal place of business is 1938 New Highway, Farmingdale, New York, and its telephone number is (631)
694-9555.
Oyster Merger Sub I, Inc.
Merger Sub I was formed by Bioventus solely in contemplation of the merger, has not conducted any business and has no assets, liabilities or obligations of any nature other than as set forth in the merger agreement. By operation of the merger, Merger Sub I will be merged with and into Misonix, with Misonix continuing as the surviving corporation. Merger Sub’s principal executive offices are located at 4721 Emperor Boulevard, Suite 100, Durham, North Carolina 27703, and its telephone number is (919)
474-6700.
Oyster Merger Sub II, LLC
Merger Sub II was formed by Bioventus solely in contemplation of the merger, has not conducted any business and has no assets, liabilities or obligations of any nature other than as set forth in the merger agreement. By operation of the merger, following the first merger, Misonix will be merged with and into Merger Sub II, with Merger Sub II continuing as the surviving entity (renamed as Misonix LLC) and a wholly owned subsidiary of Bioventus. Merger Sub’s principal executive offices are located at 4721 Emperor Boulevard, Suite 100, Durham, North Carolina 27703, and its telephone number is (919)
474-6700.
The Mergers and the Merger Agreement
(Pages 137 and 198)
The terms and conditions of the merger are contained in the merger agreement, a copy of which is attached as
Annex A
hereto. Bioventus and Misonix encourage you to read the merger agreement carefully and in its entirety, as it is the legal document that governs the merger.

 
19

Table of Contents
The merger agreement provides that, subject to the terms and conditions of the merger agreement, Merger Sub I will be merged with and into Misonix, with Misonix continuing as the surviving corporation and subsequently, Misonix will be merged with and into Merger Sub II, with Merger Sub II continuing as the surviving entity in the second merger and as a wholly owned subsidiary of Bioventus.
Merger Consideration
(Page 137)
If the mergers are completed, each issued and outstanding share of Misonix common stock (other than treasury shares of Misonix, shares held by a subsidiary of Misonix, Bioventus or Merger Sub I, and shares held by Misonix stockholders who have not voted in favor of the Misonix merger proposal and perfected and not withdrawn a demand for appraisal rights pursuant to Delaware law) will be converted into the right to receive either an amount in cash equal to $28.00 or 1.6839 validly issued, fully paid and
non-assessable
shares of Bioventus class A common stock, based on the election of the holder thereof and, in each case, subject to automatic proration and adjustment in accordance with the terms of the merger agreement, as described under “The Merger Agreement—The Merger Consideration”
Proration and Reallocation
(Page 137)
The aggregate amount of cash payable by Bioventus in the mergers will be equal to $10.50 multiplied by the number of outstanding shares of Misonix common stock at 5:00 p.m., New York City time, on the election deadline. In order to deliver this aggregate cash amount, the merger agreement provides for pro rata adjustments to, and reallocation of, the cash and stock elections made by Misonix stockholders, as well as the allocation of consideration to be paid with respect to shares of Misonix common stock as to which no election regarding the form of merger consideration to be paid to them, is received prior to the election deadline. Such no election shares will be exchanged for the cash consideration, the stock consideration or a combination of both. Additionally, depending on the elections made by other Misonix stockholders, each Misonix stockholder who elects to receive Bioventus class A common stock for their shares in the mergers, referred to as “stock election shares” may receive a portion of their consideration in cash, and each Misonix stockholder who elects to receive cash for their shares in the mergers, referred to as “cash election shares” may receive a portion of their consideration in Bioventus class A common stock.
If the elected cash consideration, which is the amount equal to the aggregate number of cash election shares multiplied by $28.00, exceeds the available cash amount, then:
 
   
all stock election shares and all no election shares will be exchanged for 1.6839 shares of Bioventus class A common stock; and
 
   
a portion of the cash election shares of each Misonix stockholder will be exchanged for $28.00 in cash as follows: cash election shares exchanged for $28.00 in cash =
(number of such stockholder’s cash election shares) * (maximum cash amount)
elected cash consideration
If the elected cash consideration is less than the available cash amount, which difference we refer to as the shortfall amount, then:
 
   
all cash election shares will be exchanged for the cash consideration; and
 
   
all stock election shares and no election shares will be treated in the following manner:
 
   
if the shortfall amount is less than or equal to the product of the aggregate number of no election shares and $28.00, which we refer to as the “no election value”, then (1) all stock election shares will be exchanged for 1.6839 shares of Bioventus class A common stock, and (2) a portion of the

 
20

Table of Contents
 
no election shares of each Misonix stockholder, calculated as follows, will be exchanged for $28.00 in cash as follows (and the remaining portion of such stockholder’s no election shares, if any, will be exchanged for 1.6839 shares of Bioventus class A common stock):
no election shares exchanged for cash consideration =
(number of no election shares of such stockholder) * (shortfall amount)
(no election value)
 
   
if the shortfall amount is more than the no election value, then (1) all no election shares will be exchanged for $28.00 in cash and (2) a portion of the stock election shares of each stockholder will be exchanged for $28.00 in cash as follows (and the remaining portion of such stockholder’s stock election shares will be exchanged for 1.6839 shares of Bioventus class A common stock):
stock election shares exchanged for cash consideration =
(number of stock election shares of such stockholder) * (shortfall amount – no election value)
(aggregate number of stock election shares) * $28.00
If the elected cash consideration equals the available cash amount, then: (1) all cash election shares will be converted into the right to receive $28.00 in cash and (2) all stock election shares and all no election shares will be converted into the right to receive 1.6839 shares of Bioventus class A common stock.
See “The Merger Agreement—Proration”.
Election Procedures
(Page 138)
The exchange agent will mail to Misonix stockholders of record not less than 30 days prior to the anticipated closing date of the first merger a letter of election and transmittal. The letter of election and transmittal enables Misonix stockholders to choose to make a cash election, a stock election or no election with respect to each share of Misonix common stock eligible to receive the merger consideration. Misonix intends to issue a press release at least five business days prior to the expiration of the election period informing Misonix stockholders of the expiration of the election period, which expiration we refer to as the “election deadline”, to make their election and return their completed letters of election and transmittal. If a Misonix stockholder holds shares of Misonix common stock through a bank, brokerage firm or other nominee, such bank, brokerage firm, or other nominee, as applicable, will provide such stockholder with instructions on how to make an election. Election forms must be returned to the broker, bank or nominee in time for it to respond prior to the election deadline, therefore, you are encouraged to pay close attention to, and abide by, any election deadlines provided by the bank, brokerage firm or other nominee holding your shares, as that deadline may be earlier than the election deadline described in this joint proxy statement/prospectus.
Any election will have been properly made only if the exchange agent has actually received a properly completed letter of election and transmittal by the election deadline. Any election form may be revoked or changed by written notice received by the exchange agent prior to the election deadline. If an election form is revoked, the shares of Misonix common stock as to which such election previously applied will be no election shares unless an election is subsequently submitted by the Misonix stockholder prior to the election deadline. For Misonix share certificates and Misonix book-entry shares not held through DTC, Misonix stockholders should complete and return the letter of election and transmittal to the exchange agent even if the stockholder is making no election because the exchange agent will require your transmittal information requested in the letter. Stockholders who do not return a letter of election and transmittal to the exchange agent prior to the election deadline will be mailed a letter of transmittal from the exchange agent following the consummation of the merger. See “The Merger Agreement—Election Procedures”.

 
21

Table of Contents
Treatment of Misonix Equity Awards
(Page 204)
Each outstanding Misonix stock option held by employees and directors of Misonix who meet the
S-8
definition of “employee” shall (i) become fully vested immediately upon the effective time and (ii) be assumed by Bioventus and converted automatically into an option to purchase Bioventus class A common stock based on the option exchange ratio (with the exercise price with respect to such option being adjusted based on the option exchange ratio). Aside from the foregoing adjustments, the assumed options will generally remain subject to the same vesting and other terms and conditions that applied to such awards immediately prior to the effective time.
Each outstanding Misonix stock option held by an individual who does not meet the
S-8
definition of “employee” will become fully vested and be settled in cash immediately prior to the effective time in an amount equal to the product of (x) the number of shares of Misonix common stock subject to the applicable option and (y) the excess, if any, of (i) the average of the volume-weighted average trading prices per share of Bioventus Class A Common Stock on Nasdaq (as reported by Bloomberg L.P.) on each of the five consecutive trading days ending on (and including) the trading day that is three trading days prior to the date of the effective time over (ii) the per share exercise price of such option.
See the section entitled “The Merger Agreement—Treatment of Misonix Equity Awards” of this joint proxy statement/prospectus.
Recommendation of the Bioventus Board of Directors; Bioventus’ Reasons for the Merger
(Page 155)
The Bioventus board unanimously recommends that you vote “
FOR
” the Bioventus share issuance proposal and “
FOR
” the Bioventus adjournment proposal. For a description of some of the factors considered by the Bioventus board in reaching its decision to approve the merger agreement and the transactions contemplated thereby, including the merger and the share issuance, and additional information on the recommendation of the Bioventus board, see “The Mergers—Recommendation of the Bioventus Board of Directors; Bioventus’ Reasons for the Merger.”
Recommendation of the Misonix Board of Directors; Misonix’s Reasons for the Merger
(Page 158)
The Misonix board unanimously recommends that you vote “
FOR
” the Misonix merger proposal, “
FOR
” the Misonix compensation proposal and “
FOR
” the Misonix adjournment proposal. For a description of some of the factors considered by the Misonix board in reaching its decision to approve the merger agreement and the transactions contemplated thereby, including the merger, and additional information on the recommendation of the Misonix board, see “The Mergers—Recommendation of the Misonix Board of Directors; Misonix’s Reasons for the Merger.”
Opinions of Bioventus’ Financial Advisor
Opinion of Perella Weinberg
(Page 165;
Annex B
)
Bioventus retained Perella Weinberg Partners LP, or Perella Weinberg, to act as its financial advisor in connection with the mergers. Bioventus selected Perella Weinberg based on its qualifications, expertise and reputation and its knowledge of the business and affairs of Bioventus, Misonix and the industries in which Bioventus and Misonix conduct their respective businesses. Perella Weinberg and its affiliates, as part of their investment banking business, are continually engaged in performing financial analyses with respect to businesses and their securities in connection with mergers and acquisitions, leveraged buyouts and other transactions as well as for corporate and other purposes.
On July 28, 2021, Perella Weinberg rendered its oral opinion, subsequently confirmed in writing, to the Bioventus board that, as of such date and based upon and subject to the various assumptions made, procedures

 
22

Table of Contents
followed, matters considered and qualifications and limitations set forth therein, the merger consideration to be paid by Bioventus pursuant to the merger agreement, consisting of, at the option of the holders of Misonix common stock issued and outstanding immediately prior to the effective time of the first merger, (other than treasury shares of Misonix, shares held by a subsidiary of Misonix, Bioventus or Merger Sub I, and shares held by Misonix stockholders who have not voted in favor of the Misonix merger proposal and perfected and not withdrawn a demand for appraisal rights pursuant to Delaware law), and subject to certain limitations and proration procedures set forth in the merger agreement (as to which Perella Weinberg expressed no opinion), (i) $28.00 in cash per share of Misonix common stock, or the cash election consideration, or (ii) 1.6839 shares of Bioventus common stock per share of Misonix common stock, or the stock election consideration was, as of the date of the opinion, fair, from a financial point of view, to Bioventus.
The full text of Perella Weinberg’s written opinion, dated July 29, 2021 which sets forth, among other things, the assumptions made, procedures followed, matters considered and qualifications and limitations on the review undertaken by Perella Weinberg, is attached hereto as
Annex
 B
and is incorporated by reference herein. Perella Weinberg’s opinion was not intended to be and does not constitute a recommendation to any holder of Bioventus common stock or any other person as to how such person should vote or otherwise act with respect to the mergers or any other matter. Perella Weinberg’s opinion does not in any manner address the prices at which Misonix common stock or Bioventus common stock will trade at any time. In addition, Perella Weinberg expressed no opinion as to the fairness of the mergers to the holders of any class of securities, creditors or other constituents of Bioventus or Misonix or as to the underlying decision by any person to engage in the mergers or as to the relative merits of the mergers compared to alternative transactions or business strategies. Perella Weinberg provided its opinion for the information and assistance of the Bioventus board in connection with, and for the purposes of its evaluation of, the mergers. This summary is qualified in its entirety by reference to the full text of the opinion. Opinion of Misonix’s Financial Advisor.
Opinion of JP Morgan Securities
(Page 176;
Annex C
)
 
J.P. Morgan rendered an oral opinion to the Misonix board on July 28, 2021 (subsequently confirmed in writing on July 29, 2021) to the effect that, as of such date and based on and subject to the assumptions made, procedures followed, matters considered and other limitations on the review undertaken by J.P. Morgan in preparing its opinion, the merger consideration to be paid to the holders of Misonix common stock in the merger was fair, from a financial point of view, to such holders, as more fully described in the section entitled “Opinion of Misonix’s Financial Advisor” of this joint proxy statement/prospectus. The full text of the written opinion of J.P. Morgan, dated July 29, 2021, which sets forth, among other things, the assumptions made, procedures followed, matters considered and limitations on the review undertaken by J.P. Morgan in preparing its opinion, is attached as Annex C to this joint proxy statement/prospectus and is incorporated herein by reference.
The Bioventus Special Meeting
(Page 119)
In light of ongoing developments related to the
COVID-19
pandemic, the Bioventus special meeting will be held solely in a virtual meeting format via live webcast on [●], 2021, beginning at [●], Eastern Time. Bioventus stockholders will be able to virtually attend and vote at the Bioventus special meeting by visiting the Bioventus special meeting website at www.virtualshareholdermeeting.com/BVS2021SM.
The purposes of the Bioventus special meeting are as follows:
 
   
Bioventus Proposal 1
: Approval of the Share Issuance.
To consider and vote on the Bioventus share issuance proposal; and
 
   
Bioventus Proposal 2
: Adjournment of the Bioventus Special Meeting.
To consider and vote on the Bioventus adjournment proposal.

 
23

Table of Contents
Completion of the mergers is conditioned on the approval of the Bioventus share issuance proposal (Bioventus Proposal 1) by Bioventus stockholders.
Only holders of record of shares of Bioventus common stock outstanding as of the close of business on [●], 2021 (the Bioventus record date) are entitled to notice of, and to vote at, the Bioventus special meeting or any adjournment or postponement thereof. Bioventus stockholders may cast one vote for each share of Bioventus common stock that they own of record as of the Bioventus record date.
A quorum of Bioventus stockholders is necessary to hold the Bioventus special meeting. A quorum will exist at the Bioventus special meeting if holders of record of shares of Bioventus common stock representing a majority in voting power of the stock issued and outstanding and entitled to vote at the meeting, is present in person, or by remote communication, if applicable, or represented by proxy. All shares of Bioventus common stock represented by a valid proxy and all abstentions will be counted as present for purposes of establishing a quorum. All of the proposals for consideration at the Bioventus special meeting are considered
“non-routine”
matters under Nasdaq rules, and, therefore, brokers are not permitted to vote on any of the matters to be considered at the Bioventus special meeting unless they have received instructions from the beneficial owners. As a result, no “broker
non-votes”
are expected at the Bioventus special meeting, and shares held in “street name” will not be counted as present for the purpose of determining the existence of a quorum unless the Bioventus stockholder provides their bank, broker or other nominee with voting instructions for at least one of the proposals brought before the Bioventus special meeting.
Assuming a quorum is present at the Bioventus special meeting, approval of the Bioventus share issuance proposal requires the affirmative vote of the holders of a majority of the issued and outstanding shares of Bioventus common stock that are virtually present via the Bioventus special meeting website or represented by proxy and entitled to vote at the Bioventus special meeting on the Bioventus share issuance proposal. Accordingly, any shares not virtually present or represented by proxy (including due to the failure of an Bioventus stockholder who holds shares in “street name” through a bank, broker or other nominee to provide voting instructions to such bank, broker or other nominee) will have no effect on the outcome of the Bioventus share issuance proposal. An abstention or other failure of any shares virtually present or represented by proxy and entitled to vote at the Bioventus special meeting on the Bioventus share issuance proposal to vote on the Bioventus share issuance proposal will have the same effect as a vote “
AGAINST
” the Bioventus share issuance proposal. However, assuming a quorum is present at the Bioventus special meeting, if an Bioventus stockholder who holds shares in “street name” through a bank, broker or other nominee provides voting instructions for one or more other proposals, but not for the Bioventus share issuance proposal, voting power will deemed to be withheld with respect to the Bioventus share issuance proposal and such failure to provide voting instructions will have no effect on the Bioventus share issuance proposal.
Whether or not a quorum is present at the Bioventus special meeting, approval of the Bioventus adjournment proposal requires the affirmative vote of the holders of a majority of the issued and outstanding shares of Bioventus common stock that are virtually present via the Bioventus special meeting website or represented by proxy and entitled to vote at the Bioventus special meeting on the Bioventus adjournment proposal. Accordingly, any shares not virtually present or represented by proxy (including due to the failure of an Bioventus stockholder who holds shares in “street name” through a bank, broker or other nominee to provide voting instructions to such bank, broker or other nominee) will have no effect on the outcome of the Bioventus adjournment proposal. An abstention or other failure of any shares virtually present or represented by proxy and entitled to vote on the Bioventus adjournment proposal to vote at the Bioventus special meeting on the Bioventus adjournment proposal will have the same effect as a vote “
AGAINST
” the Bioventus adjournment proposal. However, if an Bioventus stockholder who holds shares in “street name” through a bank, broker or other nominee provides voting instructions for one or more other proposals, but not for the Bioventus adjournment proposal, voting power will deemed to be withheld with respect to the Bioventus adjournment proposal and such failure to provide voting instructions will have no effect on the Bioventus adjournment proposal.

 
24

Table of Contents
The Misonix Special Meeting
(Page 128)
The purpose of the Misonix special meeting is to consider and vote on each of the following proposals, each of which is further described in this joint proxy statement/prospectus:
 
   
Misonix Proposal 1
: Adoption of the Merger Agreement.
To consider and vote on the Misonix merger proposal;
 
   
Misonix Proposal 2
:
Approval, on an Advisory
Non-Binding
Basis, of Certain Merger-Related Compensatory Arrangements with Misonix’s Named Executive Officers.
To consider and vote on the Misonix compensation proposal; and
 
   
Misonix Proposal 3
:
Adjournment of the Misonix Special Meeting.
To consider and vote on the Misonix adjournment proposal.
Completion of the mergers is conditioned on the approval of the Misonix merger proposal (Misonix Proposal 1) by Misonix stockholders.
Only holders of record of shares of Misonix common stock outstanding as of the close of business on [●], 2021 (the Misonix record date) are entitled to notice of, and to vote at, the Misonix special meeting or any adjournment or postponement thereof. Misonix stockholders may cast one vote for each share of Misonix common stock that they own of record as of the Misonix record date.
A quorum of Misonix stockholders is necessary to conduct the Misonix special meeting. The presence of the holders of a majority of the outstanding shares of Misonix common stock entitled to vote at the Misonix special meeting will constitute a quorum. Shares of Misonix common stock represented at the Misonix special meeting in person or by a properly authorized and submitted proxy (submitted by mail, by telephone or over the Internet), entitled to vote, but not voted, including shares for which a Misonix stockholder directs an “abstention” from voting, will be counted for purposes of determining a quorum. However, because all of the proposals for consideration at the Misonix special meeting are considered
“non-routine”
matters under Nasdaq rules, shares held in “street name” will not be counted as present for the purpose of determining the existence of a quorum unless the Misonix stockholder provides their bank, broker or other nominee with voting instructions for at least one of the proposals at the Misonix special meeting. If a quorum is not present, Misonix expects that the Misonix special meeting will be adjourned or postponed until the holders of the number of shares of Misonix common stock required to constitute a quorum attend. At any subsequent reconvening of the Misonix special meeting, all proxies will be voted in the same manner as the proxies would have been voted at the original convening of the Misonix special meeting, except for any proxies that have been effectively revoked or withdrawn prior to the subsequent meeting.
The Misonix special meeting will be held at Misonix’s corporate offices, located at 1938 New Highway, Farmingdale, NY 11735 on [●], 2021, beginning at [●], Eastern Time. As part of Misonix’s precautions regarding the novel coronavirus or
COVID-19,
Misonix is planning for the possibility that the meeting may be held solely by means of remote communications. If Misonix takes this step, Misonix will announce the decision to do so in advance, and details on how to participate, including details on how to inspect a list of stockholders of record, will be posted on our website at www.misonix.com and filed with the SEC as proxy material.
Assuming a quorum is present at the Misonix special meeting, approval of the Misonix merger proposal requires the affirmative vote of the holders of a majority of the outstanding shares of Misonix common stock. For the Misonix compensation proposal, a Misonix stockholder may indicate “FOR,” “AGAINST” or “ABSTAIN” on the proxy card. Brokerage firms and nominees will not have the authority to vote their customers’ unvoted shares on the Misonix merger proposal or to vote their customers’ shares if the customers have not furnished voting

 
25

Table of Contents
instructions within a specified period of time prior to the Misonix special meeting. Any shares not present or represented by proxy (including due to the failure of a Misonix stockholder who holds shares of Misonix common stock in “street name” through a bank, broker or other nominee to provide voting instructions to such bank, broker or other nominee) and any abstention, or other failure of any shares of Misonix common stock present or represented by proxy and entitled to vote at the Misonix special meeting on the Misonix merger proposal to vote on the Misonix merger proposal, will each have the same effect as a vote
“AGAINST”
the Misonix merger proposal.
Assuming a quorum is present at the Misonix special meeting, approval of the Misonix compensation proposal requires the affirmative vote of the holders of a majority of the votes cast on the Misonix compensation proposal by holders of Misonix common stock present or represented by proxy at the Misonix special meeting. For the Misonix compensation proposal, a Misonix stockholder may indicate “FOR,” “AGAINST” or “ABSTAIN” on the proxy card. For purposes of determining the number of votes cast with respect to the Misonix compensation proposal, only those votes cast “FOR” or “AGAINST” are included. Brokerage firms and nominees will not have the authority to vote their customers’ unvoted shares on the Misonix compensation proposal or to vote their customers’ shares if the customers have not furnished voting instructions within a specified period of time prior to the Misonix special meeting. Abstentions and broker
non-votes
are counted only for purposes of determining whether a quorum is present at the meeting and therefore will have no effect on the outcome of the vote for the Misonix compensation proposal. Approval of the Misonix compensation proposal is not a condition to completion of the mergers, and the vote with respect to this proposal is advisory only and will not be binding on Misonix, the surviving corporation, the surviving company or Bioventus. If the mergers are completed, the transactions-related executive compensation may be paid to Misonix’s named executive officers to the extent payable in accordance with the terms of the compensation arrangements even if Misonix stockholders fail to approve, by
non-binding,
advisory vote, the Misonix compensation proposal.
Whether or not a quorum is present at the Misonix special meeting, approval of the Misonix adjournment proposal requires the affirmative vote of the holders of a majority in voting power of the shares of Misonix common stock present or represented by proxy at the Misonix special meeting. Accordingly, any shares not present or represented by proxy (including due to the failure of a Misonix stockholder who holds shares in “street name” through a bank, broker or other nominee to provide voting instructions to such bank, broker or other nominee) will have no effect on the outcome of the Misonix adjournment proposal. An abstention, or other failure of any shares of Misonix common stock present or represented by proxy and entitled to vote at the Misonix special meeting on the Misonix adjournment proposal to vote on the Misonix adjournment proposal, will have the same effect as a vote “
AGAINST
” the Misonix adjournment proposal. However, if a Misonix stockholder who holds shares of Misonix common stock in “street name” through a bank, broker or other nominee provides voting instructions for one or more other proposals, but not for the Misonix adjournment proposal, voting power will deemed to be withheld with respect to the Misonix adjournment proposal and such failure to provide voting instructions will have no effect on the Misonix adjournment proposal.
Support Agreements
Subsequent to the execution of the merger agreement, Misonix entered into a voting agreement (the “Bioventus support agreement”) with EW Healthcare Partners Acquisition Fund, L.P., White Pine Medical, LLC (a subsidiary of EW Partners Acquisition Fund, L.P.), Smith & Nephew, Inc., Smith & Nephew USD Ltd and
AMP-CF
Holdings, LLC (together, the “Bioventus supporting stockholders”), pursuant to which such stockholders have agreed, among other things, to vote the shares of Bioventus common stock that they beneficially own at the time such vote is taken in favor of Bioventus share issuance proposal and against approval of any proposal made in opposition to, in competition with, or inconsistent with, the merger agreement or the transaction. As of the record date for the Bioventus special meeting, such stockholders beneficially own approximately [●]% of the outstanding shares of Bioventus common stock. Therefore, the Bioventus supporting
 
26

Table of Contents
stockholders hold a sufficient number of shares of Bioventus common stock in order to approve the Bioventus share issuance proposal. On July 29, 2021, in connection with execution of the merger agreement, each of the Bioventus supporting stockholders have entered into lock up agreements with Bioventus (each a “lock up agreement”) restricting the sale and transfer of the capital stock of Bioventus for a period of 90 or 180 days, subject to the terms of the lock up agreement.
Subsequent to the execution of the merger agreement, Bioventus entered into a voting agreement (the “Misonix support agreement”) with each of Stavros G. Vizirgianakis, 1315 Capital, LLC, SV Life Sciences Fund VI Strategic Partners, L.P. and SV Life Sciences Fund VI, L.P. (together, the “Misonix supporting stockholders”), pursuant to which such stockholders have agreed, among other things, to vote the shares of Misonix common stock that they own at the time such vote is taken in favor of the Misonix merger proposal and Misonix compensation proposal and against approval of any proposal made in opposition to, in competition with, or inconsistent with, the merger agreement or the transaction. As of the record date for the Misonix special meeting, the Misonix supporting stockholders beneficially own approximately [●]% of the outstanding shares of Misonix common stock.
Interests of Bioventus Directors and Executive Officers in the Mergers
(Page 337)
Other than with respect to continued service for, employment by and the right to continued indemnification by the combined company, as of the date of this joint proxy statement/prospectus, Bioventus directors and executive officers do not have interests in the mergers that are different from, or in addition to, the interests of other Bioventus stockholders generally. See “Interests of Bioventus Directors and Executive Officers in the Mergers.”
Interests of Misonix Directors and Executive Officers in the Merger
(Page 338)
In considering the recommendations of the Misonix board, Misonix stockholders should be aware that Misonix directors and executive officers have interests in the mergers, including financial interests, which may be different from, or in addition to, the interests of other Misonix stockholders generally. The Misonix board was aware of and considered these interests, among other matters, when it determined that the mergers are fair to and in the best interests of Misonix and its stockholders, approving and declaring advisable the merger agreement and the transactions contemplated thereby, and recommending that Misonix stockholders approve the Misonix mergers. These interests are discussed in more detail under “Interests of Misonix Directors and Executive Officers in the Mergers.”
For an estimate of the value of the benefits and financial interests that the Misonix named executive officers may become eligible to receive as a result of their interests in the mergers, assuming, among other things, that the merger was completed on August 31, 2021 and each such named executive officer experienced a qualifying termination of employment immediately thereafter, see “Interests of Misonix Directors and Executive Officers in the Mergers—Quantification of Payments and Benefits to Misonix Named Executive Officers—Golden Parachute Compensation.”
Governance of the Combined Company
(Page 205)
Bioventus has agreed to appoint Stavros Vizirgianakis and Patrick Beyer, each a member of the Misonix board, the opportunity to join the Bioventus board as of the effective time, with such directors to hold office until the earliest to occur of the appointment or election and qualification of his or her respective successor or his or her death, resignation, disqualification or proper removal.
No other governance changes are planned in connection with the mergers.
 
27

Table of Contents
Organizational Documents and Directors and Officers of the Surviving Corporation
(Page 205)
At the effective time, Misonix’s certificate of incorporation as in effect immediately prior to the effective time and Misonix’s bylaws as in effect immediately prior to the effective time will continue to be the certificate of incorporation and the bylaws of the surviving company of the first merger. At the second effective time, the certificate of formation and the limited liability company agreement of Merger Sub II in effect immediately prior to the second effective time, will continue to be the certificate of formation and the limited liability company agreement of Merger Sub II, as the surviving entity of the second merger.
Certain Beneficial Owners of Bioventus Common Stock
(Page 369)
At the close of business on September 1, 2021, the latest practicable date prior to the date of this joint proxy statement/prospectus, Bioventus directors and executive officers and their affiliates, as a group, owned and were entitled to vote less than 1% of the shares of Bioventus common stock outstanding on such date. Although none of them has entered into any agreement obligating them to do so, Bioventus currently expects that all Bioventus directors and executive officers will vote their shares “
FOR
” the Bioventus share issuance proposal and “
FOR
” the Bioventus adjournment proposal. For more information regarding the security ownership of Bioventus directors and executive officers, see “Certain Beneficial Owners of Bioventus Common Stock—Security Ownership of Bioventus Directors and Executive Officers.”
Certain Beneficial Owners of Misonix Common Stock
(Page 372)
At the close of business on September 1, 2021, the latest practicable date prior to the date of this joint proxy statement/ prospectus, Misonix directors and executive officers and their affiliates, as a group, owned and were entitled to vote approximately 31.62% of the shares of Misonix common stock outstanding on such date. On July 29, 2021, Stavros Vizirgianakis, Misonix’s Chief Executive Officer and Director, entered into a Voting and Support Agreement with Bioventus and the stockholders named therein, pursuant to which he agreed to, among other things, vote his shares of Misonix common stock in favor of the adoption of the Misonix merger proposal. Although no Misonix director or executive officer other than Mr. Vizirgianakis has entered into any agreement obligating them to vote their shares of Misonix common stock in favor of the proposals at the special meeting, Misonix currently expects that all Misonix directors and executive officers will vote their shares of Misonix common stock “FOR” the Misonix merger proposal, “FOR” the Misonix compensation proposal and “FOR” the Misonix adjournment proposal. See “Interests of Misonix Directors and Executive Officers in the Merger” and the arrangements described in Misonix’s Annual Report on Form 10-K, which is incorporated by reference in this joint proxy statement/prospectus.
Regulatory Approvals
(Page 195)
Bioventus, Merger Sub I, Merger Sub II and Misonix have each agreed to cooperate with each other and to use (and to cause their subsidiaries to use) reasonable best efforts to take, or cause to be taken, all actions, and to do, or cause to be done, all things necessary to cause the conditions to the closing to be satisfied as promptly as reasonably practicable (and in any event no later than the end date) and to consummate and make effective the transactions contemplated by the merger agreement, including to obtain all required regulatory approvals as promptly as practicable, subject to certain limits. See “The Mergers—Regulatory Approvals.”
The obligations of Bioventus and Misonix to consummate the mergers are subject to, among other conditions, the termination or expiration of any waiting period (or any extension thereof) applicable to the transactions contemplated by the merger agreement under the HSR Act.
 
28

Table of Contents
Ownership of the Combined Company
(Page 196)
Based on the number of shares of Bioventus and Misonix common stock outstanding as of September 1, 2021, the latest practicable date prior to the date of this joint proxy statement/prospectus, upon completion of the merger, former Misonix stockholders are expected to own approximately 25% of the outstanding shares of Bioventus common stock and Bioventus stockholders immediately prior to the merger are expected to own approximately 75% of the outstanding shares of Bioventus common stock. The relative ownership interests of Bioventus stockholders and former Misonix stockholders in the combined company immediately following the merger will depend on the number of shares of Bioventus and Misonix common stock issued and outstanding immediately prior to the merger.
Appraisal Rights
(Page 361)
Pursuant to Section 262 of the DGCL, Misonix stockholders who do not vote in favor of Misonix merger proposal and who comply with the applicable requirements of Section 262 of the DGCL have the right to seek appraisal of such shares by the Delaware Court of Chancery and to receive payment in cash of the fair value of those shares. It is possible that the fair value as determined by the Delaware Court of Chancery may be more or less than, or the same as, the per share value of the merger consideration.
Misonix stockholders who wish to preserve their appraisal rights must make a demand for appraisal prior to the time the Misonix stockholder vote is taken on the Misonix merger proposal. In addition to submitting a demand for appraisal, such Misonix stockholders must continuously hold such shares through the effective time, must not vote in favor of the Misonix merger proposal, must not surrender their shares in exchange for the merger consideration, and must otherwise follow the procedures prescribed by Section 262 of the DGCL.
You are encouraged to read Section 262 of the DGCL carefully and in their entirety. Due to the complexity of the procedures for exercising your appraisal rights, Misonix stockholders who are considering exercising such rights are encouraged to seek the advice of legal counsel. Failure to strictly comply with these provisions will result in the loss of appraisal rights. See the section entitled “Appraisal Rights” of this joint proxy statement/prospectus for additional information and the text of Section 262 of the DGCL reproduced in its entirety as
Annex D
to this proxy statement/prospectus.
Bioventus stockholders are not entitled to appraisal rights in connection with the mergers.
Conditions to the Completion of the Mergers
(Page 222)
The obligations of each of Bioventus and Misonix to complete the mergers are subject to the satisfaction or waiver, as of the closing, of each of the following conditions:
 
   
the registration statement on Form
S-4
of which this joint proxy statement/prospectus forms a part must have become effective in accordance with the provisions of the Securities Act, no stop order may have been issued by the SEC and remain in effect with respect to the Form
S-4
and no proceedings for that purpose may have been commenced or threatened in writing by the SEC and not withdrawn;
 
   
approval by Misonix stockholders of the Misonix merger proposal must have been obtained;
 
   
approval by Bioventus stockholders of the Bioventus share issuance proposal must have been obtained;
 
   
any waiting period (or any agreed upon extension of any waiting period or commitment not to consummate the mergers for any period of time) applicable to the consummation of the mergers under the HSR Act must have expired or been terminated by the relevant governmental entity, and there must be no pending agreement between Bioventus and any governmental entity not to close;
 
   
the shares of Bioventus class A common stock to be issued pursuant to the first merger, including the shares of Bioventus class A common stock to be issued upon the exercise of converted Misonix stock

 
29

Table of Contents
 
options and upon vesting of converted Misonix RSUs, must have been approved for listing (subject to notice of issuance) on Nasdaq; and
 
   
no law or order preventing, enjoining or making illegal the consummation of the mergers may have been entered, issued or adopted by any court of competent jurisdiction or other governmental entity of competent jurisdiction and remain in effect.
In addition, each party’s obligation to complete the mergers is subject to, among other things, the accuracy of certain representations and warranties of the other party and the compliance by such other party with certain of its covenants, in each case, subject to the materiality standards set forth in the merger agreement, and the absence of the occurrence of any material adverse effect.
Neither Bioventus nor Misonix can be certain when, or if, the conditions to the mergers will be satisfied or waived, or that the mergers will be completed.
See “The Merger Agreement—Conditions to the Completion of the Mergers.”
No Solicitation of Acquisition Proposals
(Page 211)
As more fully described under “The Merger Agreement—No Solicitation of Acquisition Proposals,” subject to the exceptions summarized below, Bioventus and Misonix have each agreed that they will not (a) solicit, initiate, knowingly encourage, knowingly induce, knowingly assist or knowingly facilitate any inquiries regarding, or the submission or announcement by any person (other than, in the case of Misonix, Bioventus or in the case of Bioventus, Misonix, or its respective affiliates and representatives) of, any proposal or offer that constitutes, or would reasonably be expected to lead to, an acquisition proposal (as defined under “The Merger Agreement—No Solicitation of Acquisition Proposals”) (with certain exceptions related to each board of directors informing itself of an acquisition proposal), (b) furnish any information regarding such party or its subsidiaries (other than to the other party and its subsidiaries) or afford access to such party’s or its subsidiaries’ representatives, books, records or property, in each case in connection with, or for the purpose of soliciting, initiating, encouraging or facilitating, or in response to, any inquiry, proposal or offer that constitutes or would reasonably be expected to lead to an acquisition proposal, (c) engage in, enter into, continue or otherwise participate in any discussions or negotiations with any person (other than, in the case of Bioventus, Misonix, or in the case of Misonix, Bioventus, or its respective representatives) with respect to any acquisition proposal or any inquiry, proposal or offer that would reasonably be expected to lead to an acquisition proposal (with certain exceptions related to each board of directors informing itself of an acquisition proposal), (d) approve, adopt, recommend, agree to or enter into, or publicly propose to approve, adopt, recommend, agree to or enter into, any letter of intent, memorandum of understanding or similar document, agreement, commitment or agreement in principle with respect to any acquisition proposal or (e) resolve or agree to do any of the foregoing.
Notwithstanding the restrictions described above, if at any time prior to obtaining approval of the Misonix merger proposal, in the case of Misonix, or the Bioventus share issuance proposal, in the case of Bioventus, Bioventus or Misonix, as applicable, receives a bona fide, written acquisition proposal after the date of the merger agreement that did not result from a breach of the
non-solicitation
provisions in the merger agreement and that the Bioventus board or the Misonix board, as applicable, determines in good faith (after consultation with its outside legal counsel and financial advisor) that such acquisition proposal constitutes or would reasonably be expected to lead to a superior proposal (as defined under “The Merger Agreement—No Solicitation of Acquisition Proposals”), Bioventus or Misonix, as applicable, may (a) engage in discussions or negotiations with the party making such acquisition proposal and (b) following the receipt from such party making the acquisition proposal, (or there is then in effect with such party) an executed confidentiality agreement with nondisclosure provisions at least as restrictive of such third party as the
non-disclosure
agreement with Bioventus or Misonix, as applicable, furnish information to such party with respect to Bioventus or Misonix, as applicable, in either case, subject to certain conditions and obligations in the merger agreement.
 
30

Table of Contents
Bioventus and Misonix have also agreed to notify the other (a) promptly following (and in any event, within 48 hours of the receipt of) any acquisition proposal or any inquiry or request for information with respect to an acquisition proposal or that is reasonably likely to lead to an acquisition proposal and (b) to keep the other party reasonably informed on a current basis (and in any event, within 48 hours) as to the status of any acquisition proposal, including informing the other party of any material change to such acquisition proposal’s terms, the status of any negotiations, and any change in its intentions. See “The Merger Agreement—No Solicitation of Acquisition Proposals.”
No Change of Recommendation
(Page 214)
The merger agreement provides that, among other restrictions and subject to certain exceptions, neither the Bioventus board nor the Misonix board may (a) withhold, withdraw, modify, amend or qualify (or publicly propose to do so), in a manner adverse the other party, the Bioventus board’s recommendation to Bioventus stockholders to approve the share issuance or the Misonix board’s recommendation to Misonix stockholders to adopt the merger agreement, as applicable, or (b) approve, recommend or declare advisable (or publicly propose to do so) any acquisition proposal.
Notwithstanding the restrictions described above, at any time prior to obtaining the approval by Bioventus stockholders of the Bioventus share issuance proposal or by Misonix stockholders of the Misonix merger proposal, as the case may be, the Bioventus board or the Misonix board, as applicable, may make a change of recommendation and/or terminate the merger agreement to concurrently enter into a definitive agreement with respect to an acquisition proposal if it determines in good faith (after consultation with its outside legal counsel and financial advisor) that such acquisition proposal is a superior proposal and that failure to take such action with respect to such acquisition proposal would reasonably be expected to be inconsistent with the such board of directors’ fiduciary duties to such party and its stockholders under applicable laws (and subject to compliance with certain obligations set forth in the merger agreement, including providing the other party with prior notice and the opportunity to negotiate for a period to make such acquisition proposal no longer a superior proposal and payment of a the applicable termination fee in connection with any such termination of the merger agreement).
In addition, the Bioventus board or the Misonix board, as the case may be, is permitted under certain circumstances, prior to obtaining stockholder approval of the Bioventus share issuance proposal, in the case of Bioventus, or the Misonix merger proposal, in the case of Misonix, and subject to compliance with certain obligations set forth in the merger agreement (including providing the other party with prior notice and the opportunity to negotiate during such notice period to amend the terms of the merger agreement) to make a change of recommendation in response to an intervening event (unrelated to an acquisition proposal) if the Bioventus board or the Misonix board, as applicable, determines in good faith (after consultation with its outside legal counsel and financial advisor) that the failure to do so would be reasonably likely to be inconsistent with its fiduciary duties. See “The Merger Agreement—No Change of Recommendation.”
Termination of the Merger Agreement
(Page 225)
The merger agreement may be terminated:
 
   
by mutual written consent of Bioventus and Misonix at any time prior to the effective time;
 
   
by either Bioventus or Misonix, if the merger has not been consummated at or prior to the end date, provided, that the end date will be automatically extended in the event the only closing condition not satisfied or waived is the condition related to antitrust laws (however, a party may not terminate the merger agreement if such party’s material breach of any of its obligations under the merger agreement materially contributed to the failure of the closing to have occurred by the end date);
 
   
by either Bioventus or Misonix at any time prior to the effective time if a relevant legal restraint permanently preventing, enjoining or making illegal the consummation of the mergers shall have

 
31

Table of Contents
 
become final and
non-appealable;
provided, that the party seeking to terminate the merger agreement must have used reasonable best efforts to prevent the entry of and to remove such relevant legal restraint in accordance with the merger agreement;
 
   
by Bioventus at any time prior to Misonix obtaining its required stockholder approval, if the Misonix board has made a change in recommendation or Misonix has willfully breached in any material respect the covenants applicable to it regarding
non-solicitation,
special meetings and changes in recommendation;
 
   
by Misonix at any time prior to Bioventus obtaining its required stockholder approval, if (a) the Bioventus board has made a change in recommendation, (b) Bioventus has willfully breached in any material respect the covenants applicable to it regarding
non-solicitation,
special meetings and changes in recommendation or (c) if Bioventus has materially breached its representations and warranties regarding financing and solvency under the merger agreement or its covenants regarding financing and financing cooperation under the merger agreement, and (i) any such breach is not cured by the earlier of the end date or prior to the twentieth business day after Misonix gives written notice of such breach to Bioventus, (ii) all of the conditions, the satisfaction or waiver of which would be necessary to trigger the obligation of Bioventus to consummate the mergers (not including the condition related to the certificate to be provided by Misonix), have been satisfied and continue to be satisfied (other than those conditions that by their nature cannot be satisfied other than at the closing), (iii) Misonix has committed to Bioventus that Misonix is ready, willing and able to consummate the transactions contemplated by the merger agreement, and (iv) Bioventus, Merger Sub I or Merger Sub II fails to consummate the transactions contemplated by the merger agreement by the earlier of the end date or within two business days following the written notice delivered by Misonix to Bioventus following the expiration of the cure period specified above;
 
   
by Misonix, if prior to obtaining its required stockholder approval, (a) the Misonix board has authorized Misonix to enter into a definitive agreement relating to a superior proposal in material compliance with the merger agreement and (b) substantially concurrently with the termination of the merger agreement, Misonix enters into the definitive agreement relating to a superior proposal and pays Bioventus the applicable termination fee pursuant to the merger agreement;
 
   
by either Bioventus or Misonix, if the approval by Misonix stockholders of the Misonix merger proposal has not been obtained after a vote on approval of such proposal has been taken at the Misonix special meeting (including any postponement or adjournment thereof);
 
   
by either Bioventus or Misonix, if the approval by Bioventus stockholders of the Bioventus share issuance proposal has not been obtained after a vote on approval of such proposal has been taken at the Bioventus special meeting (including any postponement or adjournment thereof);
 
   
by Bioventus (a) if any of Misonix’s representations and warranties contained in the merger agreement are inaccurate such that the conditions to closing would not be satisfied or (b) if Misonix has breached any covenant in the merger agreement and such breach would result in the failure of a condition to closing, provided, that if an inaccuracy in any of Misonix’s representations and warranties or a breach of a covenant of Misonix is curable by Misonix by the end date and Misonix is continuing to exercise its reasonable best efforts to cure such inaccuracy or breach, then Bioventus may not terminate the merger agreement under this paragraph on account of such inaccuracy or breach unless such inaccuracy or breach shall remain uncured for a period of thirty business days commencing on the date that Misonix receives written notice of such inaccuracy or breach from Bioventus; provided, further, that Bioventus shall not have the right to terminate the merger agreement pursuant to this paragraph if Bioventus is then in breach of any of its representations, warranties or agreements contained in the merger agreement, which breach would give rise to the failure of a condition to closing; or

 
32

Table of Contents
   
by Misonix if: (a) any of Bioventus’, Merger Sub I’s or Merger Sub II’s representations and warranties contained in the merger agreement are inaccurate such that the conditions to closing would not be satisfied; or (b) any of Bioventus’ covenants contained in the merger agreement will have been breached such that the conditions to closing would not be satisfied; provided, however, that for purposes of clauses (a) and (b) above, if an inaccuracy in any of Bioventus’, Merger Sub I’s or Merger Sub II’s representations and warranties or a breach of a covenant of Bioventus is curable by Bioventus by the end date and Bioventus is continuing to exercise its reasonable best efforts to cure such inaccuracy or breach, then Misonix may not terminate the merger agreement under this paragraph on account of such inaccuracy or breach unless such inaccuracy or breach shall remain uncured for a period of thirty business days commencing on the date that Bioventus receives written notice of such inaccuracy or breach from Misonix; provided, further, that Misonix shall not have the right to terminate the merger agreement pursuant to this paragraph if Misonix is then in breach of any of its representations, warranties or agreements contained in the merger agreement, which breach would give rise to the failure of a condition to closing.
See “The Merger Agreement—Termination of the Merger Agreement.”
Termination
Fees
(Page 226)
Bioventus and Misonix have each agreed to pay a termination fee of $20,661,000 in cash (the “termination fee”) to the other party, if the merger agreement is terminated in certain circumstances involving a change of recommendation, breach of certain covenants of such party or termination of the merger agreement to enter into a superior proposal, in each case by the party obligated to pay the fee. Bioventus and Misonix are also required to pay the applicable termination fee if the party obligated to pay the termination fee enters into or consummates a superior proposal following certain terminations of the merger agreement, including a termination due to such party’s failure to obtain the required stockholder approval.
A termination fee will be payable by a party only once and not in duplication even though the termination fee may be payable by such party pursuant to multiple circumstances. Furthermore, except in the case of fraud or intentional and material breach of the merger agreement, if a party receives a termination fee, then the termination fee will be the recipient’s sole and exclusive remedy against the other party, its affiliates and its and their respective representatives in connection with the merger agreement. See “The Merger Agreement—Termination Fees.”
Accounting Treatment
(Page 197)
Bioventus prepares its financial statements in accordance with GAAP. The mergers will be accounted for using the acquisition method of accounting under the provisions of Accounting Standards Codification (“ASC”) 805, Business Combinations, with Bioventus representing the accounting acquirer under this guidance. Bioventus will record assets acquired, including identifiable intangible assets, and liabilities assumed from Misonix at their respective fair values at the date of completion of the mergers. Any excess of the purchase price over the net fair value of such assets and liabilities will be recorded as goodwill.
The financial condition and results of operations of Bioventus after completion of the mergers will reflect Misonix after completion of the mergers, but will not be restated retroactively to reflect the historical financial condition or results of operations of Misonix. The earnings of Bioventus following completion of the mergers will reflect acquisition accounting adjustments, including the effect of changes in the carrying value for assets and liabilities on depreciation expense and amortization expense. Indefinite-lived intangible assets, including goodwill, will not be amortized but will be tested for impairment at least annually, and all tangible and intangible assets including goodwill will be tested for impairment when certain indicators are present. If, in the future, Bioventus determines that tangible or intangible assets (including goodwill) are impaired, Bioventus would record an impairment charge at that time.

 
33

Table of Contents
U.S. Federal Income Tax Consequences of the Mergers
(Page 343)
For U.S. federal income tax purposes, the first merger and the second merger, taken together, are intended to qualify as a “reorganization” within the meaning of Section 368(a) of the Code. Assuming the mergers so qualify, a U.S. holder (as defined under “Material U.S. Federal Income Tax Consequences of the First Merger and Second Merger”) of Misonix common stock generally will not recognize any gain or loss for U.S. federal income tax purposes upon the exchange of Misonix common stock for Bioventus class A common stock in the mergers, except with respect to cash received by Misonix stockholders in lieu of fractional shares of Bioventus common stock, but a U.S. holder of Misonix common stock generally will recognize any gain for U.S. federal income tax purposes upon the exchange of Misonix common stock for cash consideration.
See “Material U.S. Federal Income Tax Consequences of the First Merger and the Second Merger” for a more complete description of certain U.S. federal income tax consequences of the mergers. You are urged to consult your own tax advisor as to the specific tax consequences to you of the mergers in light of your particular circumstances.
Comparison of Stockholders’ Rights
(Page 351)
Upon completion of the merger, Misonix stockholders receiving shares of Bioventus common stock will become Bioventus stockholders. The rights of Bioventus stockholders will be governed by the DGCL and the Bioventus charter and bylaws in effect at the effective time. As Bioventus and Misonix are both Delaware corporations, the rights of Bioventus and Misonix stockholders are not materially different. However, there are certain differences in the rights of Bioventus stockholders under the Bioventus charter and bylaws and of Misonix stockholders under the Misonix charter and bylaws. See “Comparison of Stockholders’ Rights.”
Listing of Bioventus Common Stock; Delisting and Deregistration of Misonix Common Stock
(Page 197)
It is a condition to the merger that the shares of Bioventus common stock to be issued to Misonix stockholders in the merger be approved for listing on Nasdaq, subject to official notice of issuance. If the transaction is completed, Misonix common stock will be delisted from Nasdaq and deregistered under the Exchange Act, following which Misonix will no longer be required to file periodic reports with the SEC with respect to Misonix common stock.
Misonix has agreed to cooperate with Bioventus prior to the closing to cause the Misonix common stock to be delisted from Nasdaq and be deregistered under the Exchange Act as soon as practicable after the effective time.
Risk Factors
(Page 39)
In evaluating the merger agreement, the merger and the share issuance, you should carefully read this joint proxy statement/prospectus and give special consideration to the factors discussed under “Risk Factors.”
Recent Developments
On July 15, 2020, BV LLC made a $15.0 million equity investment in CartiHeal (2009) Ltd. (“CartiHeal”), a privately-held company headquartered in Israel and developer of the proprietary
Agili-C
implant for the treatment of joint surface lesions in traumatic and osteoarthritic joints. Concurrent with the July 15, 2020 investment, BV LLC entered into an Option and Equity Purchase Agreement with CartiHeal and its shareholders, which provides BV LLC with an exclusive option to acquire 100% of CartiHeal’s shares, or the Call Option, and provides CartiHeal with a put option that would require BV LLC to purchase 100% of CartiHeal’s shares under certain conditions, or the Put Option. The Call Option is exercisable by BV LLC at any time. The Put Option is

 
34

Table of Contents
only exercisable by CartiHeal upon pivotal clinical trial success, including achievement of certain secondary endpoints and FDA approval of the
Agili-C
device with a label consistent in all respects with pivotal clinical trial success. If not previously exercised, the Call Option and the Put Option terminate 45 days following FDA approval of
Agili-C
(subject to final review by BV LLC of updated disclosures by CartiHeal). Should the Put Option or Call Option be exercised and the acquisition of CartiHeal consummated, consideration for the acquisition of all of the shares of CartiHeal pursuant to the Option and Equity Purchase Agreement would be $350.0 million in cash, subject to customary adjustments, all of which would be payable at closing, with an additional $150.0 million payable upon achievement of certain sales milestones related to
Agili-C.
On August 27, 2021, the Bioventus board, after its review of the statistical report for CartiHeal’s pivotal clinical trial and determination that the results of the statistical report indicated a Pivotal Clinical Trial Success (as contemplated by the Option and Equity Purchase Agreement), approved BV LLC’s continued pursuit of a potential acquisition of CartiHeal. BV LLC thereafter deposited $50.0 million in escrow in accordance with the terms of the Option and Equity Purchase Agreement. Should the Put Option or Call Option be exercised and the acquisition of CartiHeal consummated, the escrowed funds will be applied towards the consideration payable by BV LLC pursuant to the Option and Equity Purchase Agreement. The closing of the transaction is subject to, among other things (including customary closing conditions), the valid exercise of the Call Option or the Put Option. CartiHeal plans to submit the clinical module of their PMA later this year, and the decision from the FDA is expected in the second half of 2022.
Litigation Relating to the Merger
(Page 197)
O
n September 16, 2021, a purported stockholder of Misonix filed an action in the United States District Court for the Southern District of New York, captioned Ciccotelli v. Misonix, Inc. et al., Case No. 1:21-cv-07773 (S.D.N.Y.). The complaint asserts claims under Section 14(a) and Section 20(a) of the Exchange Act and SEC Rule 14a-9 promulgated thereunder, challenging the adequacy of disclosures in the proxy statement/prospectus filed with the SEC on September 8, 2021, regarding Misonix and Bioventus’s projections and J.P. Morgan’s financial analysis. The complaint purports to seek, among other relief, (i) injunctive relief preventing the parties from proceeding with the merger, (ii) rescission in the event that the merger is consummated, and (iii) an award of costs, including attorneys’ and experts’ fees. More information can be found under “The Merger—Litigation Relating to the Merge
r.”

 
35

Table of Contents
MARKET PRICE AND DIVIDEND INFORMATION
Bioventus Class A Common Stock
Bioventus class A common stock is currently listed on The Nasdaq Global Select Market under the symbol “BVS.”
The closing price of Bioventus class A common stock on July 28, 2021, the trading day immediately prior to the public announcement of the Merger on July 29, 2021, as reported on The Nasdaq Global Select Market, was $17.15 per share.
Because the market price of Bioventus class A common stock is subject to fluctuation, the market value of the shares of Bioventus class A common stock that Misonix stockholders who elect the stock election consideration will be entitled to receive in the first merger may increase or decrease.
As of [●], 2021, the record date for the Bioventus special meeting, there were approximately [●] holders of record of Bioventus class A common stock.
Dividends
Bioventus has never declared or paid any cash dividends on Bioventus class A common stock and does not anticipate paying cash dividends on Bioventus class A common stock for the foreseeable future. Notwithstanding the foregoing, any determination to pay cash dividends subsequent to the mergers will be at the discretion of the combined company’s then-current board of directors and will depend upon a number of factors, including the combined company’s results of operations, financial condition, future prospects, contractual restrictions, restrictions imposed by applicable law and other factors the then-current board of directors deems relevant.
 
36

Table of Contents
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
The registration statement on Form
S-4
of which this joint proxy statement/prospectus forms a part, the documents that Bioventus and Misonix refer you to in the registration statement and oral statements made or to be made by Bioventus and Misonix include certain “forward-looking statements” within the meaning of, and subject to the safe harbor created by, Section 27A of the Securities Act, Section 21E of the Exchange Act and the Private Securities Litigation Reform Act of 1995, which are referred to as the “safe harbor provisions.” Statements contained or incorporated by reference in the registration statement of which this joint proxy statement/prospectus forms a part that are not historical facts are forward-looking statements, including statements about the beliefs and expectations of Bioventus and Misonix management relating to the merger and future financial condition and performance. Words such as “believe,” “continue,” “could,” “expect,” “anticipate,” “intends,” “estimate,” “forecast,” “project,” “should,” “may,” “will,” “would” or the negative thereof and similar expressions are intended to identify such forward-looking statements that are intended to be covered by the safe harbor provisions. Investors are cautioned that any forward-looking statements are subject to known and unknown risks and uncertainties, many of which are beyond the control of both companies, and which may cause actual results and future trends to differ materially from those matters expressed in, or implied or projected by, such forward-looking statements, which speak only as of the date of this joint proxy statement/prospectus. Although these forward-looking statements are based on assumptions that Bioventus and Misonix management, as applicable, believe to be reasonable, they can give no assurance that these expectations will prove to be correct. Investors are cautioned not to place undue reliance on these forward-looking statements. Among the risks and uncertainties that could cause actual results to differ from those described in forward-looking statements are the following:
 
   
the occurrence of any change, event, series of events or circumstances that could give rise to the termination of the merger agreement, including a termination of the merger agreement under circumstances that could require Bioventus to pay a termination fee to Misonix or require Misonix to pay a termination fee to Bioventus;
 
   
uncertainties related to the timing of the receipt of required regulatory approvals for the merger and the possibility that Bioventus and Misonix may be required to accept conditions that could reduce or eliminate the anticipated benefits of the merger as a condition to obtaining regulatory approvals or that the required regulatory approvals might not be obtained at all;
 
   
the price of Bioventus and Misonix common stock could change before the completion of the merger, including as a result of uncertainty as to the long-term value of the common stock of the combined company or as a result of broader stock market movements;
 
   
the possibility that the parties are unable to complete the merger due to the failure of Bioventus stockholders to approve the share issuance or of Misonix stockholders to adopt the merger agreement, or the failure to satisfy any of the other conditions to the completion of the merger, or unexpected delays in satisfying any conditions;
 
   
delays in closing, or the failure to close, the merger for any reason, could negatively impact Bioventus, Misonix or the combined company;
 
   
risks that the pendency or completion of the merger and the other transactions contemplated by the merger agreement disrupt current plans and operations, which may adversely impact Bioventus’s or Misonix’s respective businesses;
 
   
difficulties or delays in integrating the businesses of Bioventus and Misonix following completion of the merger or fully realizing the anticipated synergies or other benefits expected from the merger;
 
   
certain restrictions during the pendency of the proposed merger that may impact the ability of Bioventus or Misonix to pursue certain business opportunities or strategic transactions;
 
   
the risk of legal proceedings that have been or may be instituted against Bioventus, Misonix, their directors and/or others relating to the merger;
 
37

Table of Contents
   
risks related to the diversion of the attention and time of Bioventus or Misonix management from ongoing business concerns;
 
   
the risk that the proposed merger or any announcement relating to the proposed merger could have an adverse effect on the ability of Bioventus or Misonix to retain and hire key personnel or maintain relationships with customers, suppliers, distributors, vendors, strategic partners or other third parties, including regulators and other governmental authorities or agencies, or on Bioventus’s or Misonix’s respective operating results and businesses generally;
 
   
the potentially significant amount of any costs, fees, expenses, impairments or charges related to the merger;
 
   
the potential dilution of Bioventus and Misonix stockholders’ ownership percentage of the combined company as compared to their ownership percentage of Bioventus or Misonix, as applicable, prior to the merger;
 
   
the business, economic, political and other conditions in the countries in which Bioventus or Misonix operate;
 
   
events beyond the control of Bioventus and Misonix, such as acts of terrorism or the continuation or worsening of the
COVID-19
pandemic and changes in applicable law, including changes in Bioventus’s or Misonix’s estimates of their expected tax rate based on current tax law;
 
   
the potential dilution of the combined company’s earnings per share as a result of the merger;
 
   
Bioventus and Misonix directors and executive officers having interests in the merger that are different from, or in addition to, the interests of Bioventus and Misonix stockholders generally; and
 
   
the possibility that the combined company’s results of operations, cash flows and financial position after the merger may differ materially from the unaudited pro forma condensed combined financial information contained in this proxy statement/prospectus.
For further discussion of these and other risks, contingencies and uncertainties applicable to Bioventus and Misonix, their respective businesses and the proposed merger, see “Risk Factors” in this joint proxy statement/prospectus and in similarly titled sections in Bioventus’s and Misonix’s other filings with the SEC that are incorporated by reference herein. See “Where You Can Find More Information.”
All subsequent written or oral forward-looking statements attributable to Bioventus, Misonix or any person acting on either of their behalf are expressly qualified in their entirety by these cautionary statements. Neither Bioventus nor Misonix is under any obligation to update, alter or otherwise revise any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future events or otherwise, and each expressly disclaims any obligation to do so, except as may be required by law.
 
38

Table of Contents
RISK FACTORS
In considering how to vote on the proposals to be considered and voted on at the Bioventus and Misonix special meetings, you are urged to carefully consider all of the information contained or incorporated by reference in this joint proxy statement/prospectus. See “Where You Can Find More Information.” You should also read and consider the risks associated with each of the businesses of Bioventus and Misonix because those risks will affect the combined company. The risks associated with the business of Bioventus are presented below and the risks associated with the business of Misonix can be found in Misonix Annual Report on Form
10-K
for the fiscal year ended June 30, 2021, as such risks may be updated or supplemented in Misonix’s subsequently filed Quarterly Reports on
Form 10-Q
and Current Reports on Form
8-K
(excluding any information and exhibits furnished under Item 2.02 or 7.01 thereof), each of which is incorporated by reference in this joint proxy statement/prospectus. In addition, you are urged to carefully consider the following material risks relating to the merger and the businesses of Bioventus, Misonix and the combined company.
Risk Factor Summary
Risks Relating to the Mergers
 
   
Because the exchange ratio is fixed and will not be adjusted in the event of any change in the price of either Bioventus or Misonix common stock, the value of the consideration that Misonix stockholders will receive in the first merger is uncertain.
 
   
The market price of Bioventus common stock will continue to fluctuate after the mergers.
 
   
The mergers may not be completed and the merger agreement may be terminated in accordance with its terms.
 
   
The termination of the merger agreement could negatively impact Bioventus or Misonix and the trading prices of the Bioventus or Misonix common stock.
Risks Relating to the Combined Company
 
   
Combining the businesses of Bioventus and Misonix may be more difficult, costly or time-consuming than expected and the combined company may fail to realize the anticipated benefits of the merger, which may adversely affect the combined company’s business results and negatively affect the value of the combined company’s common stock.
 
   
The failure to successfully integrate the businesses and operations of Bioventus and Misonix in the expected time frame may adversely affect the combined company’s future results.
 
   
The combined company may not be able to retain customers, suppliers or distributors, or customers, suppliers or distributors may seek to modify contractual relationships with the combined company, which could have an adverse effect on the combined company’s business and operations. Third parties may terminate or alter existing contracts or relationships with Bioventus or Misonix.
 
   
The combined company may be exposed to increased litigation, which could have an adverse effect on the combined company’s business and operations.
 
   
The Bioventus and Misonix unaudited prospective financial information is inherently subject to uncertainties, the unaudited pro forma condensed combined financial information included in this document is preliminary and the combined company’s actual financial position and results of operations after the transaction may differ materially from these estimates and the unaudited pro forma condensed combined financial information included in this joint proxy statement/prospectus. The unaudited pro forma condensed combined financial information does not reflect the effect of any divestitures that may be required in connection with the transaction.
 
39

Table of Contents
Risks Relating to Bioventus
 
   
Bioventus’ business may continue to experience adverse impacts as a result of the
COVID-19
pandemic.
 
   
Bioventus is highly dependent on a limited number of products.
 
   
Bioventus’ long-term growth depends on its ability to develop, acquire and commercialize new products, line extensions or expanded indications.
 
   
Bioventus may be unable to successfully commercialize newly developed or acquired products or therapies in the United States.
 
   
Bioventus’ products and operations are subject to extensive governmental regulation, and its failure to comply with applicable requirements could cause its business to suffer.
 
   
Bioventus may be subject to enforcement action if it engages in improper claims submission practices and resulting audits or denials of Bioventus’ claims by government agencies could reduce Bioventus’ net sales or profits.
 
   
The FDA regulatory process is expensive, time-consuming and uncertain, and the failure to obtain and maintain required regulatory clearances and approvals could prevent Bioventus from commercializing its products.
 
   
Protection of Bioventus’ intellectual property rights may be difficult and costly, and Bioventus’ inability to protect its intellectual property could adversely affect its competitive position.
 
   
Bioventus depends on certain technologies that are licensed to it. Bioventus does not control the intellectual property rights covering these technologies and any loss of Bioventus’ rights to these technologies or the rights licensed to Bioventus could prevent Bioventus from selling Bioventus’ products, which could adversely impact its business, results of operations and financial condition.
 
   
In the past, Bioventus identified material weaknesses in its internal control over financial reporting. If Bioventus experiences additional material weaknesses in the future or otherwise fails to maintain an effective system of internal controls, Bioventus may not be able to accurately or timely requirements applicable to public companies, which may adversely affect investor confidence in Bioventus, and, as a result, the market price of Bioventus class A common stock.
 
   
Bioventus is a “controlled company” within the meaning of Nasdaq listing standards and, as a result, will qualify for, and intend to rely on, exemptions from certain corporate governance requirements. You will not have the same protections afforded to stockholders of companies that are subject to such requirements.
 
   
Bioventus’ principal asset is Bioventus’ interest in BV LLC, and, accordingly, Bioventus depends on distributions from BV LLC to pay Bioventus’ taxes and expenses, including payments under the Tax Receivable Agreement. BV LLC’s ability to make such distributions may be subject to various limitations and restrictions.
 
   
The TRA with Smith & Nephew, Inc. (“the continuing LLC owner”) requires Bioventus to make cash payments to it in respect of certain tax benefits to which Bioventus is or may become entitled, and Bioventus expects that the payments it will be required to make could be significant.
 
   
Taking advantage of the reduced disclosure requirements applicable to “emerging growth companies” may make Bioventus class A common stock less attractive to investors.
 
40

Table of Contents
Risks Relating to the Mergers
Because the exchange ratio is fixed and will not be adjusted in the event of any change in the price of either Bioventus or Misonix common stock, the value of the consideration that Misonix stockholders will receive in the first merger is uncertain.
Upon completion of the first merger, each issued and outstanding share of Misonix common stock (other than treasury shares and shares held by Bioventus, Merger Sub I or Merger Sub II and shares held by Misonix stockholders who have not voted in favor of the Misonix merger proposal and prefected and not withdrawn a demand for appraisal rights pursuant to Delaware law) will be converted into the right to receive either an amount in cash equal to $28.00 or 1.6839 validly issued, fully paid and
non-assessable
shares of Bioventus class A common stock, based on the election of the holder thereof and subject to proration in accordance with the terms of the merger agreement. Bioventus stockholders will continue to own their existing shares of Bioventus common stock. The exchange ratio for the stock election consideration is fixed in the merger agreement and will not be adjusted for changes in the market price of either Bioventus or Misonix common stock prior to the completion of the mergers. The market prices of Bioventus and Misonix common stock have fluctuated prior to and after the date of the announcement of the merger agreement and will continue to fluctuate from the date of this joint proxy statement/prospectus to the dates of the Bioventus and Misonix special meetings, and through the date the mergers are consummated.
Because the exchange ratio is fixed, the market value of the stock election consideration to Misonix stockholders will fluctuate with the market price of the Bioventus class A common stock and will not be known at the time that Misonix stockholders vote on the mergers. Similarly, Bioventus stockholders will not know or be able to determine at the time of the Bioventus special meeting the market value of the shares of Bioventus common stock to be issued to those Misonix stockholders receiving the stock election consideration pursuant to the merger agreement compared to the market value of the shares of Misonix common stock that are being exchanged in the first merger.
Stock price changes may result from a variety of factors, including, among others, general market and economic conditions, changes in Bioventus’ or Misonix’s respective businesses, operations and prospects, the uncertainty as to the extent of the duration, scope and impact of the
COVID-19
pandemic, market assessments of the likelihood that the mergers will be completed, interest rates, general market, industry and economic conditions and other factors generally affecting the respective prices of Bioventus and Misonix common stock, federal, state and local legislation, governmental regulation and legal developments in the industry segments in which Bioventus and Misonix operate, and the timing of the mergers and receipt of required regulatory approvals.
Many of these factors are beyond the control of Bioventus and Misonix, and neither Bioventus nor Misonix is permitted to terminate the merger agreement solely due to a decline in the market price of the common stock of the other party. You are urged to obtain current market quotations for Bioventus and Misonix common stock in determining whether to vote in favor of the Bioventus share issuance proposal, in the case of Bioventus stockholders, or the Misonix merger proposal, in the case of Misonix stockholders.
The market price of Bioventus common stock will continue to fluctuate after the mergers.
Upon completion of the first merger, Misonix stockholders who receive the stock election consideration will become holders of Bioventus common stock. The market price of the common stock of the combined company will continue to fluctuate, potentially significantly, following completion of the mergers, including for the reasons described above. As a result, former Misonix stockholders could lose some or all of the value of their investment in Bioventus common stock. In addition, any significant price or volume fluctuations in the stock market generally could have a material adverse effect on the market for, or liquidity of, the Bioventus common stock received in the first merger, regardless of the combined company’s actual operating performance.
The mergers may not be completed and the merger agreement may be terminated in accordance with its terms.
The mergers are subject to a number of conditions that must be satisfied, including the approval by Bioventus stockholders of the Bioventus share issuance proposal and approval by Misonix stockholders of the Misonix
 
41

Table of Contents
merger proposal, or waived (to the extent permitted), in each case prior to the completion of the mergers. These conditions are described under “The Merger Agreement—Conditions to the Completion of the Mergers.” These conditions to the completion of the mergers, some of which are beyond the control of Bioventus and Misonix, may not be satisfied or waived in a timely manner or at all, and, accordingly, the merger may be delayed or not completed.
Additionally, either Bioventus or Misonix may terminate the merger agreement under certain circumstances, including, among other reasons, if the mergers are not completed by the end date. Under the merger agreement, Bioventus and Misonix will each be required to pay a termination fee of $20,661,000 to the other party if the merger agreement is terminated in certain circumstances, including if the respective party’s board changes its recommendation in connection with the mergers. Additionally, Misonix may terminate the merger agreement if it enters into an alternative acquisition agreement with respect to a superior proposal and pays Bioventus the termination fee. See “The Merger Agreement—Termination of the Merger Agreement” and “The Merger Agreement—Termination Fee” for a more complete discussion of the circumstances under which the merger agreement could be terminated and when a termination fee may be payable by Bioventus or Misonix.
The termination of the merger agreement could negatively impact Bioventus or Misonix and the trading prices of the Bioventus or Misonix common stock.
If the mergers are not completed for any reason, including because Bioventus stockholders fail to approve the Bioventus share issuance proposal or because Misonix stockholders fail to approve the Misonix merger proposal, the ongoing businesses of Bioventus and Misonix may be adversely affected and, without realizing any of the expected benefits of having completed the mergers, Bioventus and Misonix would be subject to a number of risks, including the following:
 
   
each company may experience negative reactions from the financial markets, including negative impacts on its stock price;
 
   
each company may experience negative reactions from its customers, suppliers, distributors and employees;
 
   
each company will be required to pay its respective costs relating to the mergers, such as financial advisory, legal, financing and accounting costs and associated fees and expenses, whether or not the mergers are completed;
 
   
the merger agreement places certain restrictions on the conduct of each company’s business prior to completion of the mergers and such restrictions, the waiver of which is subject to the consent of the other company (not to be unreasonably withheld, conditioned or delayed), which may have prevented Bioventus and Misonix from taking actions during the pendency of the mergers that would have been beneficial (see “The Merger Agreement—Conduct of Business Prior to Completion of the Mergers” for a description of the restrictive covenants applicable to Bioventus and Misonix); and
 
   
matters relating to the mergers (including integration planning) will require substantial commitments of time and resources by Bioventus and Misonix management, which could otherwise have been devoted to
day-to-day
operations or to other opportunities that may have been beneficial to Bioventus or Misonix, as applicable, as an independent company.
The market price for shares of Bioventus common stock may be affected by factors different from, or in addition to, those that historically have affected or currently affect the market prices of shares of Bioventus or Misonix common stock.
Upon consummation of the first merger, Bioventus stockholders and the Misonix stockholders who receive the stock election consideration will both hold shares of common stock in the combined company. Bioventus’ businesses differ from those of Misonix, and Misonix’s businesses differ from those of Bioventus, and,
 
42

Table of Contents
accordingly, the results of operations of the combined company will be affected by some factors that are different from those currently or historically affecting the results of operations of Bioventus and Misonix. The results of operations of the combined company may also be affected by factors different from those that currently affect or have historically affected either Bioventus or Misonix. For a discussion of the businesses of each of Bioventus and Misonix and some important factors to consider in connection with those businesses, see “The Parties to the Mergers” and the other information contained or incorporated in this joint proxy statement/prospectus. See “Where You Can Find More Information.”
Based on the number of shares of Misonix common stock outstanding as of September 1, 2021, the latest practicable date prior to the date of this joint proxy statement/prospectus, it is expected that Bioventus will issue approximately 18,322,984 million shares of Bioventus common stock in the first merger. Former Misonix stockholders may decide not to hold the shares of Bioventus common stock that they will receive in the first merger, and Bioventus stockholders may decide to reduce their investment in Bioventus as a result of the changes to Bioventus’ investment profile as a result of the transaction. Such sales of Bioventus common stock could have the effect of depressing the market price for Bioventus common stock.
The shares of common stock of the combined company to be received by Misonix stockholders as a result of the first merger will have rights different from the shares of Misonix common stock.
Upon completion of the transaction, Misonix stockholders will no longer be stockholders of Misonix, but will instead become stockholders of Bioventus. As Bioventus and Misonix are both Delaware corporations, the rights of Bioventus and Misonix stockholders are not materially different. However, there are certain differences in the rights of Bioventus stockholders under Bioventus’ amended and restated certificate of incorporation, which is referred to as the “Bioventus charter,” and Bioventus’ amended and restated bylaws, which are referred to as the “Bioventus bylaws,” and of Misonix stockholders under Misonix’s amended and restated certificate of incorporation, which is referred to as the “Misonix charter,” and Misonix’s amended and restated bylaws, which are referred to as the “Misonix bylaws.” See “Comparison of Stockholders’ Rights” for a discussion of these rights.
After the transaction, Misonix stockholders will have a significantly lower ownership and voting interest in Bioventus than they currently have in Misonix and will exercise less influence over management and policies of the combined company.
Based on the number of shares of Bioventus and Misonix common stock outstanding on September 1, 2021, the latest practicable date prior to the date of this joint proxy statement/prospectus, upon completion of the first merger, former Misonix stockholders are expected to own approximately 25% of the outstanding shares of Bioventus common stock and Bioventus stockholders immediately prior to the first merger are expected to own approximately 75% of the outstanding shares of Bioventus common stock. Consequently, former Misonix stockholders will have less influence over the management and policies of the combined company than they currently have over the management and policies of Misonix.
Until the completion of the transaction or the termination of the merger agreement in accordance with its terms, Bioventus and Misonix are each prohibited from entering into certain transactions and taking certain actions that might otherwise be beneficial to Bioventus, Misonix and/or their respective stockholders.
From and after the date of the merger agreement and prior to completion of the transaction, the merger agreement restricts Bioventus and Misonix from taking specified actions without the consent of the other party and requires that the business of each company and its respective subsidiaries be conducted in the ordinary course in all material respects. These restrictions may prevent Bioventus or Misonix, as applicable, from taking actions during the pendency of the transaction that would have been beneficial. Adverse effects arising from these restrictions during the pendency of the transaction could be exacerbated by any delays in consummation of the transaction or termination of the merger agreement. See “The Merger Agreement—Conduct of Business Prior to Completion of the Mergers.”
 
43

Table of Contents
Obtaining required approvals and satisfying closing conditions may prevent or delay completion of the transaction.
The transaction is subject to a number of conditions to closing as specified in the merger agreement. These closing conditions include, among others, the effectiveness of the registration statement on Form
S-4
of which this joint proxy statement/prospectus forms a part registering the Bioventus common stock issuable pursuant to the merger agreement and the absence of any stop order or proceedings by the SEC with respect thereto, the expiration or earlier termination of any applicable waiting period (or any extension thereof), and the receipt of required approvals, under U.S. antitrust laws, approval for listing on Nasdaq of the shares of Bioventus common stock to be issued pursuant to the merger agreement, and the absence of governmental restraints or prohibitions preventing the consummation of the transaction. To the extent required, foreign investment filings will also be made, though these are not closing conditions. The obligation of each of Bioventus and Misonix to consummate the transaction is also conditioned on, among other things, the truth and accuracy of the representations and warranties made by the other party on the date of the merger agreement and on the closing date (subject to certain materiality and material adverse effect qualifiers), and the performance by the other party in all material respects of its obligations under the merger agreement. No assurance can be given that the required stockholder, governmental and regulatory consents and approvals will be obtained or that the required conditions to closing will be satisfied, and, if all required consents and approvals are obtained and the required conditions are satisfied, no assurance can be given as to the terms, conditions and timing of such consents and approvals. Any delay in completing the transaction could cause the combined company not to realize, or to be delayed in realizing, some or all of the benefits that Bioventus and Misonix expect to achieve if the transaction is successfully completed within its expected time frame. For a more complete summary of the conditions that must be satisfied or waived prior to completion of the transaction, see “The Merger Agreement—Conditions to the Completion of the Mergers.”
Bioventus and Misonix must obtain certain regulatory approvals and clearances to consummate the transaction, which, if delayed, not granted or granted with burdensome or unacceptable conditions, could prevent, substantially delay or impair consummation of the transaction, result in additional expenditures of money and resources or reduce the anticipated benefits of the transaction.
The completion of the transaction is subject to the termination or expiration of any applicable waiting period (or extension thereof) under the HSR Act, which occurred as of 11:59 p.m., Eastern Time, on September 13, 2021.
Under the HSR Act, the transaction may not be completed until Notification and Report Forms have been filed with the U.S. Federal Trade Commission, which is referred to as the “FTC,” and the U.S. Department of Justice, which is referred to as the “DOJ,” and the applicable waiting period (or any extension thereof) has expired or been terminated. A transaction requiring notification under the HSR Act may not be completed until the expiration of the applicable
30-day
waiting period following the parties’ filing of their respective HSR notifications or the early termination of that waiting period, at the earliest. Each of Bioventus and Misonix filed an HSR notification with the FTC and the DOJ on August 12, 2021. Effective as of 11:59 p.m., Eastern Time, on September 13, 2021, the waiting period under the HSR Act expired with respect to the transactions contemplated by the merger agreement.
At any time before or after consummation of the transaction, notwithstanding the expiration or termination of the applicable waiting period under the HSR Act, the DOJ or the FTC, or any state, could take such action under competition laws as it deems necessary or desirable in the public interest, including seeking to enjoin the completion of the transaction, seeking divestiture of substantial assets of the parties or requiring the parties to license, or hold separate, assets or to terminate existing relationships and contractual rights. Under certain circumstances, private parties may also seek to take legal action against the transaction under competition laws.
There is no assurance that Bioventus and Misonix will obtain all required regulatory clearances or approvals on a timely basis, or at all. Failure to obtain the necessary clearances in any of these jurisdictions could substantially delay or prevent the consummation of the transaction, which could negatively impact both Bioventus and Misonix.
 
44

Table of Contents
Failure to attract, motivate and retain executives and other key employees could diminish the anticipated benefits of the transaction.
The success of the transaction will depend in part on the combined company’s ability to retain the talents and dedication of the professionals currently employed by Bioventus and Misonix. It is possible that these employees may decide not to remain with Bioventus or Misonix, as applicable, while the transaction is pending, or with the combined company. If key employees terminate their employment, or if an insufficient number of employees are retained to maintain effective operations, the combined company’s business activities may be adversely affected and management’s attention may be diverted from successfully integrating Bioventus and Misonix to hiring suitable replacements, all of which may cause the combined company’s business to suffer. In addition, Bioventus and Misonix may not be able to locate suitable replacements for any key employees that leave either company or offer employment to potential replacements on reasonable terms. In addition, there could be disruptions to or distractions for the workforce and management, including disruptions associated with integrating employees into the combined company. No assurance can be given that the combined company will be able to attract or retain key employees of Bioventus and Misonix to the same extent that those companies have been able to attract or retain their own employees in the past.
The transaction, and uncertainty regarding the transaction, may cause customers, suppliers, distributors or strategic partners to delay or defer decisions concerning Bioventus or Misonix and adversely affect each company’s ability to effectively manage its respective business.
The transaction will happen only if the stated conditions are met, including the approval of the Bioventus share issuance proposal, the approval of the Misonix merger proposal and the receipt of required regulatory approvals, among other conditions. Many of the conditions are beyond the control of Bioventus and Misonix, and both parties also have certain rights to terminate the merger agreement. Accordingly, there may be uncertainty regarding the completion of the transaction. This uncertainty may cause customers, suppliers, distributors, vendors, strategic partners or others that deal with Bioventus or Misonix to delay or defer entering into contracts with Bioventus or Misonix or making other decisions concerning Bioventus or Misonix or seek to change or cancel existing business relationships with Bioventus or Misonix, which could negatively affect their respective businesses. Any delay or deferral of those decisions or changes in existing agreements could have an adverse impact on the respective businesses of Bioventus and Misonix, regardless of whether the transaction is ultimately completed.
In addition, the merger agreement restricts Bioventus, Misonix and their respective subsidiaries from taking certain actions during the pendency of the transaction without the consent of the other parties. These restrictions may prevent Bioventus and Misonix from pursuing attractive business opportunities or strategic transactions that may arise prior to the completion of the transaction. See “The Merger Agreement—Conduct of Business Prior to Completion of the Mergers” for a description of the restrictive covenants to which each of Bioventus and Misonix is subject.
The opinions rendered to Bioventus and Misonix from their respective financial advisors will not reflect changes in circumstances between the dates of such opinions and the completion of the transaction.
Perella Weinberg delivered its oral opinion to the Bioventus board on July 28, 2021, which opinion was subsequently confirmed in a written opinion dated as of July 29, 2021, to the effect that as of such date and subject to the procedures followed, assumptions made, qualifications and limitations on the review undertaken and other matters considered in connection with the preparation of the opinion, the merger consideration to be paid by Bioventus pursuant to the merger agreement was fair, from a financial point of view, to Bioventus.
J.P. Morgan rendered its oral opinion to the Misonix board on July 28, 2021, which opinion was subsequently confirmed in writing dated as of July 29, 2021, to the effect that, as of such date and based on and subject to the assumptions made, procedures followed, matters considered and other limitations on the review undertaken by J.P. Morgan in preparing its opinion, the merger consideration to be paid to the holders of Misonix common
 
45

Table of Contents
stock in the merger was fair, from a financial point of view, to such holders, as more fully described in the section entitled “Opinion of Misonix’s Financial Advisor”. The full text of the written opinion of J.P. Morgan, dated July 29, 2021, which sets forth, among other things, the assumptions made, procedures followed, matters considered and limitations on the review undertaken by J.P. Morgan in preparing its opinion, is attached as Annex C to this joint proxy statement/prospectus and is incorporated herein by reference.
Neither Bioventus nor Misonix has obtained, nor will either of them obtain, an updated opinion from Perella Weinberg or J.P. Morgan, as applicable, regarding the fairness, from a financial point of view, of the merger consideration or exchange ratio, including as of the date of this joint proxy statement/prospectus or of the special meetings, or prior to the completion of the transaction. Each of the respective opinions of Perella Weinberg and J.P. Morgan was necessarily based on general financial, economic, monetary, market and other conditions and circumstances as in effect on, and the information made available to Perella Weinberg and J.P. Morgan as applicable, only as of the dates of the respective opinions of Perella Weinberg and J.P. Morgan, and such opinions do not address the fairness of the merger consideration, from a financial point of view, at the time the transaction is completed. Changes in the operations and prospects of Bioventus or Misonix, general financial, economic, monetary, market and other conditions, circumstances and factors that may be beyond the control of Bioventus and Misonix, and on which each of the respective opinions of Perella Weinberg and J.P. Morgan was based, may alter the value of Bioventus or Misonix or the prices of shares of Bioventus or Misonix common stock by the time the mergers are completed. The opinions of Perella Weinberg and J.P. Morgan do not speak as of any date other than the respective dates of such opinions. The recommendation of the Bioventus board that Bioventus stockholders vote “
FOR
” the Bioventus share issuance proposal and “
FOR
” the Bioventus adjournment proposal and the recommendation of the Misonix board that Misonix stockholders vote “
FOR
” the Misonix merger proposal, “
FOR
” the Misonix compensation proposal and “
FOR
” the Misonix adjournment proposal are each made as of the date of this joint proxy statement/prospectus. For a description of the opinions that Bioventus and Misonix received from their respective financial advisors, see “The Merger—Opinion of Bioventus’ Financial Advisor” and “The Merger—Opinion of Misonix’s Financial Advisor.”
Whether or not the transaction is completed, the announcement and pendency of the mergers could cause disruptions in the businesses of Bioventus and Misonix, which could have an adverse effect on their respective businesses and financial results.
Whether or not the transaction is completed, the announcement and pendency of the mergers could cause disruptions in the businesses of Bioventus and Misonix, including by diverting the attention of Bioventus and Misonix management toward the completion of the transaction. In addition, Bioventus and Misonix have each diverted significant management resources in an effort to complete the transaction and are each subject to restrictions contained in the merger agreement on the conduct of their respective businesses. If the transaction is not completed, Bioventus and Misonix will have incurred significant costs, including the diversion of management resources, for which they will have received little or no benefit.
Misonix directors and executive officers have interests and arrangements that may be different from, or in addition to, those of Misonix stockholders generally.
When considering the recommendations of the Misonix board on how to vote on the proposals described in this joint proxy statement/prospectus, Misonix stockholders should be aware that Misonix directors and executive officers have interests in the transaction that are different from, or in addition to, those of Misonix stockholders generally. These interests include the continued service of certain Misonix directors as directors of the combined company, the treatment in the mergers of outstanding equity, equity-based and incentive awards, severance arrangements, other compensation and benefit arrangements, and the right to continued indemnification of former Misonix directors and officers by the combined company.
 
46

Table of Contents
Misonix stockholders should be aware of these interests when they consider the recommendations of the Misonix board that they vote to approve the Misonix merger proposal. The Misonix board was aware of and considered these interests when it determined that the transaction was fair to and in the best interests of Misonix and its stockholders, approved and declared advisable the merger agreement, and recommended that Misonix stockholders adopt the merger agreement. The interests of Misonix directors and executive officers are described in more detail under “Interests of Misonix Directors and Executive Officers in the Mergers.”
Bioventus or Misonix may waive one or more of the closing conditions without
re-soliciting
stockholder approval.
To the extent permitted by law, Bioventus or Misonix may determine to waive, in whole or part, one or more of the conditions to their respective obligations to consummate the mergers. Bioventus and Misonix currently expect to evaluate the materiality of any waiver and its effect on Bioventus or Misonix stockholders, as applicable, in light of the facts and circumstances at the time to determine whether any amendment of this joint proxy statement/prospectus or any
re-solicitation
of proxies is required in light of such waiver. Any determination as to whether to waive any condition to the transaction, and as to whether to
re-solicit
stockholder approval and/or amend this joint proxy statement/prospectus as a result of such waiver, will be made by Bioventus or Misonix, as applicable, at the time of such waiver based on the facts and circumstances as they exist at that time.
The merger agreement contains provisions that could discourage a potential competing acquirer that might be willing to pay more to acquire or merge with either Bioventus or Misonix.
The merger agreement contains “no shop” provisions that restrict the ability of Bioventus and Misonix to, among other things (each as described under “The Merger Agreement—No Solicitation of Acquisition Proposals”):
 
   
solicit, initiate, knowingly encourage, knowingly induce, knowingly assist, or knowingly facilitate any inquiries regarding, or the submission or announcement by any person of, any proposal or offer that constitutes, or would reasonably be expected to lead to, an acquisition proposal;
 
   
furnish any information regarding Bioventus, Misonix or their respective subsidiaries in connection with, for the purpose of soliciting, initiating, encouraging or facilitating, or in response to, an acquisition proposal;
 
   
engage in or otherwise participate in any discussions or negotiations with any person with respect to any acquisition proposal or any inquiry, proposal or offer that would reasonably be expected to lead to an acquisition proposal; or
 
   
approve, adopt, recommend, agree to, or enter into, or propose to approve, adopt, recommend, agree to, or enter into, any letter of intent or similar document, agreement, commitment, or agreement in principle with respect to any acquisition proposal.
Furthermore, there are only limited exceptions to the requirement under the merger agreement that neither the Bioventus nor Misonix boards of directors withdraw, modify, amend or qualify the Bioventus recommendation or the Misonix recommendation, as applicable (each as defined under “The Merger Agreement—Representations and Warranties”). Although the Bioventus or Misonix board is permitted to effect a change of recommendation, after complying with certain procedures set forth in the merger agreement, in response to a superior proposal or to an intervening event (if the applicable board of directors determines in good faith after consultation with its outside legal counsel and its financial advisor that a failure to do so would be reasonably likely to be inconsistent with its fiduciary duties under applicable law), such change of recommendation by the Misonix board would entitle Bioventus to terminate the merger agreement and collect a termination fee from Misonix. See “The Merger Agreement—Termination of the Merger Agreement” and “The Merger Agreement—Termination Fees.”
 
47

Table of Contents
These provisions could discourage a potential competing acquirer from considering or proposing an acquisition or merger, even if it were prepared to pay consideration with a higher value than that implied by the exchange ratio in the first merger, or might result in a potential competing acquirer proposing to pay a lower per share price than it might otherwise have proposed to pay because of the added expense of the termination fee.
The transaction will involve substantial costs.
Bioventus and Misonix have incurred and expect to incur
non-recurring
costs associated with combining the operations of the two companies, as well as transaction fees and other costs related to the transaction. As of the date of this joint proxy statement/prospectus, Bioventus and Misonix estimate that their aggregate costs associated with the transaction and related transactions will be approximately $18.0 million and $10.4 million, respectively. These costs include filing and registration fees with the SEC, printing and mailing costs associated with this joint proxy/registration statement, and legal, accounting, investment banking, consulting, public relations and proxy solicitation fees. These costs do not include severance and retention payments that may be made to certain Misonix employees and costs that will be incurred in connection with the integration of Bioventus’ and Misonix’s businesses. Some of these costs are payable by Bioventus or Misonix regardless of whether the transaction is completed.
The combined company will also incur restructuring and integration costs in connection with the mergers. The costs related to restructuring will be expensed as a cost of the ongoing results of operations of either Bioventus or the combined company. There are processes, policies, procedures, operations, technologies and systems that must be integrated in connection with the mergers and the integration of Misonix’s business. Although Bioventus expects that the elimination of duplicative costs, strategic benefits, and additional income, as well as the realization of other efficiencies related to the integration of the businesses, may offset incremental transaction, merger-related and restructuring costs over time, any net benefit may not be achieved in the near term or at all. Many of these costs will be borne by Bioventus even if the mergers are not completed. While Bioventus has assumed that certain expenses would be incurred in connection with the transaction, there are many factors beyond Bioventus’ control that could affect the total amount or the timing of the integration and implementation expenses.
Bioventus stockholders will not be entitled to appraisal rights in the transaction, though Misonix stockholders will be entitled to appraisal rights in the transaction.
Appraisal rights are statutory rights that, if applicable under law, enable stockholders of a corporation to dissent from an extraordinary transaction, such as a merger, and to demand that such corporation pay the fair value for their shares as determined by a court in a judicial proceeding instead of receiving the consideration offered to such stockholders in connection with the extraordinary transaction. Under the DGCL, stockholders generally do not have appraisal rights if the shares of stock they hold are either listed on a national securities exchange or held of record by more than 2,000 holders. Notwithstanding the foregoing, appraisal rights are available if stockholders are required by the terms of the merger agreement to accept for their shares anything other than (a) shares of stock of the surviving corporation, (b) shares of stock of another corporation that will either be listed on a national securities exchange or held of record by more than 2,000 holders, (c) cash in lieu of fractional shares or (d) any combination of the foregoing.
Because the mergers are of Merger Sub with and into Misonix and then Misonix with and into Merger Sub II and holders of Bioventus common stock will continue to hold their shares following completion of the mergers, holders of Bioventus common stock are not entitled to appraisal rights in connection with the mergers.
Pursuant to Section 262 of the DGCL, Misonix stockholders who do not vote in favor of Misonix merger proposal and who comply with the applicable requirements of Section 262 of the DGCL have the right to seek appraisal of such shares by the Delaware Court of Chancery and to receive payment in cash of the fair value of those shares. It is possible that the fair value as determined by the Delaware Court of Chancery may be more or less than, or the same as, the per share value of the merger consideration.
 
48

Table of Contents
Misonix stockholders who wish to preserve their appraisal rights must make a demand for appraisal prior to the time the Misonix stockholder vote is taken on the Misonix merger proposal. In addition to submitting a demand for appraisal, such Misonix stockholders must continuously hold such shares through the effective time, must not vote in favor of the Misonix merger proposal, must not surrender their shares in exchange for the merger consideration, and must otherwise follow the procedures prescribed by Section 262 of the DGCL.
Misonix stockholders are encouraged to read Section 262 of the DGCL carefully and in their entirety. Due to the complexity of the procedures for exercising your appraisal rights, Misonix stockholders who are considering exercising such rights are encouraged to seek the advice of legal counsel. Failure to strictly comply with these provisions will result in the loss of appraisal rights. See the section entitled “Appraisal Rights” of this joint proxy statement/prospectus for additional information and the text of Section 262 of the DGCL reproduced in its entirety as
Annex D
to this proxy statement/prospectus. See “Appraisal Rights.”
Lawsuits filed against Bioventus and/or Misonix may delay or prevent the transaction from being completed.
Bioventus, Misonix and members of the Bioventus and Misonix boards of directors may in the future be parties, among others, to various claims and litigation related to the merger agreement and the merger, including putative shareholder class actions. See “The Mergers—Litigation Relating to the Mergers.” Among other remedies, the plaintiffs in such matters are seeking to enjoin the transaction. The results of complex legal proceedings are difficult to predict, and could prevent or delay the merger from being completed in a timely manner, and could result in substantial costs to Bioventus and Misonix, including, but not limited to, costs associated with the indemnification of their respective directors and officers. The existence of litigation relating to the merger could also impact the likelihood of obtaining the required approvals from either Bioventus or Misonix stockholders. Moreover, the pending litigation and any future additional litigation could be time consuming and expensive, could divert the attention of Bioventus and Misonix management away from their regular businesses and, if any one of these lawsuits is adversely resolved against either Bioventus or Misonix, could have a material adverse effect on Bioventus’ or Misonix’s respective financial condition.
One of the conditions to the completion of the mergers is that no relevant legal restraint (as defined in the merger agreement) will be in effect. As such, any relevant legal restraint may delay or prevent the mergers from becoming effective.
Risks Relating to the Combined Company
Combining the businesses of Bioventus and Misonix may be more difficult, costly or time-consuming than expected and the combined company may fail to realize the anticipated benefits of the merger, which may adversely affect the combined company’s business results and negatively affect the value of the combined company’s common stock.
The success of the mergers will depend on, among other things, the ability of Bioventus and Misonix to combine their businesses in a manner that facilitates growth opportunities and realizes expected cost savings. Bioventus and Misonix have entered into the merger agreement because each believes that the transaction is fair to and in the best interests of their respective stockholders and that combining the businesses of Bioventus and Misonix will produce benefits and cost savings. See “The Mergers—Recommendation of the Bioventus Board of Directors; Bioventus’ Reasons for the Mergers” and “The Mergers—Recommendation of the Misonix Board of Directors; Misonix’s Reasons for the Mergers.”
However, Bioventus and Misonix must successfully combine their respective businesses in a manner that permits these benefits to be realized. In addition, the combined company must achieve the anticipated growth and cost savings without adversely affecting current revenues and investments in future growth. If the combined company is not able to successfully achieve these objectives, the anticipated benefits of the transaction may not be rea